US20090135886A1 - Transbody communication systems employing communication channels - Google Patents

Transbody communication systems employing communication channels Download PDF

Info

Publication number
US20090135886A1
US20090135886A1 US12/324,798 US32479808A US2009135886A1 US 20090135886 A1 US20090135886 A1 US 20090135886A1 US 32479808 A US32479808 A US 32479808A US 2009135886 A1 US2009135886 A1 US 2009135886A1
Authority
US
United States
Prior art keywords
module
signal
frequency
beacon
functionality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/324,798
Inventor
Timothy Robertson
Kenneth C. Crandall
Lawrence W. Arne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteus Digital Health Inc
Original Assignee
Proteus Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteus Biomedical Inc filed Critical Proteus Biomedical Inc
Priority to US12/324,798 priority Critical patent/US20090135886A1/en
Assigned to PROTEUS BIOMEDICAL, INC. reassignment PROTEUS BIOMEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARNE, LAWRENCE W., CRANDALL, KENNETH C., ROBERTSON, TIMOTHY
Publication of US20090135886A1 publication Critical patent/US20090135886A1/en
Assigned to PROTEUS DIGITAL HEALTH, INC. reassignment PROTEUS DIGITAL HEALTH, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PROTEUS BIOMEDICAL, INC.
Priority to US16/789,361 priority patent/US11612321B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04BTRANSMISSION
    • H04B13/00Transmission systems characterised by the medium used for transmission, not provided for in groups H04B3/00 - H04B11/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0031Implanted circuitry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/07Endoradiosondes
    • A61B5/073Intestinal transmitters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6861Capsules, e.g. for swallowing or implanting
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04BTRANSMISSION
    • H04B13/00Transmission systems characterised by the medium used for transmission, not provided for in groups H04B3/00 - H04B11/00
    • H04B13/005Transmission systems in which the medium consists of the human body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37211Means for communicating with stimulators
    • A61N1/37252Details of algorithms or data aspects of communication system, e.g. handshaking, transmitting specific data or segmenting data

Definitions

  • Transbody communications generally refers to transmission of a signal from an in vivo location to a receiver location, e.g., a second in vivo location, a receiver location extracorporeally associated with the body, etc.
  • noisy transmission environments may distort and corrupt communication data.
  • the noisy transmission environments include the body.
  • communication devices may err in signal generation and measurement related to the communication data.
  • various devices and combinations of devices may exact high power consumption, resulting in a relatively short life cycle for the devices inside the body. Such a short life cycle may result in replacement surgeries and other inconvenient, expensive, and/or high-risk procedures.
  • the system includes an in vivo transmitter to transmit an encoded signal; a transbody functionality module to facilitate communication of the encoded signal; and a receiver to receive the encoded signal to at least facilitate accurate transbody communications and conserve power consumption.
  • the system may further include at least one of a beacon functionality module, a frequency hopping functionality module, and a collision avoidance functionality module. Related methods and apparatus are also provided.
  • FIG. 1 illustrates a communication environment, including a transbody communication system having a transbody functionality module.
  • FIG. 2 illustrates the transbody functionality module of FIG. 1 in greater detail.
  • FIG. 3A illustrates a beacon wakeup module providing a sniff period longer than a transmit signal repetition period.
  • FIG. 3B illustrates a beacon wakeup module providing a short but frequent sniff period and a long transmit packet are provided.
  • FIG. 4A illustrates a resonant, narrow band analog circuit.
  • FIG. 4B illustrates classic power detection circuit.
  • FIG. 5 illustrates beacon functionality having a long period of a continuous wave tone.
  • FIG. 6 illustrates a beacon functionality wherein a beacon is associated with one frequency and a message is associated with another frequency.
  • FIG. 7 illustrates a beacon functionality associated with a two-beacon scheme.
  • FIG. 8 illustrates a beacon functionality associated with a beacon signal where frequency is a function of time.
  • FIG. 9 further illustrates a beacon functionality associated with a beacon signal where frequency is a function of time.
  • FIG. 10 illustrates a collision avoidance functionality having one collision avoidance technique.
  • FIGS. 11A-11D illustrate a collision avoidance functionality having another collision avoidance approach.
  • FIGS. 12A and 12B illustrate a collision avoidance functionality having a technique to detect a low amplitude signal in a noisy environment.
  • Transbody communication systems employing communication channels.
  • Various aspects facilitate accurate communications in noisy environments as well as provide enhanced power conservation features. More particularly, various aspects may be associated with transbody communication systems, e.g., an in vivo transmitter and a signal receiver (sometimes referred to herein as a “receiver”) associated with a body.
  • the receiver may be configured to receive and decode a signal from the in vivo transmitter.
  • Various aspects of the invention are characterized by employing a specific communication channel having transbody functionality, e.g., via a transbody functionality module. Related methods are also provided.
  • the invention may have broad applicability to medical and non-medical fields.
  • the medical fields include, for example, transbody communications systems associated with various medical and therapeutic devices, e.g., cardiac devices, ingestible devices, etc.
  • the non-medical fields include, for example, body associated devices such as gaming devices incorporating physiologic sensing functionality, etc.
  • FIG. 1 illustrates a communication environment 100 , including a transbody communication system 102 .
  • the transbody communication system 102 comprises, for example, an in vivo transmitter 104 , a transbody functionality module 106 , and a receiver 108 .
  • the in vivo transmitter 104 transmits a signal, e.g., an encoded signal, via the transbody communication module 104 to the receiver 108 , as hereinafter described in detail.
  • an in vivo transmitter 102 includes any in vivo device capable of transmitting a signal, e.g., an encoded signal.
  • the in vivo transmitter 102 may be associated with various devices, e.g., cardiac-related devices, ingestible devices, neural-stimulation related devices, medications, etc.
  • the in vivo transmitter 102 may be wholly or partially integrated with such a device, medication, etc.
  • Such a device is a pharma-informatics enabled pharmaceutical composition, described in PCT Application Serial No. US2006/016370.
  • Another example is an ingestible event marker (IEM) and a personal receiver, described in U.S. Provisional Patent Application Ser. No. 60/949,223.
  • Still another example is a smart parenteral device, described in PCT/US2007/15547.
  • Yet another example is a smart implantable fluid transport device, described in U.S. Provisional Patent Application Ser. No. 60/989,078.
  • Still further examples include implantable physiologic event recorders, described in U.S. Pat. Nos.
  • the signal transmitted by the device generally includes any signal, data, identifier, representative thereof, etc.
  • Signals include encoded signals, e.g., encode at origin and decoded at destination. Examples of signals include an identifier of a pharmaceutical, a parenteral delivery device, an ingestible event marker, etc., supra.
  • the signal may be transmitted from the in vivo transmitter 104 via the transbody functionality module 106 to the receiver 108 .
  • the transbody functionality module 106 generally uses protocol(s), communication channels, etc., capable of facilitating accurate receipt of signals, data, etc. and/or facilitating low power consumption.
  • Such transbody functionality modules 106 include beacon functionality frequency hopping functionality and collision avoidance functionality.
  • the transbody functionality module 106 may be implemented as software, e.g., digital signal processing software; hardware, e.g., a circuit; or combinations thereof.
  • Communication media for transmission may vary.
  • the body of a patient may be employed as a conduction medium for the signal.
  • the signal is conducted between the in vivo transmitter and the receiver via body fluids, etc. in another aspect, the signal is transmitted via radio frequency (RF) transmission.
  • RF radio frequency
  • FIG. 2 illustrates the transbody functionality module 106 of FIG. 1 in greater detail.
  • the transbody functionality modules includes a beacon functionality module 200 , a frequency hopping functionality module 202 , and a collision avoidance functionality module 204 .
  • the beacon functionality module 200 may employ one or more of the following: a beacon wakeup module 200 A, a beacon signal module 200 B, a wave/frequency module 200 C, a multiple frequency module 200 D, and a modulated signal module 200 E.
  • the beacon functionality module 200 may be associated with beacon communications, e.g., a beacon communication channel, a beacon protocol, etc.
  • beacons are typically signals sent either as part of a message or to augment a message (sometimes referred to herein as “beacon signals”).
  • the beacons may have well-defined characteristics, such as frequency. Beacons may be detected readily in noisy environments and may be used for a trigger to a sniff circuit, such as those described above.
  • the beacon functionality module 200 may comprise the beacon wakeup module 200 A, having wakeup functionality.
  • Wakeup functionality generally comprises the functionality to operate in high power modes only during specific times, e.g., short periods for specific purposes, e.g., to receive a signal, etc.
  • An important consideration on a receiver portion of a system is that it be of low power. This feature may be advantageous in an implanted receiver, to provide for both small size and to preserve a long-functioning electrical supply from a battery.
  • the beacon wakeup module 200 A may enable these advantages by having the receiver operate in a high power mode for very limited periods of time. Short duty cycles of this kind can provide optimal system size and energy draw features.
  • the receiver may “wake up” periodically, and at low energy consumption, to perform a “sniff function” via, for example, a sniff circuit.
  • the term “sniff function” generally refers to a short, low-power function to determine if a transmitter is present. If a transmitter signal is detected by the sniff function, the device may transition to a higher power communication decode mode. If a transmitter signal is not present, the receiver may return, e.g., immediately return, to sleep mode. In this manner, energy is conserved during relatively long periods when a transmitter signal is not present, while high-power capabilities remain available for efficient decode mode operations during the relatively few periods when a transmit signal is present.
  • FIG. 3A illustrates the beacon wakeup module 200 A wherein a sniff period 300 is longer than a transmit signal repetition period 302 .
  • the time function is provided on the x axis.
  • the transmit signal repeats periodically, with a sniff function also running.
  • the sniff period 300 is typically longer than the transmit signal repetition period 302 .
  • the sniff function e.g., implemented as a sniff circuit, is guaranteed to have at least one transmission to occur each time the sniff circuit is active.
  • FIG. 3B illustrates the beacon wakeup module 200 A wherein a short but frequent sniff period 306 and a long transmit packet 308 are provided.
  • the sniff circuit will activate at some point during the transmit time. In this manner, the sniff circuit may detect the transmit signal and switch into a high power decode mode.
  • An additional beacon wakeup aspect is to provide the “sniffing” function in a continuous mode.
  • this aspect of the transbody beacon transmission channel may exploit the fact that the total energy consumption is the product of average power consumption and time.
  • the system may minimize the total energy consumption by having very short periods of activity, in which case the periods of activity are averaged down to a small number.
  • a low continuous sniff activity is provided.
  • the configuration provides a sufficiently low power so that the transmission receiver runs continuously with a total energy consumption at an appropriate level for the parameters of a specific system.
  • the system may be passive. Two examples of circuit implementations are provided.
  • FIG. 4A illustrates a resonant, narrow band analog circuit 400 , including input antenna 402 , inductor 404 , and capacitors 406 .
  • the resonant, narrow band analog circuit 400 may have a high impedance.
  • An LC resonator may be provided that is tuned to the frequency of the transmitted signal. The voltage across the LC circuit may be measured, and run into a comparator. When the voltage measurement exceeds a certain value, a gate may be triggered. The circuitry goes then into a high power mode.
  • FIG. 4B shows a classic power detect circuit 408 .
  • the power detect circuit 408 may be of those known in the art, such as those used in an AM radio to give a light signal that indicates receipt of a radio signal.
  • the power detect circuit 408 is an LC resonant circuit, i.e., a tank circuit. When a signal of the LC resonant frequency is present, the LC tank circuit ‘rings up’. Because the circuit has a high Q, its voltage increases dramatically. That voltage is rectified by the diode. When that voltage exceeds a threshold set by Vref, a comparator is triggered. The comparator informs the microprocessor that a signal/circuit is present and directs it to enter the high power mode.
  • Each of the above-described circuits may be very low powered and may comprise only passive components, with the exception of the comparator.
  • the comparator may also be of very low power.
  • Each circuit may operate continuously.
  • Each circuit may inform the microprocessor when a transmitter is present, e.g., a signal is transmitted, to go into the high power mode.
  • a useful prerequisite may be a well defined frequency for the transmitter.
  • a type of beacon signal associated with the present transbody communication channel is a continuous wave, single frequency tone.
  • the continuous single frequency tone triggers either of the circuits in FIG. 4A or 4 B, when they are tuned to the correct frequency.
  • the beacon signal module 200 B may provide for beacon signals to be detected digitally, as shown in FIG. 3A or 3 B. This may be accomplished by sampling the beacon signals with an A->D converter. The beacon signals are put in a digital processing system. Beacon signals are detected by a single frequency tone which has a very strong characteristic.
  • FIG. 5 Examples of such systems are provided in FIG. 5 .
  • FIG. 5 illustrates beacon functionality having a long period of a continuous wave tone, e.g., via the wave/frequency module 200 C.
  • the beacon signal consists of a long period of the continuous wave tone.
  • This continuous wave tone has both a modulated portion, which holds the information, and unmodulated portion. In this frequency domain, there is typically a period of well defined frequency. The modulation tends to smear the frequency spectrum.
  • This portion of the wave tone serves as the beacon. It has a single tone in the frequency domain, and is easily recognizable in the spectrogram.
  • Either of the methods shown previously can detect the single frequency tone. This frequency tone alerts the processing circuitry that a message is coming. It then it moves into decode mode so that the message can be understood. In FIG. 5 , this is shown as one packet.
  • FIG. 6 illustrates beacon functionality wherein a beacon is associated with one frequency, e.g., a beacon channel, and a message is associated with another frequency, e.g., a message channel.
  • a beacon is associated with one frequency, e.g., a beacon channel
  • a message is associated with another frequency, e.g., a message channel.
  • the solid line represents the beacon from Transmit Signal 1 .
  • the dashed line represents the beacon from Transmit Signal 2 .
  • the Transmit Signal 2 's beacon might overlap with that of Transmit Signal 1 , as depicted.
  • Message Signal 1 and Message Signal 2 can be at different frequencies from their respective beacons.
  • One advantage may be that the beacon from Transmit Signal 2 does not interfere with the message from Transmit Signal 1 at all, even though they are transmitted at the same time.
  • the beacon from the second transmit signal would most likely obscure the message from the first transmit signal.
  • the beacon channel is a well defined frequency band.
  • a message is provided in the channel where the data are actually transmitted. Interference between different messages in the message channel can be handled through collision avoidance, described below. While FIG. 6 is shown with two transmitters, it will be apparent to one of ordinary skill in the art to modify the system so as to scale it to many more transmitters. The requirements of a particular system may, to some extent, dictate the particular architecture of that system.
  • FIG. 7 illustrates beacon functionality associated with a two-beacon scheme, e.g., Beacon 1 and Beacon 2 .
  • the beacon is a continuous wave signal, or a signal with a very simple modulation, it will be a simple matter to detect the carrier frequency of the beacon signal.
  • the beacon is at frequency 2 f
  • the message is at frequency f, as shown in FIG. 7 .
  • the value of f can be determined from the beacon channel.
  • the frequency is known exactly.
  • This aspect may be used, inter alia, to address frequency uncertainty.
  • This approach may provide a workable system for message channel modulations which do not have well defined carrier frequencies.
  • message channel modulations are spread spectrum modulations.
  • An attempt to determine the frequency of a spread spectrum modulation in and by itself, can be difficult because there is not a well defined peak in the frequency spectrum.
  • having the beacon channel accompanying the message channel with a well-defined mathematical relationship allows the message channel frequency to be determined precisely from the beacon channel. The message channel can then be demodulated based on that information.
  • the beacon could have a simple modulation on it.
  • An example of such an aspect is using on-off keying (OOK), or simple frequency modulation.
  • OOK on-off keying
  • simple frequency modulation of particular utility is a frequency key shifting (FSK) two tone beacon signal created by two different divide ratios of the master silicon oscillator. This may provide both a unique spectral signature and the frequency ratio of the two tones are invariant to the frequency drift of the silicon oscillator, e.g., an IEM silicon oscillator.
  • the frequency ratio metric may provide a high probability that the signal detected is sourced by the preferred source device, e.g., the IEM.
  • This approach gives the beacon a distinctive signature that is uniquely identifiable from other interferers. In this manner, the system does not risk confusing the beacon with other jammers from the environment.
  • One key characteristic of the frequency is that it stands out as distinctive, and still has a well-defined mathematical relationship in terms of carrier frequency.
  • FIG. 8 illustrates beacon functionality associated with a beacon signal where frequency is a function of time.
  • the carrier frequency is set by a silicon oscillator, and not by a crystal oscillator. This introduces a large uncertainty in characteristic frequency. Determination of that frequency may be a key challenge, both in terms of decoding the packet and detecting the beacon frequency.
  • FIGS. 4A and 4B provide an example of this approach. If these circuits have high power (Q), the frequency uncertainty may cause the beacon to fall outside of the response function of the sniff circuits. Thus, as illustrated in FIGS. 8 and 9 another type of beacon may be employed.
  • Frequency 700 is ramped over some range, providing a message.
  • Two narrow band filters are provided. The signal is ramped from an f high to an f low .
  • Two narrow band filters are tuned to f 1 and f 2 , e.g., via the multiple frequency module 200 D. Frequencies f 1 and f 2 fall between f high and f low .
  • the output of the filter at f 1 shows no power, shows a blip in power as the beacon frequency is ramped through f 1 at time t 1 , and then shows no power.
  • the output of the filter at f 2 would show no power, show a blip in power as the beacon frequency is ramped through f 2 at time t 2 , and then shows no power.
  • an analog sniff circuit is employed which triggers on the time difference between t 1 and t 2 .
  • This can be implemented digitally or in an analog approach. In this case, when the circuit is set on time t 1 , if time t 2 falls within some defined window t 0 , it indicates that a signal is present.
  • the ramp is a very distinctive signature. Frequency f 1 firing will be detected, and (by example) 10 ms later, f 2 firing is detected. If those two events happen within the defined time interval to, plus or minus t′, it indicates that a signal is present. The wakeup circuit is then triggered. The resulting design provides a very low power analog circuit. An important application of the circuit is to determine the frequency as shown in FIG. 8 .
  • the beacon may be modulated to assure that its signature will be distinctive, e.g., via the modulated signal module 200 E.
  • One approach to this method is to have the beacon alternate between two frequencies. When this alternation is detected with the well-defined frequency difference and well-defined time period, the confidence level can be very high that a beacon had been detected, rather than some background signal. A similar result can be achieved with on-off keying, in a frequency modulation keying approach.
  • any standard modulation technique can be applied to a beacon to give it a distinctive character.
  • data may be imprinted on the beacon, to avoid it being confused with any other signal.
  • the sniff circuit triggers only on the beacon.
  • beacon approaches There are multiple beacon approaches available to avoid interference.
  • transmitter 1 could have beacons at multiple frequencies, e.g., via multiple frequency module 200 D, to avoid effects from interference.
  • the aspect is simply to have beacons at different frequencies to avoid contention between the beacons.
  • a frequency ratio of a beacon and data channel is invariant to frequency error in the ingestible event marker system to provide additional assurance of detection of the encoded signal.
  • the frequency hopping functionality module 202 may be associated with the specific communications channel(s), frequency hopping protocol, etc. As such, various aspects may utilize one or more frequency hopping protocols. For example, the receiver may search the designated range of frequencies in which the transmission could fall. When a single proper decode is achieved, the in vivo transmitter has accomplished its mission of communicating its digital information payload to the receiver.
  • the transmitted frequency uncertainty provided by random frequency hopping, e.g., via a random module 202 A, may create multiple benefits.
  • One such benefit may be easy implementation on a small die.
  • the in vivo transmitter carrier frequency oscillator can be an inaccurate free running oscillator that is easily implemented on a small portion of a 1 mm die. Accuracies on the order of +/ ⁇ 20 are easily tolerated. This is because the receiver employs frequency searching algorithms.
  • Another such benefit may be extended battery life.
  • the probability of the transmitter transmitting on a clear channel that can be received by the frequency agile receiver may be significantly enhanced due to random frequency hopping.
  • Still another benefit may be minimized collision events in high volume environments.
  • the useful frequency spectrum for use in volume conduction applications ranges from about 3 kHz to 150 kHz.
  • the in vivo transmitter supra, having a received signal level in the range of 1 to 100 ⁇ V may compete with narrow band interfering signals on the order of hundreds to thousands of ⁇ V in the same frequency spectrum.
  • a frequency hopping channel or protocol may be employed in which the in vivo transmitter randomly frequency hops a narrow band transmitted signal, e.g., a modulated signal such as a binary phase shift keying (BPSK) signal or FSK signal, output on each transmission.
  • BPSK binary phase shift keying
  • the collision avoidance functionality module may be associated with the specific communications channel(s), collision avoidance protocols, etc.
  • various aspects may utilize various collision avoidance protocol techniques associated with the specific communications channel(s). Collision avoidance techniques may be particularly useful, for example, in environments where two or more in vivo transmitters are present, e.g., where an individual ingests multiple IEMs. In such an environment, if the various in vivo transmitters send their signals continuously, the transmission of one may obscure the transmission from all the other in vivo transmitters. As a result, failure to detect signals may increase significantly.
  • Various aspects may include various collision avoidance approaches, alone or in various combinations.
  • One such approach employs multiple transmit frequencies. By using frequency-selective filtering, the transmitter broadcasting at f 1 can be distinguished from the transmitter broadcasting at f 2 , even if they are transmitting simultaneously.
  • An alternative to this approach is illustrated in FIG. 9 .
  • FIG. 10 illustrates a first collision avoidance technique, e.g., via a transmitter module 204 A, wherein Transmitter 1 is broadcasting on f 1 .
  • Transmitter 2 is broadcasting on f 2 .
  • a receiver and two band pass filters are provided, e.g., via multiple band pass filter module 204 E.
  • Band pass filter 1 is sensitive to f 1
  • band pass filter 2 is sensitive to f 2 .
  • FIGS. 11A-11D illustrate another collision avoidance approach.
  • the specific communications channel(s) may employ duty cycle modulation, e.g., via a duty cycle modulation module 204 B, wherein a transmitter need not transmit all the time. If two transmitters, e.g., xmtr 1 and xmtr 2 , are not transmitting simultaneously, they will not interfere with each other. For example, If two transmitters are used which have low duty cycles, such as broadcasting 10% of the time and off 90% of the time, then probabilistically there is only a 20% chance that the signals will overlap with each other. In this manner, collisions may be avoided.
  • transmitter 1 e.g., xmtr 1
  • transmitter 2 e.g., xmtr 2
  • that probability can be controlled by changing the duty cycle and the frequency spread.
  • the overlap can be controlled, however, by dithering the duty cycle and the frequency spread, e.g., via dither module 204 F and spread spectrum module 204 D, respectively. In this manner, otherwise occurring collisions may be avoided.
  • dashed transmitter xmtr 2 has a slightly shorter period than the solid transmitter xmtr 1 . Even though the transmitters begin broadcasting at the same time, after some number of transmissions, the transmitters come out of alignment with each other. As a result, they are now distinct from one another and otherwise occurring collisions may be avoided.
  • a similar effect can be obtained by having a spread of oscillator frequencies.
  • the silicon oscillators used for these transmitters have a spread of a few percent in frequency.
  • a 1% difference in frequency means that after a 100 transmissions, two oscillators 1008 , 1010 that began in phase with each other are no longer in phase with each other.
  • Various aspects may be based on frequency distribution or the frequencies can also be programmed to be explicitly different, e.g., to have some range of periods. Noise dithering a voltage controlled oscillator frequency can also create this frequency spread.
  • the retry period is randomized.
  • xmtr 1 broadcasts and then waits some random period of time before broadcasting again.
  • the xmtr 1 then waits another random period of time before broadcasting again, and so forth.
  • Xmtr 2 begins broadcasting at the same time. However, in this case it waits a random time before the next transmission, and waits another random time before the next transmission and so forth. In this way, the probability that two transmitters broadcast simultaneously can be controlled by affecting the standard deviation of the retry periods.
  • This approach can be based on a pseudo-random sequence that is preprogrammed into the chip. It can also be based on a real physical random number generator (thermal noise), or on the serial number on the chip. Since every transmitter has a unique serial number, some of the lower bits of the serial number can be used to program this randomization time, either directly or by using a linear shift register.
  • transbody transmission channel uses spread spectrum transmission to modulate the transmit message.
  • This approach can be direct spread spectrum or frequency hopping spread spectrum.
  • CDMA code division multiple access
  • This aspect can also be based on any of the well known codes in spread spectrum, such as Gold Codes or Kasami codes.
  • a code is selected such that there are sufficiently many that the probability of two transmitters having the same code broadcasting at the same time is sufficiently small.
  • This approach ties into the idea of using a beacon to find the carrier frequency because spread spectrum transmissions in general do not have a well defined carrier frequency. That information is determined, such as from the beacon.
  • duty cycle works very well for two or three transmitters operating simultaneously.
  • the duty cycle method breaks down when there are more than five transmitters providing data in an overlapping time frame.
  • the most straightforward method to bolster the duty cycle is to add retransmit randomization, e.g., via retransmit randomization module 204 C.
  • retransmit randomization module 204 C By adding a few bits of retransmit randomization, the effect is immediately rendered much less pronounced. In this aspect, the system can easily distinguish five to ten simultaneous transmissions.
  • Plots on long duty cycle show with three simultaneous transmitters there is about a 1% chance of a transmitter not being detected because of a collision. This is during a one minute transmit interval.
  • One important feature of some transmitters systems is that the transmitters have a finite lifetime. In systems where transmitters have very long lifetimes, these concerns may be absent.
  • the transmitter can listen for a quiet channel, for example, waiting until it hears nothing transmitting and then transmit.
  • the spread spectrum approach is quantifiable, depending on how many distinct codes are used.
  • the Kasami set of codes are used there are 32,000 distinct codes.
  • the probability of having two transmitters transmit on the same code is 1/(32,000) 2 . That probability goes up geometrically with the number of transmitters. Even doing nothing to select transmitters that have distinct codes, and relying on the randomization of code selection, it supports tens, if not hundreds, of transmitters.
  • receivers of the system are configured to selectively receive a signal in a quiet part of a given spectrum.
  • FIG. 12A shows an aspect addressing the problem of detecting a low amplitude signal in a noisy environment.
  • One approach to that problem is to find a quiet place in the noise spectrum.
  • the detector of the receiver is programmed to that frequency band.
  • the transmitter periodically broadcasts in that frequency band.
  • FIGS. 12A and 12B illustrate a technique to detect a low amplitude signal in a noisy environment.
  • power is a function of frequency.
  • the broadcast is provided in the quiet region because the least amount of interference is in that region.
  • the transmission occurs at multiple different frequencies, e.g., a ramping scheme.
  • other schemes may be used such as frequency hopping or random scheme.
  • the chosen scheme will densely covers the frequency band of interest.
  • the transmitter will eventually jump into the quiet band and eventually transmit in the quiet band.
  • SNR signal to noise ratio
  • receivers as described in any of the following applications may be configured to receive only a quiet channel: PCT application serial no. US2007/024225 titled “Active Signal Processing Personal Health Signal Receivers,” and filed on Nov. 19, 2007; WO 2006/116718; 60/866,581; 60/945,251; 60/956,694, 60/887,780 and 2006/116718; the disclosures of which applications are herein incorporated by reference.
  • transmissions are broken into two channels.
  • the first channel is used to broadcast the data.
  • a one to two percent duty cycle is performed. Immunity to collisions is enhanced by randomizing the re-broadcast rate.
  • the second channel is used to broadcast a wakeup beacon.
  • a one to two percent duty cycle is performed.
  • the packet rate is in the 10 mSec range.
  • the beacon transmissions are short, in the range of 100 to 200 uSec, when collisions are not of concern.
  • the beacon and data channel carriers are generated from the same oscillator, so from the beacon the data carrier can be calculated.
  • the receiver will turn on every 10 to 30 seconds for a 10 mSec duration. If a beacon is observed, the receiver will stay on to perform a full demodulation and decode. Otherwise, the receiver will return to sleep.
  • the above system is modified to include a frequency dither to the packet interval dither.
  • the above system is modified to include a longer duration transmission of 16 carrier cycles at 25 kHz (640 uS) with a 1 to 2 percent duty cycle. This complies with narrow band filter compatibility.
  • the above system is modified to so that the modulation as BPSK on OOK on the lower channel.
  • the above system is modified so that the modulation as OOK burst on the higher beacon channel.
  • the above system is modified so that the use of simple multidimensional parity check codes for FEC (forward error correction).
  • the signal receiver generally includes any device or component capable of receiving the signal, e.g., conductively receiving a signal via one or more specific communication channels.
  • the receiver has a small size.
  • the receiver may occupy a volume of space of about five cm 3 or fewer, such as about three cm 3 or fewer, including about one cm 3 or less.
  • the receiver has a chip size approximately ranging from ten mm 2 to two cm 2 .
  • the receivers of interest may include both external and implantable receivers.
  • the receiver may be ex vivo, i.e., present outside of the body during use.
  • External receiver may be configured in any convenient manner.
  • the externals receivers may be configured to be associated with a desirable skin location.
  • the external receivers may be configured to contact a topical skin location of a subject.
  • Configurations of interest include, but are not limited to: patches, wrist bands, belts, etc.
  • a watch or belt worn externally and equipped with suitable receiving electrodes can be used as receivers in accordance with one aspect of the present invention.
  • the receivers may provide a further communication path via which collected data can be extracted by a patient or health care practitioner.
  • an implanted collector may include conventional RF circuitry operating, e.g., in the 405-MHz medical device band, with which a practitioner can communicate.
  • the practitioner may communicate, for example, via a data retrieval device, such as a wand, etc.
  • the receiver may have output devices for providing data, e.g., audio and/or visual feedback. Examples include audible alarms, LEDs, display screens, or the like.
  • the external component may also include an interface port via which the component can be connected to a computer for reading out data stored therein.
  • the device may be positioned by a harness that is worn outside the body and has one or more electrodes that attach to the skin at different locations.
  • the receiver may be configured to be in contact with or associated with a patient only temporarily, i.e., transiently.
  • the receiver may be associated/attached/in contact while the pill, ingestible event marker, etc., is actually being ingested.
  • the receiver may be configured as an external device having two finger electrodes or handgrips.
  • the patient touches the electrodes or grabs the handgrips to complete a conductive circuit with the receiver.
  • the signal emitted by the identifier of the pill is picked up by the receiver.
  • the external receiver may include miniaturized electronics which are integrated with the electrodes to form a bandage-style patch with electrodes that, when applied, contact the skin.
  • the bandage-style may be removably attachable, e.g., via an adhesive layer or other construction.
  • a battery and electronics may also be included.
  • the bandage-style patch may be configured to be positioned on a desirable target skin site of the subject, e.g., on the chest, back, side of the torso, etc.
  • the bandage circuitry may be configured to receive signals from devices inside of the subject, e.g., from an identifier of a pharma-informatics enabled pharmaceutical composition, and then relay this information to an external processing device, e.g., a PDA, smartphone, mobile phone, handheld device, computer, etc., as described in greater detail elsewhere.
  • an external processing device e.g., a PDA, smartphone, mobile phone, handheld device, computer, etc.
  • Bandage-style devices that may be readily adapted for use in the present systems include, but are not limited to, those described in U.S. Pat. No. 6,315,719 and the like, the disclosures of which are herein incorporated by reference.
  • the receiver may be an implantable, i.e., designed and/or configured for implantation into a subject. Implantation may be on a temporary basis or a permanent basis. In these aspects, the receiver is in vivo during use.
  • implantable receivers may maintain functionality when present in a physiological environment, including a high salt, high humidity environment found inside of a body, for various periods of time. Periods of time, for example, include a few minutes to eighty years. More specific time periods include, for example, one or more hours, one or more days, one or more weeks, one or more months, and one or more years.
  • the receiver may have any convenient shape, including but not limited to: capsule-shaped, disc-shaped, etc.
  • Various receivers may have relatively small sizes. These small sizes may be achieved, for example, by incorporation of a rechargeable battery.
  • the rechargeable battery has a life span of about two weeks.
  • the rechargeable battery automatically charges from various sources, e.g., coils in the patient's bed.
  • the receiver may be configured to be placed in a number of different locations. Examples of locations include the abdomen, the small of the back, the shoulder, e.g., where implantable pulse generators are placed, etc.
  • the receiver is a standalone device, i.e., not physically connected to any other type of implantable device.
  • the receiver may be physically coupled to a second implantable device, e.g., a device which serves as a platform for one or more physiological sensors.
  • a device may be a lead, such as a cardiovascular lead.
  • the cardiovascular lead may include one or more distinct physiological sensors, e.g., where the lead is a multi-sensor lead (MSL).
  • Implantable devices of interest further include, but are not limited to: implantable pulse generators, neurostimulator devices, implantable loop recorders, etc.
  • Receivers may further include a receiver element which serves to receive the signal of interest.
  • the receiver may include a variety of different types of receiver elements, where the nature of the receiver element necessarily varies depending on the nature of the signal produced by the signal generation element.
  • the receiver may include one or more electrodes for detecting signal emitted by the signal generation element.
  • the receiver device may be provided with two electrodes that are dispersed at a predetermined distance. The predetermined distance may allow the electrodes to detect a differential voltage. The distance may vary, and in certain aspects, ranges from about 0.1 to about five cm, such as from about 0.5 to about 2.5 cm, e.g., about one cm.
  • the first electrode is in contact with an electrically conductive body element, e.g., blood
  • the second electrode is in contact with an electrically insulative body element relative to said conductive body element, e.g., adipose tissue (fat).
  • a receiver that utilizes a single electrode is employed.
  • the signal detection component may include one or more coils for detecting a signal emitted by the signal generation element.
  • the signal detection component includes an acoustic detection element for detecting signal emitted by the signal generation element.
  • a receiver may handle received data in various ways.
  • the receiver simply retransmits the data to an external device, e.g., via conventional RF communication.
  • the receiver processes the received data to determine whether to take some action such as operating an effector that is under its control, activating a visible or audible alarm, transmitting a control signal to an effector located elsewhere in the body, or the like.
  • the receiver stores the received data for subsequent retransmission to another device or for use in processing of subsequent data, e.g., detecting a change in some parameter over time.
  • the receivers may perform any combination of these and/or other operations using received data.
  • the data that are recorded on the data storage element include at least one of, if not all of, time, date, and an identifier, e.g., global unique serial number, of each composition administered to a patient.
  • the identifier may be the common name of the composition or a coded version thereof.
  • the data recorded on the data storage element of the receiver may further include medical record information of the subject with which the receiver is associated, e.g., identifying information, such as but not limited to name, age, treatment record, etc.
  • the data of interest include hemodynamic measurements.
  • the data of interest include cardiac tissue properties.
  • the data of interest include various physiologic metrics or parameters, e.g., pressure or volume measurements, temperature, activity, respiration rate, pH, etc.
  • the receivers can be configured to have a very small size.
  • the desired functionality of the receiver is achieved with one or more integrated circuits and a battery.
  • aspects of the invention include receivers that have at least a receiver element, e.g., the form of one or more electrodes (such as two spaced apart electrodes) and a power generation element, e.g., a battery, where the battery may be rechargeable, etc., as mentioned above.
  • the power generation element is converted to receive power wirelessly from an external location.
  • Additional elements that may be present in the receiver include, but are not limited to: a signal demodulator, e.g., for decoding the signal emitted from the pharma-informatics enabled identifier; a signal transmitter, e.g., for sending a signal from the receiver to an external location; a data storage element, e.g., for storing data regarding a received signal, physiological parameter data, medical record data, etc.; a clock element, e.g., for associating a specific time with an event, such as receipt of a signal; a pre-amplifier; a microprocessor, e.g., for coordinating one or more of the different functionalities of the receiver.
  • a signal demodulator e.g., for decoding the signal emitted from the pharma-informatics enabled identifier
  • a signal transmitter e.g., for sending a signal from the receiver to an external location
  • a data storage element e.g., for storing data regarding a
  • implantable versions of the receiver will have a biologically compatible enclosure, two or more sense electrodes, a power source, which could either be a primary cell or rechargeable battery, or one that is powered by broadcast inductively to a coil.
  • the receiver may also have circuitry consisting of: a demodulator to decode the transmitted signal, some storage to record events, a clock, and a way to transmit outside the body.
  • the clock and transmit functionality may, in certain aspects, be omitted.
  • the transmitter could be an RF link or conductive link to move information from local data storage to external data storage.
  • aspects include structures that have electrodes opposed to the skin, the demodulator, storage, and power.
  • the communication may be wireless or performed over one or more conductive media, e.g., wires, optical fibers, etc.
  • the same electrodes are used for receiving and transmitting signals.
  • One mode may be a wristwatch which is conductively in contact with the body. To move the data from the implant to the wristwatch, currents may be sent out the pads and received by the wristwatch.
  • RF techniques for facilitating transmission out of the body that may be employed, such as inductive protocols that use coils.
  • electric fields may be employed, using insulated electrodes, for example.
  • the components or functional blocks of the present receivers are present on integrated circuits, where the integrated circuits include a number of distinct functional blocks, i.e., modules. Within a given receiver, at least some of, e.g., two or more, up to an including all of, the functional blocks may be present in a single integrated circuit in the receiver.
  • single integrated circuit is meant a single circuit structure that includes all of the different functional blocks.
  • the integrated circuit is a monolithic integrated circuit (also known as IC, microcircuit, microchip, silicon chip, computer chip or chip) that is a miniaturized electronic circuit (which may include semiconductor devices, as well as passive components) that has been manufactured in the surface of a thin substrate of semiconductor material.
  • the integrated circuits of certain aspects of the present invention may be hybrid integrated circuits, which are miniaturized electronic circuits constructed of individual semiconductor devices, as well as passive components, bonded to a substrate or circuit board.
  • the receivers exhibit reliable decoding of an encoded signal even in the presence of substantial noise and a low SNR.
  • This functional aspect of the receivers of the invention may be provided via various schemes. Some such schemes include, for example, coherent demodulation, e.g., Costas loop demodulation, accurate low overhead iterative decoding, Forward Error Correction (FEC), and noise cancellation, e.g., as described in PCT application serial no. PCT/US2007/024225 titled “Active Signal Processing Personal Health Receivers,” and filed on Nov. 19, 2007; the disclosure of which is herein incorporated by reference.
  • coherent demodulation e.g., Costas loop demodulation
  • accurate low overhead iterative decoding e.g., Forward Error Correction (FEC)
  • FEC Forward Error Correction
  • noise cancellation e.g., as described in PCT application serial no. PCT/US2007/024225 titled “Active Signal Processing Personal Health Receivers,” and filed on Nov. 19, 2007; the disclosure of which is
  • receivers of interest include, but are not limited to, those described in: WO 2006/116718; 60/866,581; 60/945,251; 60/956,694, 60/887,780 and WO 2006/116718; the disclosures of which are herein incorporated by reference.
  • Various aspects include, for example, transmitting, via an in vivo transmitter, an encoded signal; facilitating, via a transbody functionality module, communication of the signal; and receiving, via a receiver, the encoded signal, as heretofore described.
  • the method provides characteristics of the encoded signal, wherein the characteristics optimize power consumption to facilitate the receiver in at least one of the following: spending maximum time in an inactive mode, waking up quickly, and waking up during a period of high probability that the transmitter is present.
  • beacon functionality such as facilitating, via a beacon functionality module, communication of the encoded signal; facilitating, via a frequency hopping functionality module, communication of the encoded signal; and facilitating, via a collision avoidance functionality module, communication of the encoded signal.
  • Some functionality may include, for example, providing beacon wakeup functionality; providing beacon signal functionality; generating a continuous wave, single frequency tone; providing a first frequency that is different from a data signal which is at a second frequency; and modulating the encoded signal.
  • various aspects may alternatively or optionally include steps related to frequency hopping generating random frequency hops on a narrow band transmitted signal.
  • various aspects may alternatively or optionally include steps related to collision avoidance such as transmitting, via a first in vivo transmitter and a second in vivo transmitter, at different frequencies; modulating a duty cycle; retransmitting randomly; and spreading across a frequency spectrum.
  • Modulating a duty cycle may include dithering the duty cycle and spreading among frequencies.
  • Transmitting at different frequencies may comprise providing multiple band pass filtering by different devices wherein respective signals associated with different frequencies are filtered by respective band pass fillers.
  • Various aspects may include an article, comprising, for example, a storage medium having instructions, that when executed by a computing platform, result in execution of a method of providing transbody communications employing communication channels.
  • the method may comprise various steps/combinations of steps such as transmitting, via an in vivo transmitter, an encoded signal; facilitating, via a transbody functionality module, communication of the signal; and receiving, via a receiver, the encoded signal.
  • steps such as transmitting, via an in vivo transmitter, an encoded signal; facilitating, via a transbody functionality module, communication of the signal; and receiving, via a receiver, the encoded signal.
  • the receivers are part of a body associated system or network of sensors, receivers, and optionally other devices, both internal and external, which provide a variety of different types of information that is ultimately collected and processed by a processor, such as an external processor, which then can provide contextual data about a patient as output.
  • a processor such as an external processor
  • sensor may be a member of an in-body network of devices which can provide an output that includes data about pill ingestion, one or more physiological sensed parameters, implantable device operation, etc., to an external collector of the data.
  • the external collector e.g., in the form of a health care network server, etc., of the data then combines this receiver provided data with additional relevant data about the patient, e.g., weight, weather, medical record data, etc., and may process this disparate data to provide highly specific and contextual patient specific data.
  • Systems of the subject invention include, in certain aspects, a receiver and one or more pharma-informatics enabled active agent containing compositions.
  • the pharma-informatics enabled pharmaceutical composition is an active agent-containing composition having an identifier stably associated therewith.
  • the compositions are disrupted upon administration to a subject.
  • the compositions are physically broken, e.g., dissolved, degraded, eroded, etc., following delivery to a body, e.g., via ingestion, injection, etc.
  • the compositions of these aspects are distinguished from devices that are configured to be ingested and survive transit through the gastrointestinal tract substantially, if not completely, intact.
  • the compositions include an identifier and an active agent/carrier component, where both of these components are present in a pharmaceutically acceptable vehicle.
  • the identifiers of the compositions may vary depending on the particular aspect and intended application of the composition so long as they are activated (i.e., turned on) upon contact with a target physiological location, e.g., stomach.
  • the identifier may be an identifier that emits a signal when it contacts a target body (i.e., physiological) site.
  • the identifier may be an identifier that emits a signal when interrogated after it has been activated.
  • the identifier may be any component or device that is capable of providing a detectable signal following activation, e.g., upon contact with the target site.
  • the identifier emits a signal once the composition comes into contact with a physiological target site, e.g., as summarized above.
  • a physiological target site e.g., as summarized above.
  • a patient may ingest a pill that, upon contact with the stomach fluids, generates a detectable signal.
  • compositions include an active agent/carrier component.
  • active agent/carrier component is meant a composition, which may be a solid or fluid (e.g., liquid), which has an amount of active agent, e.g., a dosage, present in a pharmaceutically acceptable carrier.
  • the active agent/carrier component may be referred to as a “dosage formulation.”
  • Active agent includes any compound or mixture of compounds which produces a physiological result, e.g., a beneficial or useful result, upon contact with a living organism, e.g., a mammal, such as a human. Active agents are distinguishable from such components as vehicles, carriers, diluents, lubricants, binders and other formulating aids, and encapsulating or otherwise protective components.
  • the active agent may be any molecule, as well as binding portion or fragment thereof, that is capable of modulating a biological process in a living subject.
  • the active agent may be a substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication.
  • the active agent may be a chemical substance, such as a narcotic or hallucinogen, which affects the central nervous system and causes changes in behavior.
  • the active agent i.e., drug
  • the target may be a number of different types of naturally occurring structures, where targets of interest include both intracellular and extracellular targets.
  • targets of interest include both intracellular and extracellular targets.
  • targets may be proteins, phospholipids, nucleic acids and the like, where proteins are of particular interest.
  • Specific proteinaceous targets of interest include, without limitation, enzymes, e.g. kinases, phosphatases, reductases, cyclooxygenases, proteases and the like, targets comprising domains involved in protein-protein interactions, such as the SH2, SH3, PTB and PDZ domains, structural proteins, e.g. actin, tubulin, etc., membrane receptors, immunoglobulins, e.g. IgE, cell adhesion receptors, such as integrins, etc, ion channels, transmembrane pumps, transcription factors, signaling proteins, and the like.
  • enzymes e.g. kinases, phosphata
  • the active agent may include one or more functional groups necessary for structural interaction with the target, e.g., groups necessary for hydrophobic, hydrophilic, electrostatic or even covalent interactions, depending on the particular drug and its intended target.
  • the drug moiety may include functional groups necessary for structural interaction with proteins, such as hydrogen bonding, hydrophobic-hydrophobic interactions, electrostatic interactions, etc., and may include at least an amine, amide, sulfhydryl, carbonyl, hydroxyl or carboxyl group, such as at least two of the functional chemical groups.
  • Drugs of interest may include cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
  • drug moieties are structures found among biomolecules, including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Such compounds may be screened to identify those of interest, where a variety of different screening protocols are known in the art.
  • the drugs may be derived from a naturally occurring or synthetic compound that may be obtained from a wide variety of sources, including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including the preparation of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
  • the drug may be obtained from a library of naturally occurring or synthetic molecules, including a library of compounds produced through combinatorial means, i.e., a compound diversity combinatorial library.
  • a library of compounds produced through combinatorial means i.e., a compound diversity combinatorial library.
  • the drug moiety employed will have demonstrated some desirable activity in an appropriate screening assay for the activity.
  • Combinatorial libraries, as well as methods for producing and screening such libraries, are known in the art and described in: U.S. Pat. Nos.
  • cardiovascular agents include, but are not limited to: cardiovascular agents; pain-relief agents, e.g., analgesics, anesthetics, anti-inflammatory agents, etc.; nerve-acting agents; chemotherapeutic (e.g., anti-neoplastic) agents; etc.
  • compositions of the invention further include a pharmaceutically acceptable vehicle (i.e., carrier).
  • a pharmaceutically acceptable vehicle i.e., carrier
  • Common carriers and excipients such as corn starch or gelatin, lactose, dextrose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid are of interest.
  • Disintegrators commonly used in the formulations of the invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
  • the systems include an external device which is distinct from the receiver (which may be implanted or topically applied in certain aspects), where this external device provides a number of functionalities.
  • an apparatus can include the capacity to provide feedback and appropriate clinical regulation to the patient.
  • Such a device can take any of a number of forms.
  • the device can be configured to sit on the bed next to the patient, e.g., a bedside monitor.
  • Other formats include, but are not limited to, PDAs, smart phones, home computers, etc.
  • the device can read out the information described in more detail in other sections of the subject patent application, both from pharmaceutical ingestion reporting and from physiological sensing devices, such as is produced internally by a pacemaker device or a dedicated implant for detection of the pill.
  • the purpose of the external apparatus is to get the data out of the patient and into an external device.
  • One feature of the external apparatus is its ability to provide pharmacologic and physiologic information in a form that can be transmitted through a transmission medium, such as a telephone line, to a remote location such as a clinician or to a central monitoring agency.
  • Systems of the invention enable a dynamic feedback and treatment loop of tracking medication timing and levels, measuring the response to therapy, and recommending altered dosing based on the physiology and molecular profiles of individual patients.
  • a symptomatic heart failure patient takes multiple drugs daily, primarily with the goal of reducing the heart's workload and improving patient quality of life.
  • Mainstays of therapy include angiotensin converting enzyme (ACE) inhibitors, ⁇ -blockers and diuretics.
  • ACE angiotensin converting enzyme
  • ⁇ -blockers ⁇ -blockers
  • diuretics diuretics
  • the systems of the invention may be employed to obtain an aggregate of information that includes sensor data and administration data.
  • an aggregate of information that includes sensor data and administration data.
  • a physiological index such as an activity index.
  • heart rate goes up a bit
  • respiration speeds up which may be employed as an indication that the person is being active. By calibrating this, the amount of calories the person is burning at that instant could be determined.
  • a particular rhythmic set of pulses or multi-axis acceleration data can indicate that a person is walking up a set of stairs, and from that one can infer how much energy they are using.
  • body fat measurement e.g. from impedance data
  • an activity index generated from a combination of measured biomarkers to generate a physiological index useful for management of a weight loss or cardiovascular health program.
  • This information can be combined with cardiac performance indicators to get a good picture of overall health, which can be combined with pharmaceutical therapy administration data.
  • a particular pharmaceutical correlates with a small increase in body temperature, or a change in the electrocardiogram.
  • the subject specific information that is collected using the systems of the invention may be transmitted to a location where it is combined with data from one or more additional individuals to provide a collection of data which is a composite of data collected from 2 or more, e.g., 5 or more, 10 or more, 25 or more, 50 or more, 100 or more, 1000 or more, etc., individuals.
  • the composite data can then be manipulated, e.g., categorized according to different criteria, and made available to one or more different types of groups, e.g., patient groups, health care practitioner groups, etc., where the manipulation of data may be such as to limit the access of any given group to the type of data that group can access.
  • data can be collected from 100 different individuals that are suffering from the same condition and taking the same medication.
  • the data can be processed and employed to develop easy to follow displays regarding patient compliance with a pharmaceutical dosage regimen and general health.
  • Patient members of the group can access this information and see how their compliance matches with other patient members of the group, and whether they are enjoying the benefits that others are experiencing.
  • doctors can also be granted access to a manipulation of the composite data to see how their patients are matching up with patients of other doctors, and obtain useful information on how real patients respond to a given therapeutic treatment regimen.
  • Additional functionalities can be provided to the groups given access to the composite data, where such functionalities may include, but are not limited to: ability to annotate data, chat functionalities, security privileges, etc.
  • the system further includes an element for storing data, i.e., a data storage element, where this element is present on an external device, such as a bedside monitor, PDA, smart phone, etc.
  • the data storage element is a computer readable medium.
  • computer readable medium refers to any storage or transmission medium that participates in providing instructions and/or data to a computer for execution and/or processing. Examples of storage media include floppy disks, magnetic tape, CD-ROM, a hard disk drive, a ROM or integrated circuit, a magneto-optical disk, or a computer readable card such as a PCMCIA card and the like, whether or not such devices are internal or external to the computer.
  • a file containing information may be “stored” on computer readable medium, where “storing” means recording information such that it is accessible and retrievable at a later date by a computer.
  • “permanent memory” refers to memory that is permanent. Permanent memory is not erased by termination of the electrical supply to a computer or processor. Computer hard-drive ROM (i.e. ROM not used as virtual memory), CD-ROM, floppy disk and DVD are all examples of permanent memory. Random Access Memory (RAM) is an example of non-permanent memory.
  • a file in permanent memory may be editable and re-writable.
  • the invention also provides computer executable instructions (i.e., programming) for performing the above methods.
  • the computer executable instructions are present on a computer readable medium. Accordingly, the invention provides a computer readable medium containing programming for use in detecting and processing a signal generated by a composition of the invention, e.g., as reviewed above.
  • the systems include one or more of: a data storage element, a data processing element, a data display element, data transmission element, a notification mechanism, and a user interface.
  • a data storage element e.g., a hard disk drive, a solid state drive, etc.
  • the above described systems are reviewed in terms of communication between an identifier on a pharmaceutical composition and a receiver.
  • the systems are not so limited.
  • the systems are composed of two or more different modules that communicate with each other, e.g., using the transmitter/receiver functionalities as reviewed above, e.g., using the monopole transmitter (e.g., antenna) structures as described above.
  • the above identifier elements may be incorporated into any of a plurality of different devices, e.g., to provide a communications system between two self-powered devices in the body, where the self-powered devices may be sensors, data receivers and storage elements, effectors, etc.
  • one of these devices may be a sensor and the other may be a communication hub for communication to the outside world.
  • This inventive aspect may take a number of forms. There can be many sensors, many senders and one receiver. They can be transceivers so both of these can take turns sending and receiving according to known communication protocols.
  • the means of communication between the two or more individual devices is the mono polar system, e.g., as described above.
  • each of these senders may be configured to take turns sending a high frequency signal into the body using a monopole pulling charge into and out of the body which is a large capacitor and a conductor.
  • the receiver a monopole receiver is detecting at that frequency the charge going into and out of the body and decoding an encrypted signal such as an amplitude modulated signal or frequency modulated signal.
  • This aspect of the present invention has broad uses. For example, multiple sensors can be placed and implanted on various parts of the body that measure position or acceleration. Without having wires connecting to a central hub, they can communicate that information through a communication medium.
  • an effective amount of a composition of the invention is administered to a subject in need of the active agent present in the composition, where “effective amount” means a dosage sufficient to produce the desired result, e.g. an improvement in a disease condition or the symptoms associated therewith, the accomplishment of a desired physiological change, etc.
  • the amount that is administered may also be viewed as a therapeutically effective amount.
  • a “therapeutically effective amount” means the amount that, when administered to a subject for treating a disease, is sufficient to effect treatment for that disease.
  • compositions may be administered to the subject using any convenient means capable of producing the desired result, where the administration route depends, at least in part, on the particular format of the composition, e.g., as reviewed above.
  • the compositions can be formatted into a variety of formulations for therapeutic administration, including but not limited to solid, semi solid or liquid, such as tablets, capsules, powders, granules, ointments, solutions, suppositories and injections.
  • administration of the compositions can be achieved in various ways, including, but not limited to: oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracheal, etc., administration.
  • a given composition may be administered alone or in combination with other pharmaceutically active compounds, e.g., which may also be compositions having signal generation elements stably associated therewith.
  • disease conditions include, but are not limited to: cardiovascular diseases, cellular proliferative diseases, such as neoplastic diseases, autoimmune diseases, hormonal abnormality diseases, infectious diseases, pain management, and the like.
  • treatment is meant at least an amelioration of the symptoms associated with the disease condition afflicting the subject, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the pathological condition being treated.
  • amelioration also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g. prevented from happening, or stopped, e.g. terminated, such that the subject no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition.
  • treating” or “treatment” of a disease includes preventing the disease from occurring in an animal that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease (prophylactic treatment), inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease).
  • a “disease” includes pain.
  • mammals or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In representative aspects, the subjects will be humans.
  • carnivore e.g., dogs and cats
  • rodentia e.g., mice, guinea pigs, and rats
  • primates e.g., humans, chimpanzees, and monkeys.
  • the subjects will be humans.
  • the subject methods are methods of managing a disease condition, e.g., over an extended period of time, such as 1 week or longer, 1 month or longer, 6 months or longer, 1 year or longer, 2 years or longer, 5 years or longer, etc.
  • the subject methods may be employed in conjunction with one or more additional disease management protocols, e.g., electrostimulation based protocols in cardiovascular disease management, such as pacing protocols, cardiac resynchronization protocols, etc; lifestyle, such a diet and/or exercise regimens for a variety of different disease conditions; etc.
  • the methods include modulating a therapeutic regimen based data obtained from the compositions.
  • data may be obtained which includes information about patient compliance with a prescribed therapeutic regimen.
  • This data with or without additional physiological data, e.g., obtained using one or more sensors, such as the sensor devices described above, may be employed, e.g., with appropriate decision tools as desired, to make determinations of whether a given treatment regimen should be maintained or modified in some way, e.g., by modification of a medication regimen and/or implant activity regimen.
  • methods of invention include methods in which a therapeutic regimen is modified based on signals obtained from the composition(s).
  • compositions include an active agent, an identifier element and a pharmaceutically acceptable carrier.
  • the identifier emits a signal in response to an interrogation
  • the identifier is interrogate, e.g., by a wand or other suitable interrogation device, to obtain a signal.
  • the obtained signal is then employed to determine historical information about the composition, e.g., source, chain of custody, etc.
  • the methods generally include obtaining the signal generation element of the composition, e.g., by retrieving it from a subject that has ingested the composition, and then determining the history of the composition from obtained signal generation element.
  • the signal generation element includes an engraved identifier, e.g., barcode or other type of identifier
  • the engraved identifier may be retrieved from a subject that has ingested the composition and then read to identify at least some aspect of the history of the composition, such as last known purchaser, additional purchasers in the chain of custody of the composition, manufacturer, handling history, etc.
  • this determining step may include accessing a database or analogous compilation of stored history for the composition.
  • Medical aspects of the present invention provide the clinician an important new tool in their therapeutic armamentarium: automatic detection and identification of pharmaceutical agents actually delivered into the body.
  • the applications of this new information device and system are multi-fold. Applications include, but are not limited to: (1) monitoring patient compliance with prescribed therapeutic regimens; (2) tailoring therapeutic regimens based on patient compliance; (3) monitoring patient compliance in clinical trials; (4) monitoring usage of controlled substances; and the like.
  • Kits may include one or more receivers of the invention, as described above.
  • the kits may include one or more dosage compositions, e.g., pharma-informatics enabled dosage compositions.
  • the dosage amount of the one or more pharmacological agents provided in a kit may be sufficient for a single application or for multiple applications. Accordingly, in certain aspects of the subject kits a single dosage amount of a pharmacological agent is present and in certain other aspects multiple dosage amounts of a pharmacological agent may be present in a kit.
  • pharmacological agent such may be packaged in a single container, e.g., a single tube, bottle, vial, and the like, or one or more dosage amounts may be individually packaged such that certain kits may have more than one container of a pharmacological agent.
  • Suitable means for delivering one or more pharmacological agents to a subject may also be provided in a subject kit.
  • the particular delivery means provided in a kit is dictated by the particular pharmacological agent employed, as describe above, e.g., the particular form of the agent such as whether the pharmacological agent is formulated into preparations in solid, semi solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols, and the like, and the particular mode of administration of the agent, e.g., whether oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracheal, etc. Accordingly, certain systems may include a suppository applicator, syringe, I.V. bag and tubing, electrode, etc.
  • kits may also include an external monitor device, e.g., as described above, which may provide for communication with a remote location, e.g., a doctor's office, a central facility etc., which obtains and processes data obtained about the usage of the composition.
  • a remote location e.g., a doctor's office, a central facility etc.
  • kits may include a smart parenteral delivery system that provides specific identification and detection of parenteral beneficial agents or beneficial agents taken into the body through other methods, for example, through the use of a syringe, inhaler, or other device that administers medicine, such as described in copending application Ser. No. 60/819,750; the disclosure of which is herein incorporated by reference.
  • the subject kits may also include instructions for how to practice the subject methods using the components of the kit.
  • the instructions may be recorded on a suitable recording medium or substrate.
  • the instructions may be printed on a substrate, such as paper or plastic, etc.
  • the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc.
  • the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc.
  • the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided.
  • An example of this aspect is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
  • kits may be packaged in suitable packaging to maintain sterility.
  • the components of the kit are packaged in a kit containment element to make a single, easily handled unit, where the kit containment element, e.g., box or analogous structure, may or may not be an airtight container, e.g., to further preserve the sterility of some or all of the components of the kit.

Abstract

Transbody communication systems employing communication channels are provided. Various aspects include, for example, an in vivo transmitter to transmit an encoded signal; a transbody functionality module to facilitate communication of the encoded signal; and a receiver to receive the encoded signal. Methods and apparatus are also provided.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • Pursuant to 35 U.S.C. § 119 (e), this application claims priority to the filing dates of the U.S. Provisional Patent Application Ser. Nos. 60/990,562 filed Nov. 27, 2007; 60/990,567 filed Nov. 27, 2007 and 60/990,572 filed Nov. 27, 2007; which applications are incorporated herein by reference for all purposes.
  • BACKGROUND
  • Communications play an important role in today's world. Transbody communications, for example, are finding increasing use in medical applications. The term “transbody communications” generally refers to transmission of a signal from an in vivo location to a receiver location, e.g., a second in vivo location, a receiver location extracorporeally associated with the body, etc.
  • Communications, however, may be susceptible to errors. In particular, noisy transmission environments may distort and corrupt communication data. The noisy transmission environments include the body. Additionally, communication devices may err in signal generation and measurement related to the communication data.
  • Further, various devices and combinations of devices may exact high power consumption, resulting in a relatively short life cycle for the devices inside the body. Such a short life cycle may result in replacement surgeries and other inconvenient, expensive, and/or high-risk procedures.
  • As such, there is a continued need for accurate communications and error-free data provided via long-lasting devices. Of particular interest is development of communications channels that may be readily deployed to reliably communicate information from an in vivo location to a receiver positioned in, or in close physical proximity to, a body.
  • SUMMARY
  • The system includes an in vivo transmitter to transmit an encoded signal; a transbody functionality module to facilitate communication of the encoded signal; and a receiver to receive the encoded signal to at least facilitate accurate transbody communications and conserve power consumption. The system may further include at least one of a beacon functionality module, a frequency hopping functionality module, and a collision avoidance functionality module. Related methods and apparatus are also provided.
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 illustrates a communication environment, including a transbody communication system having a transbody functionality module.
  • FIG. 2 illustrates the transbody functionality module of FIG. 1 in greater detail.
  • FIG. 3A illustrates a beacon wakeup module providing a sniff period longer than a transmit signal repetition period.
  • FIG. 3B illustrates a beacon wakeup module providing a short but frequent sniff period and a long transmit packet are provided.
  • FIG. 4A illustrates a resonant, narrow band analog circuit.
  • FIG. 4B illustrates classic power detection circuit.
  • FIG. 5 illustrates beacon functionality having a long period of a continuous wave tone.
  • FIG. 6 illustrates a beacon functionality wherein a beacon is associated with one frequency and a message is associated with another frequency.
  • FIG. 7 illustrates a beacon functionality associated with a two-beacon scheme.
  • FIG. 8 illustrates a beacon functionality associated with a beacon signal where frequency is a function of time.
  • FIG. 9 further illustrates a beacon functionality associated with a beacon signal where frequency is a function of time.
  • FIG. 10 illustrates a collision avoidance functionality having one collision avoidance technique.
  • FIGS. 11A-11D illustrate a collision avoidance functionality having another collision avoidance approach.
  • FIGS. 12A and 12B illustrate a collision avoidance functionality having a technique to detect a low amplitude signal in a noisy environment.
  • DETAILED DESCRIPTION
  • Transbody communication systems employing communication channels are provided. Various aspects facilitate accurate communications in noisy environments as well as provide enhanced power conservation features. More particularly, various aspects may be associated with transbody communication systems, e.g., an in vivo transmitter and a signal receiver (sometimes referred to herein as a “receiver”) associated with a body. The receiver may be configured to receive and decode a signal from the in vivo transmitter. Various aspects of the invention are characterized by employing a specific communication channel having transbody functionality, e.g., via a transbody functionality module. Related methods are also provided.
  • The invention may have broad applicability to medical and non-medical fields. The medical fields include, for example, transbody communications systems associated with various medical and therapeutic devices, e.g., cardiac devices, ingestible devices, etc. The non-medical fields include, for example, body associated devices such as gaming devices incorporating physiologic sensing functionality, etc.
  • FIG. 1 illustrates a communication environment 100, including a transbody communication system 102. The transbody communication system 102 comprises, for example, an in vivo transmitter 104, a transbody functionality module 106, and a receiver 108. In various aspects, the in vivo transmitter 104 transmits a signal, e.g., an encoded signal, via the transbody communication module 104 to the receiver 108, as hereinafter described in detail.
  • 1.0 In Vivo Transmitter
  • Implementations of the in vivo transmitter may vary widely. Generally, an in vivo transmitter 102 includes any in vivo device capable of transmitting a signal, e.g., an encoded signal.
  • In various aspects, the in vivo transmitter 102 may be associated with various devices, e.g., cardiac-related devices, ingestible devices, neural-stimulation related devices, medications, etc. The in vivo transmitter 102, for example, may be wholly or partially integrated with such a device, medication, etc.
  • One example of such a device is a pharma-informatics enabled pharmaceutical composition, described in PCT Application Serial No. US2006/016370. Another example is an ingestible event marker (IEM) and a personal receiver, described in U.S. Provisional Patent Application Ser. No. 60/949,223. Still another example is a smart parenteral device, described in PCT/US2007/15547. Yet another example is a smart implantable fluid transport device, described in U.S. Provisional Patent Application Ser. No. 60/989,078. Still further examples include implantable physiologic event recorders, described in U.S. Pat. Nos. 5,919,210, 5,989,352, 6,699,200, and 6,895,275; various systems and methods described in PCT application WO2006/116718. Still further examples include PCT application serial Nos. PCT/US2007/022257; PCT/US07/24225; PCT/US08/56296; PCT/US2008/56299 and PCT/US08/77753; and well as U.S. Provisional Application Nos. 61/034,085 and 61/105,346. Each of the foregoing is herein incorporated in its entirety by reference.
  • The signal transmitted by the device generally includes any signal, data, identifier, representative thereof, etc. Signals include encoded signals, e.g., encode at origin and decoded at destination. Examples of signals include an identifier of a pharmaceutical, a parenteral delivery device, an ingestible event marker, etc., supra.
  • 2.0 Transbody Functionality Module
  • The signal may be transmitted from the in vivo transmitter 104 via the transbody functionality module 106 to the receiver 108. The transbody functionality module 106 generally uses protocol(s), communication channels, etc., capable of facilitating accurate receipt of signals, data, etc. and/or facilitating low power consumption. Such transbody functionality modules 106 include beacon functionality frequency hopping functionality and collision avoidance functionality. Each of the foregoing is discussed in detail hereinafter.
  • In various aspects, the transbody functionality module 106, and/or one or a combination of its submodules (described hereinafter), may be implemented as software, e.g., digital signal processing software; hardware, e.g., a circuit; or combinations thereof.
  • Communication media for transmission may vary. In one aspect, the body of a patient may be employed as a conduction medium for the signal. As such, the signal is conducted between the in vivo transmitter and the receiver via body fluids, etc. in another aspect, the signal is transmitted via radio frequency (RF) transmission. One skilled in the art will recognize that other communication media are also possible.
  • FIG. 2 illustrates the transbody functionality module 106 of FIG. 1 in greater detail. In various aspects, the transbody functionality modules includes a beacon functionality module 200, a frequency hopping functionality module 202, and a collision avoidance functionality module 204.
  • 2.1 Beacon Functionality Module
  • Various aspects may employ the beacon functionality module 200. In various aspects, the beacon functionality module 200 may employ one or more of the following: a beacon wakeup module 200A, a beacon signal module 200B, a wave/frequency module 200C, a multiple frequency module 200D, and a modulated signal module 200E.
  • The beacon functionality module 200 may be associated with beacon communications, e.g., a beacon communication channel, a beacon protocol, etc. For the purpose of the present disclosure, beacons are typically signals sent either as part of a message or to augment a message (sometimes referred to herein as “beacon signals”). The beacons may have well-defined characteristics, such as frequency. Beacons may be detected readily in noisy environments and may be used for a trigger to a sniff circuit, such as those described above.
  • In one aspect, the beacon functionality module 200 may comprise the beacon wakeup module 200A, having wakeup functionality. Wakeup functionality generally comprises the functionality to operate in high power modes only during specific times, e.g., short periods for specific purposes, e.g., to receive a signal, etc. An important consideration on a receiver portion of a system is that it be of low power. This feature may be advantageous in an implanted receiver, to provide for both small size and to preserve a long-functioning electrical supply from a battery. The beacon wakeup module 200A may enable these advantages by having the receiver operate in a high power mode for very limited periods of time. Short duty cycles of this kind can provide optimal system size and energy draw features.
  • In practice, the receiver may “wake up” periodically, and at low energy consumption, to perform a “sniff function” via, for example, a sniff circuit. For the purpose of the present application, the term “sniff function” generally refers to a short, low-power function to determine if a transmitter is present. If a transmitter signal is detected by the sniff function, the device may transition to a higher power communication decode mode. If a transmitter signal is not present, the receiver may return, e.g., immediately return, to sleep mode. In this manner, energy is conserved during relatively long periods when a transmitter signal is not present, while high-power capabilities remain available for efficient decode mode operations during the relatively few periods when a transmit signal is present.
  • Several modes, and combination thereof, may be available for operating the sniff circuit. By matching the needs of a particular system to the sniff circuit configuration, an optimized system may be achieved.
  • FIG. 3A illustrates the beacon wakeup module 200A wherein a sniff period 300 is longer than a transmit signal repetition period 302. The time function is provided on the x axis. As shown, the transmit signal repeats periodically, with a sniff function also running. In practice, effectively, the sniff period 300 is typically longer than the transmit signal repetition period 302. In various aspects, there may be a relatively a long period of time between the sniff periods. In this way, the sniff function, e.g., implemented as a sniff circuit, is guaranteed to have at least one transmission to occur each time the sniff circuit is active.
  • FIG. 3B illustrates the beacon wakeup module 200A wherein a short but frequent sniff period 306 and a long transmit packet 308 are provided. The sniff circuit will activate at some point during the transmit time. In this manner, the sniff circuit may detect the transmit signal and switch into a high power decode mode.
  • An additional beacon wakeup aspect is to provide the “sniffing” function in a continuous mode. In contrast to the approaches provided above, this aspect of the transbody beacon transmission channel may exploit the fact that the total energy consumption is the product of average power consumption and time. In this aspect, the system may minimize the total energy consumption by having very short periods of activity, in which case the periods of activity are averaged down to a small number. Alternately, a low continuous sniff activity is provided. In this case, the configuration provides a sufficiently low power so that the transmission receiver runs continuously with a total energy consumption at an appropriate level for the parameters of a specific system.
  • The system may be passive. Two examples of circuit implementations are provided.
  • FIG. 4A illustrates a resonant, narrow band analog circuit 400, including input antenna 402, inductor 404, and capacitors 406. In various aspects, the resonant, narrow band analog circuit 400 may have a high impedance. An LC resonator may be provided that is tuned to the frequency of the transmitted signal. The voltage across the LC circuit may be measured, and run into a comparator. When the voltage measurement exceeds a certain value, a gate may be triggered. The circuitry goes then into a high power mode.
  • FIG. 4B shows a classic power detect circuit 408. The power detect circuit 408 may be of those known in the art, such as those used in an AM radio to give a light signal that indicates receipt of a radio signal. In one aspect, the power detect circuit 408 is an LC resonant circuit, i.e., a tank circuit. When a signal of the LC resonant frequency is present, the LC tank circuit ‘rings up’. Because the circuit has a high Q, its voltage increases dramatically. That voltage is rectified by the diode. When that voltage exceeds a threshold set by Vref, a comparator is triggered. The comparator informs the microprocessor that a signal/circuit is present and directs it to enter the high power mode.
  • Each of the above-described circuits may be very low powered and may comprise only passive components, with the exception of the comparator. The comparator may also be of very low power. Each circuit may operate continuously. Each circuit may inform the microprocessor when a transmitter is present, e.g., a signal is transmitted, to go into the high power mode. For each of these circuits, a useful prerequisite may be a well defined frequency for the transmitter.
  • A type of beacon signal associated with the present transbody communication channel is a continuous wave, single frequency tone. In such a case, the continuous single frequency tone triggers either of the circuits in FIG. 4A or 4B, when they are tuned to the correct frequency.
  • The beacon signal module 200B may provide for beacon signals to be detected digitally, as shown in FIG. 3A or 3B. This may be accomplished by sampling the beacon signals with an A->D converter. The beacon signals are put in a digital processing system. Beacon signals are detected by a single frequency tone which has a very strong characteristic.
  • Examples of such systems are provided in FIG. 5.
  • FIG. 5 illustrates beacon functionality having a long period of a continuous wave tone, e.g., via the wave/frequency module 200C. In one aspect, the beacon signal consists of a long period of the continuous wave tone. This continuous wave tone has both a modulated portion, which holds the information, and unmodulated portion. In this frequency domain, there is typically a period of well defined frequency. The modulation tends to smear the frequency spectrum. This portion of the wave tone serves as the beacon. It has a single tone in the frequency domain, and is easily recognizable in the spectrogram.
  • Either of the methods shown previously can detect the single frequency tone. This frequency tone alerts the processing circuitry that a message is coming. It then it moves into decode mode so that the message can be understood. In FIG. 5, this is shown as one packet.
  • FIG. 6 illustrates beacon functionality wherein a beacon is associated with one frequency, e.g., a beacon channel, and a message is associated with another frequency, e.g., a message channel. This configuration may be advantageous, for example, when the system is dealing with multiple transmit signals. The solid line represents the beacon from Transmit Signal 1. The dashed line represents the beacon from Transmit Signal 2. In various transmission situations, the Transmit Signal 2's beacon might overlap with that of Transmit Signal 1, as depicted.
  • Message Signal 1 and Message Signal 2 can be at different frequencies from their respective beacons. One advantage may be that the beacon from Transmit Signal 2 does not interfere with the message from Transmit Signal 1 at all, even though they are transmitted at the same time. By contrast, if an approach were taken in the example shown in FIG. 5, the beacon from the second transmit signal would most likely obscure the message from the first transmit signal.
  • In this case, the beacon channel is a well defined frequency band. A message is provided in the channel where the data are actually transmitted. Interference between different messages in the message channel can be handled through collision avoidance, described below. While FIG. 6 is shown with two transmitters, it will be apparent to one of ordinary skill in the art to modify the system so as to scale it to many more transmitters. The requirements of a particular system may, to some extent, dictate the particular architecture of that system.
  • FIG. 7 illustrates beacon functionality associated with a two-beacon scheme, e.g., Beacon 1 and Beacon 2. In this case, there is a well-defined mathematical relationship between the frequency of the beacon channel and the frequency of the message channel. If the beacon is a continuous wave signal, or a signal with a very simple modulation, it will be a simple matter to detect the carrier frequency of the beacon signal. In one case, for example, the beacon is at frequency 2 f, and the message is at frequency f, as shown in FIG. 7. In this case, the value of f can be determined from the beacon channel. As a result, if the message is to be demodulated, the frequency is known exactly.
  • This aspect may be used, inter alia, to address frequency uncertainty. This approach may provide a workable system for message channel modulations which do not have well defined carrier frequencies.
  • One example of such message channel modulations is spread spectrum modulations. An attempt to determine the frequency of a spread spectrum modulation in and by itself, can be difficult because there is not a well defined peak in the frequency spectrum. However, having the beacon channel accompanying the message channel with a well-defined mathematical relationship allows the message channel frequency to be determined precisely from the beacon channel. The message channel can then be demodulated based on that information.
  • The above description is of a beacon as a continuous single frequency tone. However, in another aspect, the beacon could have a simple modulation on it. An example of such an aspect is using on-off keying (OOK), or simple frequency modulation. In various aspects, of particular utility is a frequency key shifting (FSK) two tone beacon signal created by two different divide ratios of the master silicon oscillator. This may provide both a unique spectral signature and the frequency ratio of the two tones are invariant to the frequency drift of the silicon oscillator, e.g., an IEM silicon oscillator. The frequency ratio metric may provide a high probability that the signal detected is sourced by the preferred source device, e.g., the IEM. This approach gives the beacon a distinctive signature that is uniquely identifiable from other interferers. In this manner, the system does not risk confusing the beacon with other jammers from the environment. One key characteristic of the frequency is that it stands out as distinctive, and still has a well-defined mathematical relationship in terms of carrier frequency.
  • FIG. 8 illustrates beacon functionality associated with a beacon signal where frequency is a function of time. One problem that can occur with transmitters is that the carrier frequency is set by a silicon oscillator, and not by a crystal oscillator. This introduces a large uncertainty in characteristic frequency. Determination of that frequency may be a key challenge, both in terms of decoding the packet and detecting the beacon frequency.
  • The circuits provided in FIGS. 4A and 4B provide an example of this approach. If these circuits have high power (Q), the frequency uncertainty may cause the beacon to fall outside of the response function of the sniff circuits. Thus, as illustrated in FIGS. 8 and 9 another type of beacon may be employed. Frequency 700 is ramped over some range, providing a message. Two narrow band filters are provided. The signal is ramped from an fhigh to an flow. Two narrow band filters are tuned to f1 and f2, e.g., via the multiple frequency module 200D. Frequencies f1 and f2 fall between fhigh and flow.
  • The output of the filter at f1 shows no power, shows a blip in power as the beacon frequency is ramped through f1 at time t1, and then shows no power. Similarly, the output of the filter at f2 would show no power, show a blip in power as the beacon frequency is ramped through f2 at time t2, and then shows no power.
  • By building a timed-window comparator, an analog sniff circuit is employed which triggers on the time difference between t1 and t2. This can be implemented digitally or in an analog approach. In this case, when the circuit is set on time t1, if time t2 falls within some defined window t0, it indicates that a signal is present.
  • The ramp is a very distinctive signature. Frequency f1 firing will be detected, and (by example) 10 ms later, f2 firing is detected. If those two events happen within the defined time interval to, plus or minus t′, it indicates that a signal is present. The wakeup circuit is then triggered. The resulting design provides a very low power analog circuit. An important application of the circuit is to determine the frequency as shown in FIG. 8.
  • The beacon may be modulated to assure that its signature will be distinctive, e.g., via the modulated signal module 200E. One approach to this method is to have the beacon alternate between two frequencies. When this alternation is detected with the well-defined frequency difference and well-defined time period, the confidence level can be very high that a beacon had been detected, rather than some background signal. A similar result can be achieved with on-off keying, in a frequency modulation keying approach.
  • Any standard modulation technique can be applied to a beacon to give it a distinctive character. In various aspects, data may be imprinted on the beacon, to avoid it being confused with any other signal. In various aspects, the sniff circuit triggers only on the beacon.
  • There are multiple beacon approaches available to avoid interference. In the idea related to FIG. 6, if there are two beacons transmitting at the same time, transmitter 1 could have beacons at multiple frequencies, e.g., via multiple frequency module 200D, to avoid effects from interference. In a related approach, the aspect is simply to have beacons at different frequencies to avoid contention between the beacons.
  • In various aspects, a frequency ratio of a beacon and data channel is invariant to frequency error in the ingestible event marker system to provide additional assurance of detection of the encoded signal.
  • 2.2 Frequency Hopping Functionality Module
  • Various aspects may employ frequency hopping functionality module. The frequency hopping functionality module 202 may be associated with the specific communications channel(s), frequency hopping protocol, etc. As such, various aspects may utilize one or more frequency hopping protocols. For example, the receiver may search the designated range of frequencies in which the transmission could fall. When a single proper decode is achieved, the in vivo transmitter has accomplished its mission of communicating its digital information payload to the receiver.
  • The transmitted frequency uncertainty provided by random frequency hopping, e.g., via a random module 202A, may create multiple benefits. One such benefit, for example, may be easy implementation on a small die. To illustrate, the in vivo transmitter carrier frequency oscillator can be an inaccurate free running oscillator that is easily implemented on a small portion of a 1 mm die. Accuracies on the order of +/−20 are easily tolerated. This is because the receiver employs frequency searching algorithms.
  • Another such benefit may be extended battery life. To illustrate, over the course of the transmitter battery life, e.g., three to ten minutes, the probability of the transmitter transmitting on a clear channel that can be received by the frequency agile receiver may be significantly enhanced due to random frequency hopping.
  • Still another benefit may be minimized collision events in high volume environments. To illustrate, minimization of collision probability when multiple in vivo transmitters, e.g., ingestible event markers, are potentially transmitting simultaneously, such as in instances where the multiple ingestible event markers are ingested concurrently or in close temporal proximity. Stated differently, without frequency hopping functionality, there may be a high probability that ingestible event markers of a similar lot will transmit on the same (or nearly the same) frequency, resulting in multiple collisions.
  • In certain aspects, the useful frequency spectrum for use in volume conduction applications ranges from about 3 kHz to 150 kHz. Through detailed animal studies it has been observed that in some environments, the in vivo transmitter, supra, having a received signal level in the range of 1 to 100 μV may compete with narrow band interfering signals on the order of hundreds to thousands of μV in the same frequency spectrum. To mitigate the destructive nature of interfering signals, a frequency hopping channel or protocol may be employed in which the in vivo transmitter randomly frequency hops a narrow band transmitted signal, e.g., a modulated signal such as a binary phase shift keying (BPSK) signal or FSK signal, output on each transmission.
  • 2.3 Collision Avoidance Functionality Module
  • Various aspects may employ a collision avoidance functionality module. The collision avoidance functionality module may be associated with the specific communications channel(s), collision avoidance protocols, etc. As such, various aspects may utilize various collision avoidance protocol techniques associated with the specific communications channel(s). Collision avoidance techniques may be particularly useful, for example, in environments where two or more in vivo transmitters are present, e.g., where an individual ingests multiple IEMs. In such an environment, if the various in vivo transmitters send their signals continuously, the transmission of one may obscure the transmission from all the other in vivo transmitters. As a result, failure to detect signals may increase significantly.
  • Various aspects may include various collision avoidance approaches, alone or in various combinations.
  • One such approach employs multiple transmit frequencies. By using frequency-selective filtering, the transmitter broadcasting at f1 can be distinguished from the transmitter broadcasting at f2, even if they are transmitting simultaneously. An alternative to this approach is illustrated in FIG. 9.
  • FIG. 10 illustrates a first collision avoidance technique, e.g., via a transmitter module 204A, wherein Transmitter 1 is broadcasting on f1. Transmitter 2 is broadcasting on f2. A receiver and two band pass filters are provided, e.g., via multiple band pass filter module 204E. Band pass filter 1 is sensitive to f1, band pass filter 2 is sensitive to f2. Once signals from the transmitters, e.g., two IEMs associated with Pill 1 and Pill 2, respectively, get through their respective band pass filters, the signals go to demodulators. In various aspects, these demodulators can be implemented as separate analog circuits or in the digital domain. In this manner, collisions may be avoided.
  • FIGS. 11A-11D illustrate another collision avoidance approach. In various aspects, the specific communications channel(s) may employ duty cycle modulation, e.g., via a duty cycle modulation module 204B, wherein a transmitter need not transmit all the time. If two transmitters, e.g., xmtr1 and xmtr2, are not transmitting simultaneously, they will not interfere with each other. For example, If two transmitters are used which have low duty cycles, such as broadcasting 10% of the time and off 90% of the time, then probabilistically there is only a 20% chance that the signals will overlap with each other. In this manner, collisions may be avoided.
  • With reference to FIG. 11A, there a transmitter 1, e.g., xmtr1, that is only on 10% of the time. There is transmitter 2, e.g., xmtr2, that is also only on 10% of the time. Of course, there is some probability that they will transmit simultaneously. However, that probability can be controlled by changing the duty cycle and the frequency spread. As a result, if these two transmit periods are slightly different, they will come in and out of interference with each other. The overlap can be controlled, however, by dithering the duty cycle and the frequency spread, e.g., via dither module 204F and spread spectrum module 204D, respectively. In this manner, otherwise occurring collisions may be avoided.
  • With reference to FIG. 11B, dashed transmitter xmtr2 has a slightly shorter period than the solid transmitter xmtr1. Even though the transmitters begin broadcasting at the same time, after some number of transmissions, the transmitters come out of alignment with each other. As a result, they are now distinct from one another and otherwise occurring collisions may be avoided.
  • With reference to FIG. 11C, a similar effect can be obtained by having a spread of oscillator frequencies. In practice, the silicon oscillators used for these transmitters have a spread of a few percent in frequency. A 1% difference in frequency means that after a 100 transmissions, two oscillators 1008, 1010 that began in phase with each other are no longer in phase with each other. Various aspects may be based on frequency distribution or the frequencies can also be programmed to be explicitly different, e.g., to have some range of periods. Noise dithering a voltage controlled oscillator frequency can also create this frequency spread.
  • With respect to FIG. 11D, the retry period is randomized. In this example, xmtr1 broadcasts and then waits some random period of time before broadcasting again. The xmtr1 then waits another random period of time before broadcasting again, and so forth. Xmtr2 begins broadcasting at the same time. However, in this case it waits a random time before the next transmission, and waits another random time before the next transmission and so forth. In this way, the probability that two transmitters broadcast simultaneously can be controlled by affecting the standard deviation of the retry periods.
  • This approach can be based on a pseudo-random sequence that is preprogrammed into the chip. It can also be based on a real physical random number generator (thermal noise), or on the serial number on the chip. Since every transmitter has a unique serial number, some of the lower bits of the serial number can be used to program this randomization time, either directly or by using a linear shift register.
  • Additional aspects of the transbody transmission channel use spread spectrum transmission to modulate the transmit message. This approach can be direct spread spectrum or frequency hopping spread spectrum. As an example, any of the code division multiple access (CDMA) techniques developed for cell phones that allow for multitudes of cell phones to broadcast on the same frequency without interference can be employed in this aspect. This aspect can also be based on any of the well known codes in spread spectrum, such as Gold Codes or Kasami codes.
  • The challenge to be addressed is approached probabilistically. A code is selected such that there are sufficiently many that the probability of two transmitters having the same code broadcasting at the same time is sufficiently small. This approach ties into the idea of using a beacon to find the carrier frequency because spread spectrum transmissions in general do not have a well defined carrier frequency. That information is determined, such as from the beacon.
  • In certain applications, it is useful to combine the different techniques. By example, when there is a long duty cycle, spread spectrum transmission can be particularly valuable. In this case, the probability of a collision happening is the probability of the long duty cycle times the probability of the spread spectrum. There are no restrictions on combining techniques.
  • In calculations, it is shown that duty cycle works very well for two or three transmitters operating simultaneously. However, in regards to certain applications, the duty cycle method breaks down when there are more than five transmitters providing data in an overlapping time frame.
  • The most straightforward method to bolster the duty cycle is to add retransmit randomization, e.g., via retransmit randomization module 204C. By adding a few bits of retransmit randomization, the effect is immediately rendered much less pronounced. In this aspect, the system can easily distinguish five to ten simultaneous transmissions.
  • To get beyond ten transmissions, spread spectrum is one approach of interest. As systems go to many simultaneous transmitters, even if one has a short duty cycle, the total time that multiple transmitters are transmitting becomes a significant portion of the time and collisions become unavoidable.
  • In systems requiring only a few transmitters, system design can rely on using simpler approaches, such as long duty cycles. Multiple transmit frequencies may be employed in a controlled environment when the frequencies of the transmitters are known. For three to ten transmitters, retransmit randomization works well. Beyond ten transmitters, spread spectrum is one approach that may be employed, and it can combine spread spectrum with other techniques.
  • Plots on long duty cycle show with three simultaneous transmitters there is about a 1% chance of a transmitter not being detected because of a collision. This is during a one minute transmit interval. One important feature of some transmitters systems is that the transmitters have a finite lifetime. In systems where transmitters have very long lifetimes, these concerns may be absent.
  • For other kinds of implanted sensors, these are still very important considerations for power consumption. If the system must wait an hour before a window clear enough to transmit a signal is available, then the transmitter is using power all that time.
  • Another possibility opens up when systems have more sophisticated transmitters. The transmitter can listen for a quiet channel, for example, waiting until it hears nothing transmitting and then transmit.
  • The spread spectrum approach is quantifiable, depending on how many distinct codes are used. When the Kasami set of codes are used there are 32,000 distinct codes. In this case the probability of having two transmitters transmit on the same code is 1/(32,000)2. That probability goes up geometrically with the number of transmitters. Even doing nothing to select transmitters that have distinct codes, and relying on the randomization of code selection, it supports tens, if not hundreds, of transmitters.
  • In certain aspects, receivers of the system are configured to selectively receive a signal in a quiet part of a given spectrum. FIG. 12A shows an aspect addressing the problem of detecting a low amplitude signal in a noisy environment. One approach to that problem is to find a quiet place in the noise spectrum. The detector of the receiver is programmed to that frequency band. The transmitter periodically broadcasts in that frequency band.
  • FIGS. 12A and 12B illustrate a technique to detect a low amplitude signal in a noisy environment. With reference to FIG. 12A, in the case where the receiver surveys the noise spectrum, power is a function of frequency. There is a noisy region, quiet region, followed by a noisy region. The broadcast is provided in the quiet region because the least amount of interference is in that region.
  • In FIG. 12B, the transmission occurs at multiple different frequencies, e.g., a ramping scheme. In various aspects, other schemes may be used such as frequency hopping or random scheme. Typically, the chosen scheme will densely covers the frequency band of interest. In practice, the transmitter will eventually jump into the quiet band and eventually transmit in the quiet band. By having the receiver listen only in that quiet band, there is a good chance of receiving/decoding that signal due to the excellent signal to noise ratio (SNR.
  • The above configuration in which the receiver is employed to receive only a quiet band is not limited to systems having a collision avoidance channel, as described elsewhere in this application. Instead, receivers as described in any of the following applications may be configured to receive only a quiet channel: PCT application serial no. US2007/024225 titled “Active Signal Processing Personal Health Signal Receivers,” and filed on Nov. 19, 2007; WO 2006/116718; 60/866,581; 60/945,251; 60/956,694, 60/887,780 and 2006/116718; the disclosures of which applications are herein incorporated by reference.
  • To illustrate some of the foregoing concepts, in one aspect transmissions are broken into two channels. The first channel is used to broadcast the data. A one to two percent duty cycle is performed. Immunity to collisions is enhanced by randomizing the re-broadcast rate. The second channel is used to broadcast a wakeup beacon. A one to two percent duty cycle is performed. The packet rate is in the 10 mSec range. The beacon transmissions are short, in the range of 100 to 200 uSec, when collisions are not of concern. The beacon and data channel carriers are generated from the same oscillator, so from the beacon the data carrier can be calculated. The receiver will turn on every 10 to 30 seconds for a 10 mSec duration. If a beacon is observed, the receiver will stay on to perform a full demodulation and decode. Otherwise, the receiver will return to sleep.
  • In certain aspects, the above system is modified to include a frequency dither to the packet interval dither.
  • In certain aspects, the above system is modified to include a longer duration transmission of 16 carrier cycles at 25 kHz (640 uS) with a 1 to 2 percent duty cycle. This complies with narrow band filter compatibility.
  • In certain aspects, the above system is modified to so that the modulation as BPSK on OOK on the lower channel.
  • In certain aspects, the above system is modified so that the modulation as OOK burst on the higher beacon channel.
  • In certain aspects, the above system is modified so that the use of simple multidimensional parity check codes for FEC (forward error correction).
  • 3.0 Receiver
  • The signal receiver, sometimes referred to herein as the “receiver”, generally includes any device or component capable of receiving the signal, e.g., conductively receiving a signal via one or more specific communication channels.
  • One example of such a receiver is the personal receiver, supra. Another example of the receiver described in the in: PCT application serial no. PCT/US2006/016370 published as WO 2006/116718; PCT application serial No. PCT/2007/24225 published as WO 2008/063626; PCT application serial no. PCT/US2008/52845 published as US2008/052845; the disclosures of which applications are herein incorporated by reference.
  • Various aspects include mobile configurations of the receiver that are sized to be stably associated with a living subject in a manner that does not substantially impact movement of said living subject. In certain aspects, the receiver has a small size. To illustrate, the receiver may occupy a volume of space of about five cm3 or fewer, such as about three cm3 or fewer, including about one cm3 or less. In certain aspects, the receiver has a chip size approximately ranging from ten mm2 to two cm2.
  • The receivers of interest may include both external and implantable receivers.
  • 3.1 External Receivers
  • In external aspects, the receiver may be ex vivo, i.e., present outside of the body during use. External receiver may be configured in any convenient manner. For example, in certain aspects the externals receivers may be configured to be associated with a desirable skin location. As such, in aspects the external receivers may be configured to contact a topical skin location of a subject. Configurations of interest include, but are not limited to: patches, wrist bands, belts, etc. For instance, a watch or belt worn externally and equipped with suitable receiving electrodes can be used as receivers in accordance with one aspect of the present invention. The receivers may provide a further communication path via which collected data can be extracted by a patient or health care practitioner. For instance, an implanted collector may include conventional RF circuitry operating, e.g., in the 405-MHz medical device band, with which a practitioner can communicate. The practitioner may communicate, for example, via a data retrieval device, such as a wand, etc.
  • Where the receiver includes an external component, that component may have output devices for providing data, e.g., audio and/or visual feedback. Examples include audible alarms, LEDs, display screens, or the like. The external component may also include an interface port via which the component can be connected to a computer for reading out data stored therein. By further example, the device may be positioned by a harness that is worn outside the body and has one or more electrodes that attach to the skin at different locations.
  • In certain external aspects, the receiver may be configured to be in contact with or associated with a patient only temporarily, i.e., transiently. For example, the receiver may be associated/attached/in contact while the pill, ingestible event marker, etc., is actually being ingested.
  • To illustrate, the receiver may be configured as an external device having two finger electrodes or handgrips. Upon ingestion of a pharma-informatics enabled pill, the patient touches the electrodes or grabs the handgrips to complete a conductive circuit with the receiver. Upon emission of the signal from the pill, e.g., when the pill dissolves in the stomach, the signal emitted by the identifier of the pill is picked up by the receiver.
  • In certain aspects, the external receiver may include miniaturized electronics which are integrated with the electrodes to form a bandage-style patch with electrodes that, when applied, contact the skin. The bandage-style may be removably attachable, e.g., via an adhesive layer or other construction. A battery and electronics may also be included. The bandage-style patch may be configured to be positioned on a desirable target skin site of the subject, e.g., on the chest, back, side of the torso, etc. In these aspects, the bandage circuitry may be configured to receive signals from devices inside of the subject, e.g., from an identifier of a pharma-informatics enabled pharmaceutical composition, and then relay this information to an external processing device, e.g., a PDA, smartphone, mobile phone, handheld device, computer, etc., as described in greater detail elsewhere. Bandage-style devices that may be readily adapted for use in the present systems include, but are not limited to, those described in U.S. Pat. No. 6,315,719 and the like, the disclosures of which are herein incorporated by reference.
  • 3.2 Implantable Receivers
  • In certain aspects, the receiver may be an implantable, i.e., designed and/or configured for implantation into a subject. Implantation may be on a temporary basis or a permanent basis. In these aspects, the receiver is in vivo during use. Generally, implantable receivers may maintain functionality when present in a physiological environment, including a high salt, high humidity environment found inside of a body, for various periods of time. Periods of time, for example, include a few minutes to eighty years. More specific time periods include, for example, one or more hours, one or more days, one or more weeks, one or more months, and one or more years.
  • For implantable aspects, the receiver may have any convenient shape, including but not limited to: capsule-shaped, disc-shaped, etc. Various receivers may have relatively small sizes. These small sizes may be achieved, for example, by incorporation of a rechargeable battery. In one aspect, the rechargeable battery has a life span of about two weeks. In another aspect, the rechargeable battery automatically charges from various sources, e.g., coils in the patient's bed. The receiver may be configured to be placed in a number of different locations. Examples of locations include the abdomen, the small of the back, the shoulder, e.g., where implantable pulse generators are placed, etc.
  • In certain implantable aspects, the receiver is a standalone device, i.e., not physically connected to any other type of implantable device. In yet other aspects, the receiver may be physically coupled to a second implantable device, e.g., a device which serves as a platform for one or more physiological sensors. Such a device may be a lead, such as a cardiovascular lead. To illustrate, the cardiovascular lead may include one or more distinct physiological sensors, e.g., where the lead is a multi-sensor lead (MSL). Implantable devices of interest further include, but are not limited to: implantable pulse generators, neurostimulator devices, implantable loop recorders, etc.
  • Receivers may further include a receiver element which serves to receive the signal of interest. The receiver may include a variety of different types of receiver elements, where the nature of the receiver element necessarily varies depending on the nature of the signal produced by the signal generation element. In certain aspects, the receiver may include one or more electrodes for detecting signal emitted by the signal generation element. To illustrate, the receiver device may be provided with two electrodes that are dispersed at a predetermined distance. The predetermined distance may allow the electrodes to detect a differential voltage. The distance may vary, and in certain aspects, ranges from about 0.1 to about five cm, such as from about 0.5 to about 2.5 cm, e.g., about one cm. In certain aspects, the first electrode is in contact with an electrically conductive body element, e.g., blood, and the second electrode is in contact with an electrically insulative body element relative to said conductive body element, e.g., adipose tissue (fat). In an alternative aspect, a receiver that utilizes a single electrode is employed. In certain aspects, the signal detection component may include one or more coils for detecting a signal emitted by the signal generation element. In certain aspects, the signal detection component includes an acoustic detection element for detecting signal emitted by the signal generation element.
  • A receiver may handle received data in various ways. In some aspects, the receiver simply retransmits the data to an external device, e.g., via conventional RF communication. In other aspects, the receiver processes the received data to determine whether to take some action such as operating an effector that is under its control, activating a visible or audible alarm, transmitting a control signal to an effector located elsewhere in the body, or the like. In still other aspects, the receiver stores the received data for subsequent retransmission to another device or for use in processing of subsequent data, e.g., detecting a change in some parameter over time. The receivers may perform any combination of these and/or other operations using received data.
  • In certain aspects, the data that are recorded on the data storage element include at least one of, if not all of, time, date, and an identifier, e.g., global unique serial number, of each composition administered to a patient. The identifier may be the common name of the composition or a coded version thereof. The data recorded on the data storage element of the receiver may further include medical record information of the subject with which the receiver is associated, e.g., identifying information, such as but not limited to name, age, treatment record, etc. In certain aspects, the data of interest include hemodynamic measurements. In certain aspects, the data of interest include cardiac tissue properties. In certain aspects, the data of interest include various physiologic metrics or parameters, e.g., pressure or volume measurements, temperature, activity, respiration rate, pH, etc.
  • As summarized above, the receivers can be configured to have a very small size. In certain aspects, the desired functionality of the receiver is achieved with one or more integrated circuits and a battery. Aspects of the invention include receivers that have at least a receiver element, e.g., the form of one or more electrodes (such as two spaced apart electrodes) and a power generation element, e.g., a battery, where the battery may be rechargeable, etc., as mentioned above. As such, in certain aspects the power generation element is converted to receive power wirelessly from an external location.
  • Additional elements that may be present in the receiver include, but are not limited to: a signal demodulator, e.g., for decoding the signal emitted from the pharma-informatics enabled identifier; a signal transmitter, e.g., for sending a signal from the receiver to an external location; a data storage element, e.g., for storing data regarding a received signal, physiological parameter data, medical record data, etc.; a clock element, e.g., for associating a specific time with an event, such as receipt of a signal; a pre-amplifier; a microprocessor, e.g., for coordinating one or more of the different functionalities of the receiver.
  • Aspects of implantable versions of the receiver will have a biologically compatible enclosure, two or more sense electrodes, a power source, which could either be a primary cell or rechargeable battery, or one that is powered by broadcast inductively to a coil. The receiver may also have circuitry consisting of: a demodulator to decode the transmitted signal, some storage to record events, a clock, and a way to transmit outside the body. The clock and transmit functionality may, in certain aspects, be omitted. The transmitter could be an RF link or conductive link to move information from local data storage to external data storage.
  • For the external receivers, aspects include structures that have electrodes opposed to the skin, the demodulator, storage, and power. The communication may be wireless or performed over one or more conductive media, e.g., wires, optical fibers, etc.
  • In certain aspects, the same electrodes are used for receiving and transmitting signals. One mode may be a wristwatch which is conductively in contact with the body. To move the data from the implant to the wristwatch, currents may be sent out the pads and received by the wristwatch. There are a number of RF techniques for facilitating transmission out of the body that may be employed, such as inductive protocols that use coils. Alternatively, electric fields may be employed, using insulated electrodes, for example.
  • In certain aspects, the components or functional blocks of the present receivers are present on integrated circuits, where the integrated circuits include a number of distinct functional blocks, i.e., modules. Within a given receiver, at least some of, e.g., two or more, up to an including all of, the functional blocks may be present in a single integrated circuit in the receiver. By single integrated circuit is meant a single circuit structure that includes all of the different functional blocks. As such, the integrated circuit is a monolithic integrated circuit (also known as IC, microcircuit, microchip, silicon chip, computer chip or chip) that is a miniaturized electronic circuit (which may include semiconductor devices, as well as passive components) that has been manufactured in the surface of a thin substrate of semiconductor material. The integrated circuits of certain aspects of the present invention may be hybrid integrated circuits, which are miniaturized electronic circuits constructed of individual semiconductor devices, as well as passive components, bonded to a substrate or circuit board.
  • As reviewed above, the receivers exhibit reliable decoding of an encoded signal even in the presence of substantial noise and a low SNR. This functional aspect of the receivers of the invention may be provided via various schemes. Some such schemes include, for example, coherent demodulation, e.g., Costas loop demodulation, accurate low overhead iterative decoding, Forward Error Correction (FEC), and noise cancellation, e.g., as described in PCT application serial no. PCT/US2007/024225 titled “Active Signal Processing Personal Health Receivers,” and filed on Nov. 19, 2007; the disclosure of which is herein incorporated by reference. Other receivers of interest include, but are not limited to, those described in: WO 2006/116718; 60/866,581; 60/945,251; 60/956,694, 60/887,780 and WO 2006/116718; the disclosures of which are herein incorporated by reference.
  • Methods
  • Various aspects include, for example, transmitting, via an in vivo transmitter, an encoded signal; facilitating, via a transbody functionality module, communication of the signal; and receiving, via a receiver, the encoded signal, as heretofore described.
  • In one aspect, the method provides characteristics of the encoded signal, wherein the characteristics optimize power consumption to facilitate the receiver in at least one of the following: spending maximum time in an inactive mode, waking up quickly, and waking up during a period of high probability that the transmitter is present.
  • Further, various aspects may alternatively or optionally include such steps related to beacon functionality such as facilitating, via a beacon functionality module, communication of the encoded signal; facilitating, via a frequency hopping functionality module, communication of the encoded signal; and facilitating, via a collision avoidance functionality module, communication of the encoded signal. Some functionality may include, for example, providing beacon wakeup functionality; providing beacon signal functionality; generating a continuous wave, single frequency tone; providing a first frequency that is different from a data signal which is at a second frequency; and modulating the encoded signal.
  • Still further, various aspects may alternatively or optionally include steps related to frequency hopping generating random frequency hops on a narrow band transmitted signal.
  • Further yet, various aspects may alternatively or optionally include steps related to collision avoidance such as transmitting, via a first in vivo transmitter and a second in vivo transmitter, at different frequencies; modulating a duty cycle; retransmitting randomly; and spreading across a frequency spectrum. Modulating a duty cycle may include dithering the duty cycle and spreading among frequencies. Transmitting at different frequencies may comprise providing multiple band pass filtering by different devices wherein respective signals associated with different frequencies are filtered by respective band pass fillers.
  • Articles
  • Various aspects may include an article, comprising, for example, a storage medium having instructions, that when executed by a computing platform, result in execution of a method of providing transbody communications employing communication channels. The method, for example, may comprise various steps/combinations of steps such as transmitting, via an in vivo transmitter, an encoded signal; facilitating, via a transbody functionality module, communication of the signal; and receiving, via a receiver, the encoded signal. Various other steps are illustrated heretofore.
  • Additional System Aspects
  • In certain aspects, the receivers are part of a body associated system or network of sensors, receivers, and optionally other devices, both internal and external, which provide a variety of different types of information that is ultimately collected and processed by a processor, such as an external processor, which then can provide contextual data about a patient as output. For example that sensor may be a member of an in-body network of devices which can provide an output that includes data about pill ingestion, one or more physiological sensed parameters, implantable device operation, etc., to an external collector of the data. The external collector, e.g., in the form of a health care network server, etc., of the data then combines this receiver provided data with additional relevant data about the patient, e.g., weight, weather, medical record data, etc., and may process this disparate data to provide highly specific and contextual patient specific data.
  • Systems of the subject invention include, in certain aspects, a receiver and one or more pharma-informatics enabled active agent containing compositions. The pharma-informatics enabled pharmaceutical composition is an active agent-containing composition having an identifier stably associated therewith. In certain aspects, the compositions are disrupted upon administration to a subject. As such, in certain aspects, the compositions are physically broken, e.g., dissolved, degraded, eroded, etc., following delivery to a body, e.g., via ingestion, injection, etc. The compositions of these aspects are distinguished from devices that are configured to be ingested and survive transit through the gastrointestinal tract substantially, if not completely, intact. The compositions include an identifier and an active agent/carrier component, where both of these components are present in a pharmaceutically acceptable vehicle.
  • The identifiers of the compositions may vary depending on the particular aspect and intended application of the composition so long as they are activated (i.e., turned on) upon contact with a target physiological location, e.g., stomach. As such, the identifier may be an identifier that emits a signal when it contacts a target body (i.e., physiological) site. In addition or alternatively, the identifier may be an identifier that emits a signal when interrogated after it has been activated. The identifier may be any component or device that is capable of providing a detectable signal following activation, e.g., upon contact with the target site. In certain aspects, the identifier emits a signal once the composition comes into contact with a physiological target site, e.g., as summarized above. For example, a patient may ingest a pill that, upon contact with the stomach fluids, generates a detectable signal.
  • The compositions include an active agent/carrier component. By “active agent/carrier component” is meant a composition, which may be a solid or fluid (e.g., liquid), which has an amount of active agent, e.g., a dosage, present in a pharmaceutically acceptable carrier. The active agent/carrier component may be referred to as a “dosage formulation.”
  • “Active agent” includes any compound or mixture of compounds which produces a physiological result, e.g., a beneficial or useful result, upon contact with a living organism, e.g., a mammal, such as a human. Active agents are distinguishable from such components as vehicles, carriers, diluents, lubricants, binders and other formulating aids, and encapsulating or otherwise protective components. The active agent may be any molecule, as well as binding portion or fragment thereof, that is capable of modulating a biological process in a living subject. In certain aspects, the active agent may be a substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication. In certain aspects, the active agent may be a chemical substance, such as a narcotic or hallucinogen, which affects the central nervous system and causes changes in behavior.
  • The active agent (i.e., drug) is capable of interacting with a target in a living subject. The target may be a number of different types of naturally occurring structures, where targets of interest include both intracellular and extracellular targets. Such targets may be proteins, phospholipids, nucleic acids and the like, where proteins are of particular interest. Specific proteinaceous targets of interest include, without limitation, enzymes, e.g. kinases, phosphatases, reductases, cyclooxygenases, proteases and the like, targets comprising domains involved in protein-protein interactions, such as the SH2, SH3, PTB and PDZ domains, structural proteins, e.g. actin, tubulin, etc., membrane receptors, immunoglobulins, e.g. IgE, cell adhesion receptors, such as integrins, etc, ion channels, transmembrane pumps, transcription factors, signaling proteins, and the like.
  • The active agent (i.e., drug) may include one or more functional groups necessary for structural interaction with the target, e.g., groups necessary for hydrophobic, hydrophilic, electrostatic or even covalent interactions, depending on the particular drug and its intended target. Where the target is a protein, the drug moiety may include functional groups necessary for structural interaction with proteins, such as hydrogen bonding, hydrophobic-hydrophobic interactions, electrostatic interactions, etc., and may include at least an amine, amide, sulfhydryl, carbonyl, hydroxyl or carboxyl group, such as at least two of the functional chemical groups.
  • Drugs of interest may include cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Also of interest as drug moieties are structures found among biomolecules, including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Such compounds may be screened to identify those of interest, where a variety of different screening protocols are known in the art.
  • The drugs may be derived from a naturally occurring or synthetic compound that may be obtained from a wide variety of sources, including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including the preparation of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
  • As such, the drug may be obtained from a library of naturally occurring or synthetic molecules, including a library of compounds produced through combinatorial means, i.e., a compound diversity combinatorial library. When obtained from such libraries, the drug moiety employed will have demonstrated some desirable activity in an appropriate screening assay for the activity. Combinatorial libraries, as well as methods for producing and screening such libraries, are known in the art and described in: U.S. Pat. Nos. 5,741,713; 5,734,018; 5,731,423; 5,721,099; 5,708,153; 5,698,673; 5,688,997; 5,688,696; 5,684,711; 5,641,862; 5,639,603; 5,593,853; 5,574,656; 5,571,698; 5,565,324; 5,549,974; 5,545,568; 5,541,061; 5,525,735; 5,463,564; 5,440,016; 5,438,119; 5,223,409, the disclosures of which are herein incorporated by reference.
  • Broad categories of active agents of interest include, but are not limited to: cardiovascular agents; pain-relief agents, e.g., analgesics, anesthetics, anti-inflammatory agents, etc.; nerve-acting agents; chemotherapeutic (e.g., anti-neoplastic) agents; etc.
  • As summarized above, the compositions of the invention further include a pharmaceutically acceptable vehicle (i.e., carrier). Common carriers and excipients, such as corn starch or gelatin, lactose, dextrose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid are of interest. Disintegrators commonly used in the formulations of the invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
  • Further details about aspects of pharma-informatics enabled pharmaceutical compositions may be found in pending PCT application PCT/US2006/16370 titled “Pharma-Informatics System” and filed on Apr. 28, 2006; as well as U.S. Provisional Application Ser. Nos. 60/807,060 titled “Acoustic Pharma-Informatics System” filed on Jul. 11, 2006; 60/862,925 titled “Controlled Activation Pharma-Informatics System,” filed on Oct. 25, 2006; and 60/866,581 titled “In-Vivo Transmission Decoder,” filed on Nov. 21, 2006; the disclosures of which are herein incorporated by reference.
  • In certain aspects the systems include an external device which is distinct from the receiver (which may be implanted or topically applied in certain aspects), where this external device provides a number of functionalities. Such an apparatus can include the capacity to provide feedback and appropriate clinical regulation to the patient. Such a device can take any of a number of forms. By example, the device can be configured to sit on the bed next to the patient, e.g., a bedside monitor. Other formats include, but are not limited to, PDAs, smart phones, home computers, etc. The device can read out the information described in more detail in other sections of the subject patent application, both from pharmaceutical ingestion reporting and from physiological sensing devices, such as is produced internally by a pacemaker device or a dedicated implant for detection of the pill. The purpose of the external apparatus is to get the data out of the patient and into an external device. One feature of the external apparatus is its ability to provide pharmacologic and physiologic information in a form that can be transmitted through a transmission medium, such as a telephone line, to a remote location such as a clinician or to a central monitoring agency.
  • Systems of the invention enable a dynamic feedback and treatment loop of tracking medication timing and levels, measuring the response to therapy, and recommending altered dosing based on the physiology and molecular profiles of individual patients. For example, a symptomatic heart failure patient takes multiple drugs daily, primarily with the goal of reducing the heart's workload and improving patient quality of life. Mainstays of therapy include angiotensin converting enzyme (ACE) inhibitors, β-blockers and diuretics. For pharmaceutical therapy to be effective, it is vital that patients adhere to their prescribed regimen, taking the required dose at the appropriate time. Multiple studies in the clinical literature demonstrate that more than 50% of Class II and III heart failure patients are not receiving guideline-recommended therapy, and, of those who are titrated appropriately, only 40-60% adhere to the regimen. With the subject systems, heart failure patients can be monitored for patient adherence to therapy, and adherence performance can be linked to key physiologic measurements, to facilitate the optimization of therapy by physicians.
  • In certain aspects, the systems of the invention may be employed to obtain an aggregate of information that includes sensor data and administration data. For example, one can combine the heart rate, the respiration rate, multi-axis acceleration data, something about the fluid status, and something about temperature, and derive indices that will inform about the total activity of the subject, that can be used to generate a physiological index, such as an activity index. For instance, when there is a rise in temperature, heart rate goes up a bit, and respiration speeds up, which may be employed as an indication that the person is being active. By calibrating this, the amount of calories the person is burning at that instant could be determined. In another example, a particular rhythmic set of pulses or multi-axis acceleration data can indicate that a person is walking up a set of stairs, and from that one can infer how much energy they are using. In another aspect, body fat measurement (e.g. from impedance data) could be combined with an activity index generated from a combination of measured biomarkers to generate a physiological index useful for management of a weight loss or cardiovascular health program. This information can be combined with cardiac performance indicators to get a good picture of overall health, which can be combined with pharmaceutical therapy administration data. In another aspect, one might find for example that a particular pharmaceutical correlates with a small increase in body temperature, or a change in the electrocardiogram. One can develop a pharmacodynamic model for the metabolism of the drug, and use the information from the receiver to essentially fit the free parameters in that model to give much more accurate estimation of the levels actually present in the serum of the subject. This information could be fed back to dosing regimes. In another aspect, one can combine information from a sensor that measures uterine contractions (e.g. with a strain gauge) and that also monitors fetal heart rate, for use as a high-risk pregnancy monitor.
  • In certain aspects, the subject specific information that is collected using the systems of the invention may be transmitted to a location where it is combined with data from one or more additional individuals to provide a collection of data which is a composite of data collected from 2 or more, e.g., 5 or more, 10 or more, 25 or more, 50 or more, 100 or more, 1000 or more, etc., individuals. The composite data can then be manipulated, e.g., categorized according to different criteria, and made available to one or more different types of groups, e.g., patient groups, health care practitioner groups, etc., where the manipulation of data may be such as to limit the access of any given group to the type of data that group can access. For example, data can be collected from 100 different individuals that are suffering from the same condition and taking the same medication. The data can be processed and employed to develop easy to follow displays regarding patient compliance with a pharmaceutical dosage regimen and general health. Patient members of the group can access this information and see how their compliance matches with other patient members of the group, and whether they are enjoying the benefits that others are experiencing. In yet another aspect, doctors can also be granted access to a manipulation of the composite data to see how their patients are matching up with patients of other doctors, and obtain useful information on how real patients respond to a given therapeutic treatment regimen. Additional functionalities can be provided to the groups given access to the composite data, where such functionalities may include, but are not limited to: ability to annotate data, chat functionalities, security privileges, etc.
  • Computer Readable Media & Programming
  • In certain aspects, the system further includes an element for storing data, i.e., a data storage element, where this element is present on an external device, such as a bedside monitor, PDA, smart phone, etc. Typically, the data storage element is a computer readable medium. The term “computer readable medium” as used herein refers to any storage or transmission medium that participates in providing instructions and/or data to a computer for execution and/or processing. Examples of storage media include floppy disks, magnetic tape, CD-ROM, a hard disk drive, a ROM or integrated circuit, a magneto-optical disk, or a computer readable card such as a PCMCIA card and the like, whether or not such devices are internal or external to the computer. A file containing information may be “stored” on computer readable medium, where “storing” means recording information such that it is accessible and retrievable at a later date by a computer. With respect to computer readable media, “permanent memory” refers to memory that is permanent. Permanent memory is not erased by termination of the electrical supply to a computer or processor. Computer hard-drive ROM (i.e. ROM not used as virtual memory), CD-ROM, floppy disk and DVD are all examples of permanent memory. Random Access Memory (RAM) is an example of non-permanent memory. A file in permanent memory may be editable and re-writable.
  • The invention also provides computer executable instructions (i.e., programming) for performing the above methods. The computer executable instructions are present on a computer readable medium. Accordingly, the invention provides a computer readable medium containing programming for use in detecting and processing a signal generated by a composition of the invention, e.g., as reviewed above.
  • As such, in certain aspects the systems include one or more of: a data storage element, a data processing element, a data display element, data transmission element, a notification mechanism, and a user interface. These additional elements may be incorporated into the receiver and/or present on an external device, e.g., a device configured for processing data and making decisions, forwarding data to a remote location which provides such activities, etc.
  • The above described systems are reviewed in terms of communication between an identifier on a pharmaceutical composition and a receiver. However, the systems are not so limited. In a broader sense, the systems are composed of two or more different modules that communicate with each other, e.g., using the transmitter/receiver functionalities as reviewed above, e.g., using the monopole transmitter (e.g., antenna) structures as described above. As such, the above identifier elements may be incorporated into any of a plurality of different devices, e.g., to provide a communications system between two self-powered devices in the body, where the self-powered devices may be sensors, data receivers and storage elements, effectors, etc. In an exemplary system, one of these devices may be a sensor and the other may be a communication hub for communication to the outside world. This inventive aspect may take a number of forms. There can be many sensors, many senders and one receiver. They can be transceivers so both of these can take turns sending and receiving according to known communication protocols. In certain aspects, the means of communication between the two or more individual devices is the mono polar system, e.g., as described above. In these aspects, each of these senders may be configured to take turns sending a high frequency signal into the body using a monopole pulling charge into and out of the body which is a large capacitor and a conductor. The receiver, a monopole receiver is detecting at that frequency the charge going into and out of the body and decoding an encrypted signal such as an amplitude modulated signal or frequency modulated signal. This aspect of the present invention has broad uses. For example, multiple sensors can be placed and implanted on various parts of the body that measure position or acceleration. Without having wires connecting to a central hub, they can communicate that information through a communication medium.
  • In the methods of the subject invention in which the in vivo transmitter is a pharma-informatics enabled composition, an effective amount of a composition of the invention is administered to a subject in need of the active agent present in the composition, where “effective amount” means a dosage sufficient to produce the desired result, e.g. an improvement in a disease condition or the symptoms associated therewith, the accomplishment of a desired physiological change, etc. The amount that is administered may also be viewed as a therapeutically effective amount. A “therapeutically effective amount” means the amount that, when administered to a subject for treating a disease, is sufficient to effect treatment for that disease.
  • The composition may be administered to the subject using any convenient means capable of producing the desired result, where the administration route depends, at least in part, on the particular format of the composition, e.g., as reviewed above. As reviewed above, the compositions can be formatted into a variety of formulations for therapeutic administration, including but not limited to solid, semi solid or liquid, such as tablets, capsules, powders, granules, ointments, solutions, suppositories and injections. As such, administration of the compositions can be achieved in various ways, including, but not limited to: oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracheal, etc., administration. In pharmaceutical dosage forms, a given composition may be administered alone or in combination with other pharmaceutically active compounds, e.g., which may also be compositions having signal generation elements stably associated therewith.
  • The subject methods find use in the treatment of a variety of different conditions, including disease conditions. The specific disease conditions treatable by with the subject compositions are as varied as the types of active agents that can be present in the subject compositions. Thus, disease conditions include, but are not limited to: cardiovascular diseases, cellular proliferative diseases, such as neoplastic diseases, autoimmune diseases, hormonal abnormality diseases, infectious diseases, pain management, and the like.
  • By treatment is meant at least an amelioration of the symptoms associated with the disease condition afflicting the subject, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the pathological condition being treated. As such, treatment also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g. prevented from happening, or stopped, e.g. terminated, such that the subject no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition. Accordingly, “treating” or “treatment” of a disease includes preventing the disease from occurring in an animal that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease (prophylactic treatment), inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease). For the purposes of this invention, a “disease” includes pain.
  • A variety of subjects are treatable according to the present methods. Generally such subjects are “mammals” or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In representative aspects, the subjects will be humans.
  • In certain aspects, the subject methods, as described above, are methods of managing a disease condition, e.g., over an extended period of time, such as 1 week or longer, 1 month or longer, 6 months or longer, 1 year or longer, 2 years or longer, 5 years or longer, etc. The subject methods may be employed in conjunction with one or more additional disease management protocols, e.g., electrostimulation based protocols in cardiovascular disease management, such as pacing protocols, cardiac resynchronization protocols, etc; lifestyle, such a diet and/or exercise regimens for a variety of different disease conditions; etc.
  • In certain aspects, the methods include modulating a therapeutic regimen based data obtained from the compositions. For example, data may be obtained which includes information about patient compliance with a prescribed therapeutic regimen. This data, with or without additional physiological data, e.g., obtained using one or more sensors, such as the sensor devices described above, may be employed, e.g., with appropriate decision tools as desired, to make determinations of whether a given treatment regimen should be maintained or modified in some way, e.g., by modification of a medication regimen and/or implant activity regimen. As such, methods of invention include methods in which a therapeutic regimen is modified based on signals obtained from the composition(s).
  • In certain aspects, also provided are methods of determining the history of a composition of the invention, where the composition includes an active agent, an identifier element and a pharmaceutically acceptable carrier. In certain aspects where the identifier emits a signal in response to an interrogation, the identifier is interrogate, e.g., by a wand or other suitable interrogation device, to obtain a signal. The obtained signal is then employed to determine historical information about the composition, e.g., source, chain of custody, etc.
  • In yet other aspects where the identifier is one that survives digestion, the methods generally include obtaining the signal generation element of the composition, e.g., by retrieving it from a subject that has ingested the composition, and then determining the history of the composition from obtained signal generation element. For example, where the signal generation element includes an engraved identifier, e.g., barcode or other type of identifier, the engraved identifier may be retrieved from a subject that has ingested the composition and then read to identify at least some aspect of the history of the composition, such as last known purchaser, additional purchasers in the chain of custody of the composition, manufacturer, handling history, etc. In certain aspects, this determining step may include accessing a database or analogous compilation of stored history for the composition.
  • Utility
  • Medical aspects of the present invention provide the clinician an important new tool in their therapeutic armamentarium: automatic detection and identification of pharmaceutical agents actually delivered into the body. The applications of this new information device and system are multi-fold. Applications include, but are not limited to: (1) monitoring patient compliance with prescribed therapeutic regimens; (2) tailoring therapeutic regimens based on patient compliance; (3) monitoring patient compliance in clinical trials; (4) monitoring usage of controlled substances; and the like. Each of these different illustrative applications is reviewed in greater detail below in copending PCT Application Serial No. PCT/US2006/016370; the disclosure of which is herein incorporated by reference. Additional applications in which the subject receivers find use include, but are not limited to: U.S. provisional Application Ser. Nos. 60/887,780 titled “Receivers For Pharma-Informatics Systems,” and filed on Feb. 1, 2007; 60/956,694 titled “Personal Health Receivers,” and filed on Aug. 18, 2007 and 60/949,223 titled “Ingestible Event Marker,” and filed on Jul. 11, 2007, the disclosures of which applications are incorporated herein by reference.
  • Kits
  • Also provided are kits for practicing the subject methods. Kits may include one or more receivers of the invention, as described above. In addition, the kits may include one or more dosage compositions, e.g., pharma-informatics enabled dosage compositions. The dosage amount of the one or more pharmacological agents provided in a kit may be sufficient for a single application or for multiple applications. Accordingly, in certain aspects of the subject kits a single dosage amount of a pharmacological agent is present and in certain other aspects multiple dosage amounts of a pharmacological agent may be present in a kit. In those aspects having multiple dosage amounts of pharmacological agent, such may be packaged in a single container, e.g., a single tube, bottle, vial, and the like, or one or more dosage amounts may be individually packaged such that certain kits may have more than one container of a pharmacological agent.
  • Suitable means for delivering one or more pharmacological agents to a subject may also be provided in a subject kit. The particular delivery means provided in a kit is dictated by the particular pharmacological agent employed, as describe above, e.g., the particular form of the agent such as whether the pharmacological agent is formulated into preparations in solid, semi solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols, and the like, and the particular mode of administration of the agent, e.g., whether oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracheal, etc. Accordingly, certain systems may include a suppository applicator, syringe, I.V. bag and tubing, electrode, etc.
  • In certain aspects, the kits may also include an external monitor device, e.g., as described above, which may provide for communication with a remote location, e.g., a doctor's office, a central facility etc., which obtains and processes data obtained about the usage of the composition.
  • In certain aspects, the kits may include a smart parenteral delivery system that provides specific identification and detection of parenteral beneficial agents or beneficial agents taken into the body through other methods, for example, through the use of a syringe, inhaler, or other device that administers medicine, such as described in copending application Ser. No. 60/819,750; the disclosure of which is herein incorporated by reference.
  • The subject kits may also include instructions for how to practice the subject methods using the components of the kit. The instructions may be recorded on a suitable recording medium or substrate. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc. In other aspects, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other aspects, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this aspect is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
  • Some or all components of the subject kits may be packaged in suitable packaging to maintain sterility. In many aspects of the subject kits, the components of the kit are packaged in a kit containment element to make a single, easily handled unit, where the kit containment element, e.g., box or analogous structure, may or may not be an airtight container, e.g., to further preserve the sterility of some or all of the components of the kit.
  • It is to be understood that this invention is not limited to particular aspects described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
  • Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.
  • All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
  • It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
  • As will be apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several aspects without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
  • Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
  • Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and aspects of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary aspects shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.

Claims (20)

1. A system comprising:
an in vivo transmitter to transmit an encoded signal;
a transbody functionality module to facilitate communication of the encoded signal; and
a receiver to receive the encoded signal.
2. The system of claim 1, wherein the transbody functionality module is selected from the group consisting essentially of a beacon functionality module, a frequency hopping functionality module, and a collision avoidance functionality module.
3. The system of claim 2, wherein the beacon functionality module comprises at least one element selected from the group consisting essentially of:
a beacon wakeup module to provide beacon wakeup functionality;
a beacon signal module to provide beacon signal functionality;
a wave/frequency module to provide a continuous wave and a single frequency tone;
a multiple frequency module to provide multiple frequencies; and
a modulated signal module to provide at least one modulated encoded signal.
4. The system of claim 3, wherein a frequency ratio of a beacon and data channel is invariant to frequency error in an ingestible event marker system to provide additional assurance of detection of the encoded signal.
5. The system of claim 3, wherein the frequency hopping functionality module comprises a random module to provide random frequency hops on a narrow band transmitted signal.
6. The system of claim 3, wherein the collision avoidance functionality module comprises at least one element selected from the group consisting essentially of:
a transmitter module to provide a first in vivo transmitter transmitting at a first frequency and a second in vivo transmitter transmitting at a second frequency module;
a duty cycle modulation module to provide duty cycle modulation functionality;
a retransmit randomization module to provide random retransmittals; and
a spread spectrum module to provide spread spectrum functionality.
7. The system of claim 6, wherein the duty cycle modulation module includes a dithering module to dither a duty cycle and frequency spread module to spread the transmissions among multiple frequencies.
8. The system of claim 6, wherein the transmitter modules comprises a multiple band pass filter module to provide multiple band pass filtering by different devices wherein respective encoded signals are filtered by respective band pass filters.
9. A method comprising:
transmitting, via an in vivo transmitter, an encoded signal;
facilitating, via a transbody functionality module, communication of the signal; and
receiving, via a receiver, the encoded signal.
10. The method of claim 9, further comprising:
providing characteristics of the encoded signal, wherein the characteristics optimize power consumption to facilitate the receiver in at least one of the following: spending maximum time in an inactive mode, waking up quickly, and waking up during a period of high probability that the transmitter is present.
11. The method of claim 9, wherein the facilitating, via a transbody functionality module, communication of the signal comprises at least one of:
facilitating, via a beacon functionality module, communication of the encoded signal;
facilitating, via a frequency hopping functionality module, communication of the encoded signal; and
facilitating, via a collision avoidance functionality module, communication of the encoded signal.
12. The method of claim 11, wherein the facilitating, via a beacon functionality module communication of the signal comprises at least one of:
providing beacon wakeup functionality;
providing beacon signal functionality;
generating a continuous wave, single frequency tone;
providing a first frequency that is different from a data signal which is at a second frequency; and
modulating the encoded signal.
13. The method of claim 11, wherein the facilitating, via a frequency hopping functionality module, communication of the encoded signal comprises generating random frequency hops on a narrow band transmitted signal.
14. The method of claim 11, wherein the facilitating, via a collision avoidance functionality module, communication of the encoded signal comprises at least one of:
transmitting, via a first in vivo transmitter at a first frequency and transmitting, via a second in vivo transmitter, at a second frequency;
modulating a duty cycle;
retransmitting randomly; and
spreading across a frequency spectrum.
15. The method of claim 14, wherein the modulating a duty cycle includes dithering the duty cycle and spreading among frequencies.
16. The method of claim 14, wherein the transmitting at different frequencies comprises providing multiple band pass filtering by different devices wherein respective encoded signals are filtered by respective band pass fillers.
17. The method of claim 9 in a form of a machine-readable medium embodying a set of instructions that, when executed by a machine, causes the machine to perform the method of claim 8.
18. An article, comprising:
a storage medium having instructions, that when executed by a computing platform, result in execution of a method of providing transbody communications employing communication channels in a living body, the method comprising:
transmitting, via an in vivo transmitter, an encoded signal;
facilitating, via a transbody functionality module, communication of the signal; and
receiving, via a receiver, the encoded signal.
19. The article of claim 18, further comprising:
providing characteristics of the encoded signal, wherein the characteristics optimize power consumption to facilitate the receiver in at least one of the following: spending maximum time in an inactive mode, waking up quickly, and waking up during a period of high probability that the transmitter is present.
20. The article of claim 18, wherein the facilitating, via a transbody functionality module, communication of the signal comprises at least one of:
facilitating, via a beacon functionality module, communication of the encoded signal;
facilitating, via a frequency hopping functionality module, communication of the encoded signal; and
facilitating, via a collision avoidance functionality module, communication of the encoded signal.
US12/324,798 2007-11-27 2008-11-26 Transbody communication systems employing communication channels Abandoned US20090135886A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/324,798 US20090135886A1 (en) 2007-11-27 2008-11-26 Transbody communication systems employing communication channels
US16/789,361 US11612321B2 (en) 2007-11-27 2020-02-12 Transbody communication systems employing communication channels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99056207P 2007-11-27 2007-11-27
US99056707P 2007-11-27 2007-11-27
US99057207P 2007-11-27 2007-11-27
US12/324,798 US20090135886A1 (en) 2007-11-27 2008-11-26 Transbody communication systems employing communication channels

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/912,475 Continuation-In-Part US8847766B2 (en) 2005-04-28 2006-04-28 Pharma-informatics system
US16/789,361 Continuation US11612321B2 (en) 2007-11-27 2020-02-12 Transbody communication systems employing communication channels

Publications (1)

Publication Number Publication Date
US20090135886A1 true US20090135886A1 (en) 2009-05-28

Family

ID=40669666

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/324,798 Abandoned US20090135886A1 (en) 2007-11-27 2008-11-26 Transbody communication systems employing communication channels
US16/789,361 Active 2030-01-04 US11612321B2 (en) 2007-11-27 2020-02-12 Transbody communication systems employing communication channels

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/789,361 Active 2030-01-04 US11612321B2 (en) 2007-11-27 2020-02-12 Transbody communication systems employing communication channels

Country Status (13)

Country Link
US (2) US20090135886A1 (en)
EP (1) EP2215726B1 (en)
JP (2) JP5794782B2 (en)
KR (1) KR101586193B1 (en)
CN (1) CN101926097B (en)
AU (3) AU2008329620B2 (en)
CA (1) CA2717809A1 (en)
DK (1) DK2215726T3 (en)
ES (1) ES2661739T3 (en)
IL (1) IL206049A (en)
MY (1) MY154699A (en)
SG (1) SG190590A1 (en)
WO (1) WO2009070773A1 (en)

Cited By (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020037A1 (en) * 2006-07-11 2008-01-24 Robertson Timothy L Acoustic Pharma-Informatics System
US20080284599A1 (en) * 2005-04-28 2008-11-20 Proteus Biomedical, Inc. Pharma-Informatics System
US8036748B2 (en) 2008-11-13 2011-10-11 Proteus Biomedical, Inc. Ingestible therapy activator system and method
US8054140B2 (en) 2006-10-17 2011-11-08 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
US8114021B2 (en) 2008-12-15 2012-02-14 Proteus Biomedical, Inc. Body-associated receiver and method
WO2012042437A2 (en) 2010-09-30 2012-04-05 Koninklijke Philips Electronics N.V. Body worn sensors network with redundant parameter prioritization and temporal alignment
US8258962B2 (en) 2008-03-05 2012-09-04 Proteus Biomedical, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US20120315863A1 (en) * 2011-06-07 2012-12-13 Olympus Corporation Wireless communication terminal
US8540664B2 (en) 2009-03-25 2013-09-24 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
US8540633B2 (en) 2008-08-13 2013-09-24 Proteus Digital Health, Inc. Identifier circuits for generating unique identifiable indicators and techniques for producing same
US8545402B2 (en) 2009-04-28 2013-10-01 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US8547248B2 (en) 2005-09-01 2013-10-01 Proteus Digital Health, Inc. Implantable zero-wire communications system
US8558563B2 (en) 2009-08-21 2013-10-15 Proteus Digital Health, Inc. Apparatus and method for measuring biochemical parameters
US8583227B2 (en) 2008-12-11 2013-11-12 Proteus Digital Health, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
US8597186B2 (en) 2009-01-06 2013-12-03 Proteus Digital Health, Inc. Pharmaceutical dosages delivery system
US8718193B2 (en) 2006-11-20 2014-05-06 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US8784308B2 (en) 2009-12-02 2014-07-22 Proteus Digital Health, Inc. Integrated ingestible event marker system with pharmaceutical product
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8858432B2 (en) 2007-02-01 2014-10-14 Proteus Digital Health, Inc. Ingestible event marker systems
US8868453B2 (en) 2009-11-04 2014-10-21 Proteus Digital Health, Inc. System for supply chain management
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US8945005B2 (en) 2006-10-25 2015-02-03 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US8956288B2 (en) 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US20150095274A1 (en) * 2013-10-02 2015-04-02 Qualcomm Incorporated Method and apparatus for producing programmable probability distribution function of pseudo-random numbers
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US9031653B2 (en) 2012-07-26 2015-05-12 Nyxoah SA Internal resonance matching between an implanted device and an external device
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
US9270503B2 (en) 2013-09-20 2016-02-23 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US9268909B2 (en) 2012-10-18 2016-02-23 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
US9271897B2 (en) 2012-07-23 2016-03-01 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
US9439599B2 (en) 2011-03-11 2016-09-13 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
EP3070982A1 (en) * 2015-03-19 2016-09-21 Albert-Ludwigs-Universität Freiburg Receiving device and method for operating a receiving device
US9526909B2 (en) 2014-08-28 2016-12-27 Cardiac Pacemakers, Inc. Medical device with triggered blanking period
US9577864B2 (en) 2013-09-24 2017-02-21 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
US9592391B2 (en) 2014-01-10 2017-03-14 Cardiac Pacemakers, Inc. Systems and methods for detecting cardiac arrhythmias
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
CN106534854A (en) * 2011-03-07 2017-03-22 杜比国际公司 Method of coding and decoding images, coding and decoding device and computer programs corresponding thereto
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9669230B2 (en) 2015-02-06 2017-06-06 Cardiac Pacemakers, Inc. Systems and methods for treating cardiac arrhythmias
US9694189B2 (en) 2014-08-06 2017-07-04 Cardiac Pacemakers, Inc. Method and apparatus for communicating between medical devices
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9757570B2 (en) 2014-08-06 2017-09-12 Cardiac Pacemakers, Inc. Communications in a medical device system
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9808631B2 (en) 2014-08-06 2017-11-07 Cardiac Pacemakers, Inc. Communication between a plurality of medical devices using time delays between communication pulses to distinguish between symbols
US9853743B2 (en) 2015-08-20 2017-12-26 Cardiac Pacemakers, Inc. Systems and methods for communication between medical devices
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US9956414B2 (en) 2015-08-27 2018-05-01 Cardiac Pacemakers, Inc. Temporal configuration of a motion sensor in an implantable medical device
US9968787B2 (en) 2015-08-27 2018-05-15 Cardiac Pacemakers, Inc. Spatial configuration of a motion sensor in an implantable medical device
US10029107B1 (en) 2017-01-26 2018-07-24 Cardiac Pacemakers, Inc. Leadless device with overmolded components
US10046167B2 (en) 2015-02-09 2018-08-14 Cardiac Pacemakers, Inc. Implantable medical device with radiopaque ID tag
US10050700B2 (en) 2015-03-18 2018-08-14 Cardiac Pacemakers, Inc. Communications in a medical device system with temporal optimization
US10065041B2 (en) 2015-10-08 2018-09-04 Cardiac Pacemakers, Inc. Devices and methods for adjusting pacing rates in an implantable medical device
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10092760B2 (en) 2015-09-11 2018-10-09 Cardiac Pacemakers, Inc. Arrhythmia detection and confirmation
US10137305B2 (en) 2015-08-28 2018-11-27 Cardiac Pacemakers, Inc. Systems and methods for behaviorally responsive signal detection and therapy delivery
US10159842B2 (en) 2015-08-28 2018-12-25 Cardiac Pacemakers, Inc. System and method for detecting tamponade
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US10183170B2 (en) 2015-12-17 2019-01-22 Cardiac Pacemakers, Inc. Conducted communication in a medical device system
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10213610B2 (en) 2015-03-18 2019-02-26 Cardiac Pacemakers, Inc. Communications in a medical device system with link quality assessment
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US10220213B2 (en) 2015-02-06 2019-03-05 Cardiac Pacemakers, Inc. Systems and methods for safe delivery of electrical stimulation therapy
US10226631B2 (en) 2015-08-28 2019-03-12 Cardiac Pacemakers, Inc. Systems and methods for infarct detection
WO2019108787A1 (en) * 2017-11-29 2019-06-06 Medtronic, Inc. Tissue conduction communication between devices
US10328272B2 (en) 2016-05-10 2019-06-25 Cardiac Pacemakers, Inc. Retrievability for implantable medical devices
US10350423B2 (en) 2016-02-04 2019-07-16 Cardiac Pacemakers, Inc. Delivery system with force sensor for leadless cardiac device
US10357159B2 (en) 2015-08-20 2019-07-23 Cardiac Pacemakers, Inc Systems and methods for communication between medical devices
US10391319B2 (en) 2016-08-19 2019-08-27 Cardiac Pacemakers, Inc. Trans septal implantable medical device
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
US10413733B2 (en) 2016-10-27 2019-09-17 Cardiac Pacemakers, Inc. Implantable medical device with gyroscope
US10426962B2 (en) 2016-07-07 2019-10-01 Cardiac Pacemakers, Inc. Leadless pacemaker using pressure measurements for pacing capture verification
US10434317B2 (en) 2016-10-31 2019-10-08 Cardiac Pacemakers, Inc. Systems and methods for activity level pacing
US10434314B2 (en) 2016-10-27 2019-10-08 Cardiac Pacemakers, Inc. Use of a separate device in managing the pace pulse energy of a cardiac pacemaker
US10463305B2 (en) 2016-10-27 2019-11-05 Cardiac Pacemakers, Inc. Multi-device cardiac resynchronization therapy with timing enhancements
US10512784B2 (en) 2016-06-27 2019-12-24 Cardiac Pacemakers, Inc. Cardiac therapy system using subcutaneously sensed P-waves for resynchronization pacing management
US10529044B2 (en) 2010-05-19 2020-01-07 Proteus Digital Health, Inc. Tracking and delivery confirmation of pharmaceutical products
US10561330B2 (en) 2016-10-27 2020-02-18 Cardiac Pacemakers, Inc. Implantable medical device having a sense channel with performance adjustment
US10583301B2 (en) 2016-11-08 2020-03-10 Cardiac Pacemakers, Inc. Implantable medical device for atrial deployment
US10583303B2 (en) 2016-01-19 2020-03-10 Cardiac Pacemakers, Inc. Devices and methods for wirelessly recharging a rechargeable battery of an implantable medical device
US10617874B2 (en) 2016-10-31 2020-04-14 Cardiac Pacemakers, Inc. Systems and methods for activity level pacing
US10632313B2 (en) 2016-11-09 2020-04-28 Cardiac Pacemakers, Inc. Systems, devices, and methods for setting cardiac pacing pulse parameters for a cardiac pacing device
US10639486B2 (en) 2016-11-21 2020-05-05 Cardiac Pacemakers, Inc. Implantable medical device with recharge coil
US10668294B2 (en) 2016-05-10 2020-06-02 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker configured for over the wire delivery
US10688304B2 (en) 2016-07-20 2020-06-23 Cardiac Pacemakers, Inc. Method and system for utilizing an atrial contraction timing fiducial in a leadless cardiac pacemaker system
US10722720B2 (en) 2014-01-10 2020-07-28 Cardiac Pacemakers, Inc. Methods and systems for improved communication between medical devices
US10737102B2 (en) 2017-01-26 2020-08-11 Cardiac Pacemakers, Inc. Leadless implantable device with detachable fixation
US10758737B2 (en) 2016-09-21 2020-09-01 Cardiac Pacemakers, Inc. Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter
US10758724B2 (en) 2016-10-27 2020-09-01 Cardiac Pacemakers, Inc. Implantable medical device delivery system with integrated sensor
US10765871B2 (en) 2016-10-27 2020-09-08 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
US10780278B2 (en) 2016-08-24 2020-09-22 Cardiac Pacemakers, Inc. Integrated multi-device cardiac resynchronization therapy using P-wave to pace timing
US10821288B2 (en) 2017-04-03 2020-11-03 Cardiac Pacemakers, Inc. Cardiac pacemaker with pacing pulse energy adjustment based on sensed heart rate
US10835753B2 (en) 2017-01-26 2020-11-17 Cardiac Pacemakers, Inc. Intra-body device communication with redundant message transmission
US10870008B2 (en) 2016-08-24 2020-12-22 Cardiac Pacemakers, Inc. Cardiac resynchronization using fusion promotion for timing management
US10874861B2 (en) 2018-01-04 2020-12-29 Cardiac Pacemakers, Inc. Dual chamber pacing without beat-to-beat communication
US10881863B2 (en) 2016-11-21 2021-01-05 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker with multimode communication
US10881869B2 (en) 2016-11-21 2021-01-05 Cardiac Pacemakers, Inc. Wireless re-charge of an implantable medical device
US10894163B2 (en) 2016-11-21 2021-01-19 Cardiac Pacemakers, Inc. LCP based predictive timing for cardiac resynchronization
US10905872B2 (en) 2017-04-03 2021-02-02 Cardiac Pacemakers, Inc. Implantable medical device with a movable electrode biased toward an extended position
US10905886B2 (en) 2015-12-28 2021-02-02 Cardiac Pacemakers, Inc. Implantable medical device for deployment across the atrioventricular septum
US10905889B2 (en) 2016-09-21 2021-02-02 Cardiac Pacemakers, Inc. Leadless stimulation device with a housing that houses internal components of the leadless stimulation device and functions as the battery case and a terminal of an internal battery
US10918875B2 (en) 2017-08-18 2021-02-16 Cardiac Pacemakers, Inc. Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator
US10994145B2 (en) 2016-09-21 2021-05-04 Cardiac Pacemakers, Inc. Implantable cardiac monitor
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US11052258B2 (en) 2017-12-01 2021-07-06 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker
US11058880B2 (en) 2018-03-23 2021-07-13 Medtronic, Inc. VFA cardiac therapy for tachycardia
US11065459B2 (en) 2017-08-18 2021-07-20 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
US11071870B2 (en) 2017-12-01 2021-07-27 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials and determining a cardiac interval from a ventricularly implanted leadless cardiac pacemaker
US11116988B2 (en) 2016-03-31 2021-09-14 Cardiac Pacemakers, Inc. Implantable medical device with rechargeable battery
US11147979B2 (en) 2016-11-21 2021-10-19 Cardiac Pacemakers, Inc. Implantable medical device with a magnetically permeable housing and an inductive coil disposed about the housing
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US11158149B2 (en) 2013-03-15 2021-10-26 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US11185703B2 (en) 2017-11-07 2021-11-30 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker for bundle of his pacing
US11207532B2 (en) 2017-01-04 2021-12-28 Cardiac Pacemakers, Inc. Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system
US11207527B2 (en) 2016-07-06 2021-12-28 Cardiac Pacemakers, Inc. Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system
US11213676B2 (en) 2019-04-01 2022-01-04 Medtronic, Inc. Delivery systems for VfA cardiac therapy
US11234280B2 (en) 2017-11-29 2022-01-25 Samsung Electronics Co., Ltd. Method for RF communication connection using electronic device and user touch input
US11235163B2 (en) 2017-09-20 2022-02-01 Cardiac Pacemakers, Inc. Implantable medical device with multiple modes of operation
US11235159B2 (en) 2018-03-23 2022-02-01 Medtronic, Inc. VFA cardiac resynchronization therapy
US11235161B2 (en) 2018-09-26 2022-02-01 Medtronic, Inc. Capture in ventricle-from-atrium cardiac therapy
US11260216B2 (en) 2017-12-01 2022-03-01 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker
US11285326B2 (en) 2015-03-04 2022-03-29 Cardiac Pacemakers, Inc. Systems and methods for treating cardiac arrhythmias
US11305127B2 (en) 2019-08-26 2022-04-19 Medtronic Inc. VfA delivery and implant region detection
US11400296B2 (en) 2018-03-23 2022-08-02 Medtronic, Inc. AV synchronous VfA cardiac therapy
US11529523B2 (en) 2018-01-04 2022-12-20 Cardiac Pacemakers, Inc. Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
WO2023028164A1 (en) * 2021-08-24 2023-03-02 Canary Medical Switzerland Ag Implantable medical device with sensing and communication functionality
US11612321B2 (en) 2007-11-27 2023-03-28 Otsuka Pharmaceutical Co., Ltd. Transbody communication systems employing communication channels
US11679265B2 (en) 2019-02-14 2023-06-20 Medtronic, Inc. Lead-in-lead systems and methods for cardiac therapy
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
US11712188B2 (en) 2019-05-07 2023-08-01 Medtronic, Inc. Posterior left bundle branch engagement
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US11813466B2 (en) 2020-01-27 2023-11-14 Medtronic, Inc. Atrioventricular nodal stimulation
US11813464B2 (en) 2020-07-31 2023-11-14 Medtronic, Inc. Cardiac conduction system evaluation
US11813463B2 (en) 2017-12-01 2023-11-14 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker with reversionary behavior
US11911168B2 (en) 2020-04-03 2024-02-27 Medtronic, Inc. Cardiac conduction system therapy benefit determination
US11928614B2 (en) 2017-09-28 2024-03-12 Otsuka Pharmaceutical Co., Ltd. Patient customized therapeutic regimens

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8315224B2 (en) * 2010-01-22 2012-11-20 General Electric Company Methods and systems for reuse of radio resources in medical telemetry networks
US20130129869A1 (en) 2011-11-23 2013-05-23 Hooman Hafezi Compositions comprising a shelf-life stability component
KR101916418B1 (en) 2012-11-29 2018-11-08 삼성전자주식회사 Method and apparatus for reducing power consumption of receiver
CN105892317A (en) * 2016-03-31 2016-08-24 创领心律管理医疗器械(上海)有限公司 Implantable medical device, data outputting and receiving methods thereof and communication mechanism
TWI667860B (en) 2018-02-09 2019-08-01 鉅旺生技股份有限公司 Long-range wireless charging enhancement structure for implantable medical devices

Citations (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642008A (en) * 1968-09-25 1972-02-15 Medical Plastics Inc Ground electrode and test circuit
US3719183A (en) * 1970-03-05 1973-03-06 H Schwartz Method for detecting blockage or insufficiency of pancreatic exocrine function
US3799802A (en) * 1966-06-28 1974-03-26 F Schneble Plated through hole printed circuit boards
US4077398A (en) * 1974-10-07 1978-03-07 Baxter Travenol Laboratories, Inc. Diagnostic electrode assembly
US4077397A (en) * 1974-10-07 1978-03-07 Baxter Travenol Laboratories, Inc. Diagnostic electrode assembly
US4251795A (en) * 1977-11-29 1981-02-17 Asahi Kasei Kogyo Kabushiki Kaisha Semiconductor magnetoresistive element having a differential effect
US4494950A (en) * 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4578061A (en) * 1980-10-28 1986-03-25 Lemelson Jerome H Injection catheter and method
US4635641A (en) * 1985-10-16 1987-01-13 Murray Electronics Associates Limited Multi-element electrode
US4681111A (en) * 1985-04-05 1987-07-21 Siemens-Pacesetter, Inc. Analog and digital telemetry system for an implantable device
US5279607A (en) * 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
US5281287A (en) * 1989-07-21 1994-01-25 Iomed, Inc. Method of making a hydratable bioelectrode
US5394882A (en) * 1993-07-21 1995-03-07 Respironics, Inc. Physiological monitoring system
US5600548A (en) * 1994-08-11 1997-02-04 Sundstrand Corporation DC content control for an inverter
US5705189A (en) * 1994-08-31 1998-01-06 Roehm Gmbh Chemische Fabrik Thermoplastic material for drug coatings which dissolve in intestinal juices
US5862803A (en) * 1993-09-04 1999-01-26 Besson; Marcus Wireless medical diagnosis and monitoring equipment
US5862808A (en) * 1997-08-26 1999-01-26 Cigar Savor Enterprises Llc Cigar punch
US5868136A (en) * 1996-02-20 1999-02-09 Axelgaard Manufacturing Co. Ltd. Medical electrode
US6038464A (en) * 1998-02-09 2000-03-14 Axelgaard Manufacturing Co., Ltd. Medical electrode
US6083248A (en) * 1995-06-23 2000-07-04 Medtronic, Inc. World wide patient location and data telemetry system for implantable medical devices
US6200265B1 (en) * 1999-04-16 2001-03-13 Medtronic, Inc. Peripheral memory patch and access method for use with an implantable medical device
US6342774B1 (en) * 2001-03-27 2002-01-29 Motorola, Inc. Battery having user charge capacity control
US20020026111A1 (en) * 2000-08-28 2002-02-28 Neil Ackerman Methods of monitoring glucose levels in a subject and uses thereof
US20020032385A1 (en) * 1995-02-24 2002-03-14 Raymond Stephen A. Health monitoring system
US6358202B1 (en) * 1999-01-25 2002-03-19 Sun Microsystems, Inc. Network for implanted computer devices
US20030028226A1 (en) * 1998-06-19 2003-02-06 Medtronic, Inc. Medical management system integrated programming apparatus for communication with an implantable medical device
US6526315B1 (en) * 2000-03-17 2003-02-25 Tanita Corporation Portable bioelectrical impedance measuring instrument
US6531026B1 (en) * 1999-06-23 2003-03-11 Sony Chemicals Corp. Method for mounting electronic elements
US6680923B1 (en) * 2000-05-23 2004-01-20 Calypso Wireless, Inc. Communication system and method
US20040034295A1 (en) * 2000-09-26 2004-02-19 Marcos Salganicoff Method and apparatus for real-time estimation and control of physiological parameters
US20040092296A1 (en) * 2002-10-31 2004-05-13 Tadashi Minotani Transceiver capable of causing series resonance with parasitic capacitance
US20040121292A1 (en) * 2002-08-08 2004-06-24 Chung Bobby Hsiang-Hua Wireless data communication link embedded in simulated weapon systems
US20040122315A1 (en) * 2002-09-24 2004-06-24 Krill Jerry A. Ingestible medical payload carrying capsule with wireless communication
US20040186365A1 (en) * 2002-12-31 2004-09-23 Therasense, Inc. Continuous glucose monitoring system and methods of use
US6839659B2 (en) * 2000-06-16 2005-01-04 Isis Innovation Limited System and method for acquiring data
US6842636B2 (en) * 2002-09-27 2005-01-11 Axelgaard Manufacturing Co., Ltd. Medical electrode
US6845272B1 (en) * 1999-05-25 2005-01-18 Medicotest A/S Skin electrode
US20050021103A1 (en) * 1998-08-05 2005-01-27 Dilorenzo Daniel John Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US20050020887A1 (en) * 2001-10-11 2005-01-27 Jason Goldberg Medical monitoring device and system
US20050021370A1 (en) * 2000-08-29 2005-01-27 Medtronic, Inc. Medical device systems implemented network scheme for remote patient management
US20050017841A1 (en) * 2000-09-08 2005-01-27 Matsushita Electric Works, Ltd. Data transmission system using a human body as a signal transmission path
US20050024198A1 (en) * 1999-07-20 2005-02-03 Ward William H. Impedance matching network and multidimensional electromagnetic field coil for a transponder interrogator
US20050027205A1 (en) * 2001-12-14 2005-02-03 Lionel Tarassenko Combining measurements from breathing rate sensors
US20050043894A1 (en) * 2003-08-22 2005-02-24 Fernandez Dennis S. Integrated biosensor and simulation system for diagnosis and therapy
US20050065407A1 (en) * 2003-09-18 2005-03-24 Olympus Corporation Energy supplying coil and capsule endoscope system
US20050062644A1 (en) * 2003-09-08 2005-03-24 Leci Jonathan Ilan Capsule device to identify the location of an individual
US20050070778A1 (en) * 2003-08-20 2005-03-31 Lackey Robert P. Hydration monitoring
US20050192489A1 (en) * 2000-11-08 2005-09-01 Marshall Daniel R. Swallowable data recorder capsule medical device
US6987965B2 (en) * 2000-04-18 2006-01-17 Motorola, Inc. Programmable wireless electrode system for medical monitoring
US6990082B1 (en) * 1999-11-08 2006-01-24 Intel Corporation Wireless apparatus having a transceiver equipped to support multiple wireless communication protocols
US20060028727A1 (en) * 2002-08-20 2006-02-09 Moon John A Method and apparatus for drug product tracking using encoded optical identification elements
US20060030760A1 (en) * 2004-07-20 2006-02-09 Geiger Mark A Vital signs monitoring system with wireless pupilometer interface
US20060036134A1 (en) * 2002-09-18 2006-02-16 E-San Limited Telemedicine system
US7004395B2 (en) * 1990-05-25 2006-02-28 Broadcom Corporation Multi-level hierarchical radio-frequency communication system
US7009946B1 (en) * 2000-06-22 2006-03-07 Intel Corporation Method and apparatus for multi-access wireless communication
US7013162B2 (en) * 1999-09-21 2006-03-14 Ipr Licensing, Inc. Dual mode unit for short range, high rate and long range, lower rate data communications
US20060058602A1 (en) * 2004-08-17 2006-03-16 Kwiatkowski Krzysztof C Interstitial fluid analyzer
US7016648B2 (en) * 2001-12-18 2006-03-21 Ixi Mobile (Israel) Ltd. Method, system and computer readable medium for downloading a software component to a device in a short distance wireless network
US7020508B2 (en) * 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US20060068006A1 (en) * 1999-08-05 2006-03-30 Dimensional Foods Corporation Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same
US20060164213A1 (en) * 2005-01-26 2006-07-27 Battelle Memorial Institute Method for autonomous establishment and utilization of an active-RF tag network
US20060183993A1 (en) * 2004-12-30 2006-08-17 Eli Horn Device, system, and method for locating an in-vivo signal source
US20060229053A1 (en) * 2005-04-06 2006-10-12 Zarlink Semiconductor Ab Implantable RF telemetry devices with power saving mode
US20070002038A1 (en) * 2004-04-07 2007-01-04 Olympus Corporation Intra-subject position display system
US7161484B2 (en) * 2001-04-17 2007-01-09 Micrel Medical Devices S.A. System for monitoring medical parameters
US7160258B2 (en) * 2001-06-26 2007-01-09 Entrack, Inc. Capsule and method for treating or diagnosing the intestinal tract
US20070006636A1 (en) * 2003-04-11 2007-01-11 Oxford Biosignals Limited Method and system for analysing tachometer and vibration data from an apparatus having one or more rotary components
US7164942B2 (en) * 1998-11-09 2007-01-16 Transpharma Medical Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
US20070016089A1 (en) * 2005-07-15 2007-01-18 Fischell David R Implantable device for vital signs monitoring
US7171259B2 (en) * 2003-04-17 2007-01-30 Polar Electro Oy Method and device for measuring heart rate, and method for manufacturing the device
US7171177B2 (en) * 2004-09-07 2007-01-30 Electronics And Telecommunications Research Institute Communication apparatus and method using human body as medium
US20070027388A1 (en) * 2005-08-01 2007-02-01 Chang-An Chou Patch-type physiological monitoring apparatus, system and network
US20070027386A1 (en) * 2003-07-16 2007-02-01 Koninklijke Philips Electronics N.V. Portable electronic device and a health management system arranged for monitoring a physiological condition of an individual
US7176784B2 (en) * 2004-01-21 2007-02-13 Battelle Memorial Institute K1-53 Multi-mode radio frequency device
US20070038054A1 (en) * 2004-05-20 2007-02-15 Peter Zhou Embedded bio-sensor system
US20070049339A1 (en) * 2005-08-29 2007-03-01 Amit Barak Method and apparatus of multiple entity wireless communication adapter
US20070060800A1 (en) * 2001-06-29 2007-03-15 Darrel Drinan Gateway platform for biological monitoring and delivery of therapeutic compounds
US20070060797A1 (en) * 2005-08-31 2007-03-15 Ball James J Automatic parameter status on an implantable medical device system
US20070123772A1 (en) * 2005-07-20 2007-05-31 Neil Euliano Medication compliance system and associated methods
US20080014866A1 (en) * 2006-07-12 2008-01-17 Lipowski Joseph T Transceiver architecture and method for wireless base-stations
US20080021519A1 (en) * 2004-05-28 2008-01-24 Jan De Geest Communication Unit for a Person's Skin
US20080021521A1 (en) * 2006-07-18 2008-01-24 Cardiac Pacemakers, Inc. Implantable Medical Device Communication System
US20080027679A1 (en) * 2004-07-21 2008-01-31 Dror Shklarski Wearable Device, System and Method for Measuring Physiological and/or Environmental Parameters
US20080046038A1 (en) * 2006-06-26 2008-02-21 Hill Gerard J Local communications network for distributed sensing and therapy in biomedical applications
US20080045843A1 (en) * 2004-08-12 2008-02-21 Tomoharu Tsuji Via-Human-Body Information Transmission System and Transmitter-Receiver
US7336929B2 (en) * 2004-07-05 2008-02-26 Sony Ericsson Mobile Communications Japan, Inc. Short range wireless communication system, portable terminal apparatus, and wireless communication apparatus
US20080051667A1 (en) * 2004-05-16 2008-02-28 Rami Goldreich Method And Device For Measuring Physiological Parameters At The Hand
US20080051647A1 (en) * 2006-05-11 2008-02-28 Changwang Wu Non-invasive acquisition of large nerve action potentials (NAPs) with closely spaced surface electrodes and reduced stimulus artifacts
US7382247B2 (en) * 2003-03-21 2008-06-03 Welch Allyn, Inc. Personal status physiologic monitor system and architecture and related monitoring methods
US20080316020A1 (en) * 2007-05-24 2008-12-25 Robertson Timothy L Rfid antenna for in-body device
US20090009330A1 (en) * 2007-07-03 2009-01-08 Isao Sakama Rfid tag mounting circuit board
US20090016102A1 (en) * 1996-05-01 2009-01-15 Yusuke Jyouno Nonvolatile semiconductor memory device which stores multi-value information
US20090024045A1 (en) * 2007-07-19 2009-01-22 Rajan Prakash Mechanical function marker channel for cardiac monitoring and therapy control
US20090030297A1 (en) * 2002-09-27 2009-01-29 Medtronic Minimed, Inc. Implantable sensor method and system
US20090034209A1 (en) * 2007-08-03 2009-02-05 Samsung Electronics Co., Ltd. Multi-module combination type portable electronic device
US20090043171A1 (en) * 2007-07-16 2009-02-12 Peter Rule Systems And Methods For Determining Physiological Parameters Using Measured Analyte Values
US20090048498A1 (en) * 2007-08-17 2009-02-19 Frank Riskey System and method of monitoring an animal
US20100001841A1 (en) * 2008-07-07 2010-01-07 Cardullo Mario W Dynamically distributable nano rfid device and related method
US7647185B2 (en) * 2000-06-16 2010-01-12 Oxford Biosignals Limited Combining measurements from different sensors
US7647112B2 (en) * 2004-02-11 2010-01-12 Ethicon, Inc. System and method for selectively stimulating different body parts
US20100010330A1 (en) * 2007-06-01 2010-01-14 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
US7653031B2 (en) * 2003-03-05 2010-01-26 Timothy Gordon Godfrey Advance notification of transmit opportunities on a shared-communications channel
US20100027411A1 (en) * 2005-10-26 2010-02-04 Thomson Licensing System and Method for Compensating for a Satellite Gateway Failure
US7668437B1 (en) * 1999-09-30 2010-02-23 Sony Corporation Recording apparatus, recording method, and record medium
US20100049069A1 (en) * 2006-12-01 2010-02-25 Oxford Biosignals Limited Biomedical signal morphology analysis method
US20100049004A1 (en) * 2008-04-21 2010-02-25 Philometron, Inc. Metabolic energy monitoring system
US20100049012A1 (en) * 2006-11-21 2010-02-25 Koninklijke Philips Electronics N.V. Ingestible electronic capsule and in vivo drug delivery or diagnostic system
US20100049006A1 (en) * 2006-02-24 2010-02-25 Surendar Magar Medical signal processing system with distributed wireless sensors

Family Cites Families (330)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679480A (en) 1969-05-08 1972-07-25 Dow Chemical Co Electrical cell assembly
US3944064A (en) 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US4106348A (en) 1974-02-20 1978-08-15 U.S. Philips Corporation Device for examination by means of ultrasonic vibrations
US3893111A (en) 1974-03-14 1975-07-01 Albert Albert F System and method for remote monitoring of animal temperature
US4055178A (en) 1976-03-10 1977-10-25 Harrigan Roy Major Drug delivery device for preventing contact of undissolved drug with the stomach lining
DE2928477C3 (en) 1979-07-14 1982-04-15 Battelle-Institut E.V., 6000 Frankfurt Device for the release of substances at defined locations in the digestive tract
US4331654A (en) 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4418697A (en) 1981-08-17 1983-12-06 Francine Tama Electrode attachment method
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4564363A (en) 1983-07-13 1986-01-14 Smithkline Beckman Corporation Delayed action assembly
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
GB8422876D0 (en) 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
FR2571603B1 (en) 1984-10-11 1989-01-06 Ascher Gilles PORTABLE ELECTROCARDIOGRAM RECORDER
US4654165A (en) 1985-04-16 1987-03-31 Micro Tracers, Inc. Microingredient containing tracer
US4725997A (en) 1986-08-22 1988-02-16 Aprex Corporation Contingent dosing device
US4784162A (en) 1986-09-23 1988-11-15 Advanced Medical Technologies Portable, multi-channel, physiological data monitoring system
US4896261A (en) 1986-11-24 1990-01-23 Motorola Inc. System for scheduling serial message transmission on a bus which is adoptable for rescheduling prioritized messages using a doubly-linked list
US4876093A (en) 1987-07-02 1989-10-24 Alza Corporation Dispenser with dispersing member for delivering beneficial agent
DE3723310A1 (en) 1987-07-15 1989-01-26 John Urquhart PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US4975230A (en) 1988-06-17 1990-12-04 Vapor Technologies Inc. Method of making an open pore structure
EP0489067B1 (en) 1989-08-29 1994-03-16 William Prym GmbH & Co. KG Button fastener, in particular for items of clothing
US4987897A (en) 1989-09-18 1991-01-29 Medtronic, Inc. Body bus medical device communication system
US5395366A (en) 1991-05-30 1995-03-07 The State University Of New York Sampling capsule and process
US6605046B1 (en) 1991-06-03 2003-08-12 Del Mar Medical Systems, Llc Ambulatory physio-kinetic monitor with envelope enclosure
US5176626A (en) 1992-01-15 1993-01-05 Wilson-Cook Medical, Inc. Indwelling stent
JPH05228128A (en) 1992-02-25 1993-09-07 Olympus Optical Co Ltd Capsule for medical treatment
US5283136A (en) 1992-06-03 1994-02-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Rechargeable batteries
US5318557A (en) 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
JP3454525B2 (en) 1992-07-23 2003-10-06 三洋電機株式会社 Micromachines and power systems in micromachines
US7758503B2 (en) 1997-01-27 2010-07-20 Lynn Lawrence A Microprocessor system for the analysis of physiologic and financial datasets
US5757326A (en) 1993-03-29 1998-05-26 Seiko Epson Corporation Slot antenna device and wireless apparatus employing the antenna device
DE69532572T2 (en) 1994-03-11 2004-08-05 Ntt Docomo, Inc. TIME DIVERSITY COMMUNICATION ARRANGEMENT
IE70735B1 (en) 1994-08-15 1996-12-11 Elan Med Tech Orally administrable delivery device
US5485841A (en) 1995-02-14 1996-01-23 Univ Mcgill Ultrasonic lung tissue assessment
US5845265A (en) 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5720771A (en) 1995-08-02 1998-02-24 Pacesetter, Inc. Method and apparatus for monitoring physiological data from an implantable medical device
USD377983S (en) 1995-09-13 1997-02-11 Mohamed Sabri Cardiac monitor
US5596302A (en) 1996-01-17 1997-01-21 Lucent Technologies Inc. Ring oscillator using even numbers of differential stages with current mirrors
US5833603A (en) 1996-03-13 1998-11-10 Lipomatrix, Inc. Implantable biosensing transponder
WO1997036646A1 (en) 1996-04-01 1997-10-09 Valery Ivanovich Kobozev Electrical gastro-intestinal tract stimulator
GB9608268D0 (en) 1996-04-22 1996-06-26 Robertson James L Blister pack
US5864578A (en) 1996-04-29 1999-01-26 Golden Bridge Technology, Inc. Matched filter-based handoff method and apparatus
JPH09330159A (en) 1996-06-11 1997-12-22 Omron Corp Data processor, game controller data processing method and game processing method
US5792048A (en) 1996-09-03 1998-08-11 Schaefer; Guenter Indentification pill with integrated microchip: smartpill, smartpill with integrated microchip and microprocessor for medical analyses and a smartpill, smartbox, smartplague, smartbadge or smartplate for luggage control on commercial airliners
US5963132A (en) 1996-10-11 1999-10-05 Avid Indentification Systems, Inc. Encapsulated implantable transponder
US6394953B1 (en) 2000-02-25 2002-05-28 Aspect Medical Systems, Inc. Electrode array system for measuring electrophysiological signals
US8734339B2 (en) 1996-12-16 2014-05-27 Ip Holdings, Inc. Electronic skin patch for real time monitoring of cardiac activity and personal health management
US5928142A (en) 1996-12-17 1999-07-27 Ndm, Inc. Biomedical electrode having a disposable electrode and a reusable leadwire adapter that interfaces with a standard leadwire connector
US6122351A (en) 1997-01-21 2000-09-19 Med Graph, Inc. Method and system aiding medical diagnosis and treatment
US5921925A (en) 1997-05-30 1999-07-13 Ndm, Inc. Biomedical electrode having a disposable electrode and a reusable leadwire adapter that interfaces with a standard leadwire connector
US6409674B1 (en) 1998-09-24 2002-06-25 Data Sciences International, Inc. Implantable sensor with wireless communication
US5948227A (en) 1997-12-17 1999-09-07 Caliper Technologies Corp. Methods and systems for performing electrophoretic molecular separations
GB9801363D0 (en) 1998-01-22 1998-03-18 Danbiosyst Uk Novel dosage form
US6097927A (en) 1998-01-27 2000-08-01 Symbix, Incorporated Active symbolic self design method and apparatus
US6275476B1 (en) 1998-02-19 2001-08-14 Micron Technology, Inc. Method of addressing messages and communications system
US6141592A (en) 1998-03-06 2000-10-31 Intermedics Inc. Data transmission using a varying electric field
ATE245937T1 (en) 1998-05-13 2003-08-15 Cygnus Therapeutic Systems MONITORING PHYSIOLOGICAL ANALYTES
TW406018B (en) 1998-05-21 2000-09-21 Elan Corp Plc Improved adhesive system for medical devices
US6704602B2 (en) 1998-07-02 2004-03-09 Medtronic, Inc. Implanted medical device/external medical instrument communication utilizing surface electrodes
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
CA2341708A1 (en) 1998-09-04 2000-03-16 Wolfe Research Pty. Ltd. Medical implant system
US6204764B1 (en) 1998-09-11 2001-03-20 Key-Trak, Inc. Object tracking system with non-contact object detection and identification
US6344824B1 (en) 1998-09-18 2002-02-05 Hitachi Maxell, Ltd. Noncontact communication semiconductor device
US6217744B1 (en) 1998-12-18 2001-04-17 Peter Crosby Devices for testing fluid
US6117077A (en) 1999-01-22 2000-09-12 Del Mar Medical Systems, Llc Long-term, ambulatory physiological recorder
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US6285897B1 (en) 1999-04-07 2001-09-04 Endonetics, Inc. Remote physiological monitoring system
US6366206B1 (en) 1999-06-02 2002-04-02 Ball Semiconductor, Inc. Method and apparatus for attaching tags to medical and non-medical devices
DE19929328A1 (en) 1999-06-26 2001-01-04 Daimlerchrysler Aerospace Ag Device for long-term medical monitoring of people
US6206702B1 (en) 1999-08-24 2001-03-27 Deborah A. Hayden Methods and devices for treating unilateral neglect
US6533733B1 (en) * 1999-09-24 2003-03-18 Ut-Battelle, Llc Implantable device for in-vivo intracranial and cerebrospinal fluid pressure monitoring
US6426863B1 (en) 1999-11-25 2002-07-30 Lithium Power Technologies, Inc. Electrochemical capacitor
CA2401777A1 (en) * 1999-12-21 2001-06-28 Bozidar Ferek-Petric System for dynamic remote networking with implantable medical devices
GB9930000D0 (en) 1999-12-21 2000-02-09 Phaeton Research Ltd An ingestible device
US6294999B1 (en) 1999-12-29 2001-09-25 Becton, Dickinson And Company Systems and methods for monitoring patient compliance with medication regimens
US7039453B2 (en) 2000-02-08 2006-05-02 Tarun Mullick Miniature ingestible capsule
IL177381A0 (en) 2000-03-08 2006-12-10 Given Imaging Ltd A device for in vivo imaging
US6654638B1 (en) 2000-04-06 2003-11-25 Cardiac Pacemakers, Inc. Ultrasonically activated electrodes
US6432292B1 (en) 2000-05-16 2002-08-13 Metallic Power, Inc. Method of electrodepositing metal on electrically conducting particles
IL163684A0 (en) 2000-05-31 2005-12-18 Given Imaging Ltd Measurement of electrical characteristics of tissue
US6961285B2 (en) 2000-07-07 2005-11-01 Ddms Holdings L.L.C. Drug delivery management system
JP4428835B2 (en) 2000-08-09 2010-03-10 昭和電工株式会社 Magnetic recording medium and method for manufacturing the same
US8036731B2 (en) 2001-01-22 2011-10-11 Spectrum Dynamics Llc Ingestible pill for diagnosing a gastrointestinal tract
KR20020015907A (en) 2000-08-23 2002-03-02 정병렬 A method and system of a fitness using a game control for a beating of the heart
US6720923B1 (en) 2000-09-14 2004-04-13 Stata Labs, Llc Antenna design utilizing a cavity architecture for global positioning system (GPS) applications
US7024248B2 (en) 2000-10-16 2006-04-04 Remon Medical Technologies Ltd Systems and methods for communicating with implantable devices
US6929636B1 (en) 2000-11-08 2005-08-16 Hewlett-Packard Development Company, L.P. Internal drug dispenser capsule medical device
US6689117B2 (en) 2000-12-18 2004-02-10 Cardiac Pacemakers, Inc. Drug delivery system for implantable medical device
KR100526699B1 (en) 2001-01-17 2005-11-08 이종식 Method and System for Network Games
JP2002224053A (en) 2001-02-05 2002-08-13 Next:Kk Remote medical control system
JP2002263185A (en) 2001-03-12 2002-09-17 Sanyo Electric Co Ltd Medicine administration system and method and medicine administration device
JP2002290212A (en) 2001-03-27 2002-10-04 Nec Corp Voltage controlled oscillator
JP2002291684A (en) 2001-03-29 2002-10-08 Olympus Optical Co Ltd Endoscope for surgical operation, and outer tube
US6694161B2 (en) 2001-04-20 2004-02-17 Monsanto Technology Llc Apparatus and method for monitoring rumen pH
US6782290B2 (en) 2001-04-27 2004-08-24 Medtronic, Inc. Implantable medical device with rechargeable thin-film microbattery power source
EP1397660B1 (en) 2001-05-20 2013-05-15 Given Imaging Ltd. A floatable in vivo sensing device
AU2002311613A1 (en) 2001-06-18 2003-01-02 Given Imaging Ltd. In vivo sensing device with a circuit board having rigid sections and flexible sections
EP1414343B1 (en) 2001-07-11 2009-06-03 CNS Response, Inc. Method for predicting outcome of treatments
US20030017826A1 (en) 2001-07-17 2003-01-23 Dan Fishman Short-range wireless architecture
US6951536B2 (en) 2001-07-30 2005-10-04 Olympus Corporation Capsule-type medical device and medical system
US6650191B2 (en) 2001-09-07 2003-11-18 Texas Instruments Incorporated Low jitter ring oscillator architecture
US6604650B2 (en) 2001-09-28 2003-08-12 Koninklijke Philips Electronics N.V. Bottle-cap medication reminder and overdose safeguard
US20050137480A1 (en) 2001-10-01 2005-06-23 Eckhard Alt Remote control of implantable device through medical implant communication service band
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US7377647B2 (en) 2001-11-13 2008-05-27 Philadelphia Retina Endowment Fund Clarifying an image of an object to perform a procedure on the object
US7877273B2 (en) 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
WO2003060808A2 (en) 2002-01-11 2003-07-24 Hexalog Sa Systems and methods for medication monitoring
IL154391A (en) 2002-02-11 2009-05-04 Given Imaging Ltd Self propelled device
US6935560B2 (en) 2002-02-26 2005-08-30 Safety Syringes, Inc. Systems and methods for tracking pharmaceuticals within a facility
US20030162556A1 (en) 2002-02-28 2003-08-28 Libes Michael A. Method and system for communication between two wireless-enabled devices
US7468032B2 (en) 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
JP4363843B2 (en) * 2002-03-08 2009-11-11 オリンパス株式会社 Capsule endoscope
US7022070B2 (en) 2002-03-22 2006-04-04 Mini-Mitter Co., Inc. Method for continuous monitoring of patients to detect the potential onset of sepsis
JP3869291B2 (en) 2002-03-25 2007-01-17 オリンパス株式会社 Capsule medical device
US7654901B2 (en) 2002-04-10 2010-02-02 Breving Joel S Video game system using bio-feedback devices
US20030216622A1 (en) 2002-04-25 2003-11-20 Gavriel Meron Device and method for orienting a device in vivo
TW553735B (en) 2002-05-01 2003-09-21 Jin-Shing Luo Common electrode using human body as common electric reservoir and application thereof
JP2003325439A (en) 2002-05-15 2003-11-18 Olympus Optical Co Ltd Capsule type medical treatment device
JP2004041709A (en) 2002-05-16 2004-02-12 Olympus Corp Capsule medical care device
US6847844B2 (en) 2002-06-06 2005-01-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of data communication with implanted device and associated apparatus
US20040008123A1 (en) 2002-07-15 2004-01-15 Battelle Memorial Institute System and method for tracking medical devices
US20040019172A1 (en) 2002-07-26 2004-01-29 Tou-Hsiung Yang Biodegradable, water absorbable resin and its preparation method
US7211349B2 (en) 2002-08-06 2007-05-01 Wilson Greatbatch Technologies, Inc. Silver vanadium oxide provided with a metal oxide coating
US20040049245A1 (en) 2002-09-09 2004-03-11 Volker Gass Autonomous patch for communication with an implantable device, and medical kit for using said patch
US20040073454A1 (en) 2002-10-10 2004-04-15 John Urquhart System and method of portal-mediated, website-based analysis of medication dosing
US20050272989A1 (en) 2004-06-04 2005-12-08 Medtronic Minimed, Inc. Analyte sensors and methods for making and using them
US6959217B2 (en) 2002-10-24 2005-10-25 Alfred E. Mann Foundation For Scientific Research Multi-mode crystal oscillator system selectively configurable to minimize power consumption or noise generation
EP1437784B1 (en) 2002-11-08 2012-05-30 Honda Motor Co., Ltd. Electrode for solid polymer fuel cell
US20040133095A1 (en) * 2002-11-14 2004-07-08 Dunki-Jacobs Robert J. Methods and devices for detecting abnormal tissue cells
US20050288594A1 (en) 2002-11-29 2005-12-29 Shlomo Lewkowicz Methods, device and system for in vivo diagnosis
WO2004052343A1 (en) 2002-12-11 2004-06-24 Pfizer Products Inc. Controlled-release of an active substance into a high fat environment
US20060155174A1 (en) 2002-12-16 2006-07-13 Arkady Glukhovsky Device, system and method for selective activation of in vivo sensors
US6975174B1 (en) 2002-12-31 2005-12-13 Radioframe Networks, Inc. Clock oscillator
US7505029B2 (en) 2002-12-31 2009-03-17 Intel Corporation System and method for controlling multiple processing units with a single input device
KR100873683B1 (en) 2003-01-25 2008-12-12 한국과학기술연구원 Method and system for data communication in human body and capsule-type endoscope used therein
CA2514392A1 (en) 2003-01-29 2004-08-12 E-Pill Pharma Ltd. Active drug delivery in the gastrointestinal tract
US20040267240A1 (en) 2003-01-29 2004-12-30 Yossi Gross Active drug delivery in the gastrointestinal tract
US7002476B2 (en) 2003-01-30 2006-02-21 Leap Of Faith Technologies, Inc. Medication compliance system
JP4158097B2 (en) 2003-02-27 2008-10-01 ソニー株式会社 Authentication system
US20040193446A1 (en) 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
US7245954B2 (en) 2003-03-27 2007-07-17 Given Imaging Ltd. Measuring a gradient in-vivo
GB0308114D0 (en) 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
US7972616B2 (en) 2003-04-17 2011-07-05 Nanosys, Inc. Medical device applications of nanostructured surfaces
JP4414682B2 (en) 2003-06-06 2010-02-10 オリンパス株式会社 Ultrasound endoscope device
US7252152B2 (en) 2003-06-18 2007-08-07 Weatherford/Lamb, Inc. Methods and apparatus for actuating a downhole tool
WO2004112592A1 (en) 2003-06-24 2004-12-29 Olympus Corporation Capsule type medical device communication system, capsule type medical device, and biological information reception device
WO2005007223A2 (en) 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
JP4038575B2 (en) 2003-07-25 2008-01-30 独立行政法人産業技術総合研究所 Biosensor, biosensor device or biosensor storage method
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
WO2005016558A2 (en) 2003-08-04 2005-02-24 Microchips, Inc. Methods for accelerated release of material from a reservoir device
EP2008581B1 (en) 2003-08-18 2011-08-17 Cardiac Pacemakers, Inc. Patient monitoring, diagnosis, and/or therapy systems and methods
US20050172958A1 (en) 2003-08-20 2005-08-11 The Brigham And Women's Hospital, Inc. Inhalation device and system for the remote monitoring of drug administration
JP4398204B2 (en) 2003-08-29 2010-01-13 オリンパス株式会社 In-subject introduction apparatus and wireless in-subject information acquisition system
JP3993546B2 (en) 2003-09-08 2007-10-17 オリンパス株式会社 In-subject introduction apparatus and wireless in-subject information acquisition system
BRPI0414345A (en) 2003-09-12 2006-11-07 Bodymedia Inc method and apparatus for measuring heart-related parameters
US20050075145A1 (en) 2003-10-03 2005-04-07 Dvorak Joseph L. Method and system for coordinating use of objects using wireless communications
US20050096514A1 (en) 2003-11-01 2005-05-05 Medtronic, Inc. Gastric activity notification
US6892590B1 (en) 2003-11-04 2005-05-17 Andermotion Technologies Llc Single-balanced shield electrode configuration for use in capacitive displacement sensing systems and methods
US7101343B2 (en) 2003-11-05 2006-09-05 Temple University Of The Commonwealth System Of Higher Education Implantable telemetric monitoring system, apparatus, and method
JP2005158770A (en) 2003-11-20 2005-06-16 Matsushita Electric Ind Co Ltd Laminated substrate and manufacturing method thereof, manufacturing method and apparatus of module using the laminated substrate
US6987691B2 (en) 2003-12-02 2006-01-17 International Business Machines Corporation Easy axis magnetic amplifier
US7427266B2 (en) 2003-12-15 2008-09-23 Hewlett-Packard Development Company, L.P. Method and apparatus for verification of ingestion
JP2005185567A (en) 2003-12-25 2005-07-14 Olympus Corp Medical capsule apparatus
JP2005192821A (en) 2004-01-07 2005-07-21 Olympus Corp Capsule type medical apparatus
US7081807B2 (en) 2004-01-14 2006-07-25 Joseph Lai Automatic pill reminder bottles
US20060154642A1 (en) 2004-02-20 2006-07-13 Scannell Robert F Jr Medication & health, environmental, and security monitoring, alert, intervention, information and network system with associated and supporting apparatuses
US20050187789A1 (en) 2004-02-25 2005-08-25 Cardiac Pacemakers, Inc. Advanced patient and medication therapy management system and method
JP4921349B2 (en) 2004-02-27 2012-04-25 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Wearable wireless device for monitoring, analysis and transmission of physiological conditions
US7406105B2 (en) 2004-03-03 2008-07-29 Alfred E. Mann Foundation For Scientific Research System and method for sharing a common communication channel between multiple systems of implantable medical devices
CA2564977C (en) 2004-04-24 2014-08-12 Inrange Systems, Inc. Integrated, non-sequential, remote medication management and compliance system
US20050245794A1 (en) 2004-04-29 2005-11-03 Medtronic, Inc. Communication with implantable monitoring probe
JP4445799B2 (en) * 2004-05-24 2010-04-07 オリンパス株式会社 Intra-subject introduction device and medical device
US7653542B2 (en) 2004-05-26 2010-01-26 Verizon Business Global Llc Method and system for providing synthesized speech
US7283867B2 (en) 2004-06-10 2007-10-16 Ndi Medical, Llc Implantable system and methods for acquisition and processing of electrical signals from muscles and/or nerves and/or central nervous system tissue
JP2006006377A (en) 2004-06-22 2006-01-12 Elquest Corp Powder paper for packing medicine
US7498940B2 (en) 2004-06-22 2009-03-03 Vubiq, Inc. RFID system utilizing parametric reradiated technology
US20060001496A1 (en) 2004-07-02 2006-01-05 Abrosimov Igor A Array oscillator and polyphase clock generator
US7317378B2 (en) 2004-08-17 2008-01-08 Tagent Corporation Product identification tag device and reader
US7253716B2 (en) 2004-08-17 2007-08-07 Tagent Corporation Trackable pills with electronic ID tags
CN101010114B (en) 2004-08-27 2010-05-26 皇家飞利浦电子股份有限公司 Electronically and remotely controlled pill and system for delivering at least one medicament
GB2418144A (en) 2004-09-17 2006-03-22 Psimedica Ltd Medical device for delivery of beneficial substance
US20060065713A1 (en) 2004-09-24 2006-03-30 John Russell Kingery System and method for monitored administration of medical products to patients
US8308640B2 (en) 2004-09-30 2012-11-13 Koninklijke Philips Electronics N.V. System for automatic continuous and reliable patient identification for association of wireless medical devices to patients
US20060078765A1 (en) 2004-10-12 2006-04-13 Laixia Yang Nano-structured ion-conducting inorganic membranes for fuel cell applications
JP2008011865A (en) 2004-10-27 2008-01-24 Sharp Corp Healthcare apparatus and program for driving the same to function
IL171772A (en) 2004-11-04 2009-11-18 Given Imaging Ltd Apparatus and method for receiving device selection and combining
US7414534B1 (en) 2004-11-09 2008-08-19 Pacesetter, Inc. Method and apparatus for monitoring ingestion of medications using an implantable medical device
US7930064B2 (en) 2004-11-19 2011-04-19 Parata Systems, Llc Automated drug discrimination during dispensing
JP2008521541A (en) * 2004-12-02 2008-06-26 ギブン イメージング リミテッド In vivo electrical stimulation devices, systems, and methods
US8374693B2 (en) 2004-12-03 2013-02-12 Cardiac Pacemakers, Inc. Systems and methods for timing-based communication between implantable medical devices
US7616710B2 (en) 2004-12-08 2009-11-10 Electronics And Telecommunications Research Institute Frequency offset estimating method and receiver employing the same
US20060148254A1 (en) 2005-01-05 2006-07-06 Mclean George Y Activated iridium oxide electrodes and methods for their fabrication
JP2008526419A (en) 2005-01-18 2008-07-24 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Electronically controlled ingestible capsule for sampling fluid in the digestive tract
CN101237903A (en) 2005-01-18 2008-08-06 皇家飞利浦电子股份有限公司 System and method for controlling traversal of an ingested capsule
US7345588B2 (en) 2005-01-28 2008-03-18 Innotek, Inc. Receiver collar
JP4731936B2 (en) 2005-02-09 2011-07-27 本田技研工業株式会社 Rotary variable resistor
JP4099484B2 (en) 2005-02-09 2008-06-11 株式会社カイザーテクノロジー Communications system.
US7850645B2 (en) 2005-02-11 2010-12-14 Boston Scientific Scimed, Inc. Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power
AU2006212007A1 (en) 2005-02-11 2006-08-17 The University Court Of The University Of Glasgow Sensing device, apparatus and system, and method for operating the same
KR20060097523A (en) 2005-03-10 2006-09-14 강성철 Apparatus for automatic peeling and plating of lead wire
US20060252999A1 (en) 2005-05-03 2006-11-09 Devaul Richard W Method and system for wearable vital signs and physiology, activity, and environmental monitoring
US20060216603A1 (en) 2005-03-26 2006-09-28 Enable Ipc Lithium-ion rechargeable battery based on nanostructures
JP2006278091A (en) 2005-03-29 2006-10-12 Hitachi Maxell Ltd Coin-shaped silver-oxide battery
US20060224326A1 (en) 2005-03-31 2006-10-05 St Ores John W Integrated data collection and analysis for clinical study
CA2608144C (en) 2005-04-28 2012-11-13 Proteus Biomedical, Inc. Pharma-informatics system
US7414543B2 (en) 2005-04-28 2008-08-19 Honeywell International Inc. Multiple miniature avionic displays
WO2006122180A2 (en) 2005-05-10 2006-11-16 Par Technologies Llc Disposable fluid container with integrated pump motive assembly
CN101217945B (en) 2005-05-20 2012-07-11 陶氏环球技术有限责任公司 Oral drug compliance monitoring using radio frequency identification tags
JP4254747B2 (en) 2005-05-31 2009-04-15 カシオ計算機株式会社 Light source device and projection device
EP1904173B8 (en) 2005-06-09 2016-06-08 Medtronic, Inc. Implantable medical device with electrodes on multiple housing surfaces
WO2006130988A1 (en) 2005-06-10 2006-12-14 Telecommunications Research Laboratories Wireless communication system
US7782189B2 (en) 2005-06-20 2010-08-24 Carestream Health, Inc. System to monitor the ingestion of medicines
US7299034B2 (en) 2005-06-21 2007-11-20 Lawrence Kates System and method for wearable electronics
US20100135907A1 (en) 2005-07-22 2010-06-03 Cranley Paul E Oral Drug Compliance Monitoring Using Sound Detection
WO2007021496A2 (en) 2005-08-18 2007-02-22 Walker Digital, Llc Systems and methods for improved health care compliance
EP1920418A4 (en) 2005-09-01 2010-12-29 Proteus Biomedical Inc Implantable zero-wire communications system
JP2007068622A (en) 2005-09-05 2007-03-22 Olympus Corp Acquisition system for biological information of subject
US7673679B2 (en) 2005-09-19 2010-03-09 Schlumberger Technology Corporation Protective barriers for small devices
GB0519836D0 (en) 2005-09-29 2005-11-09 Smartlife Technology Ltd Contact sensors
GB0519837D0 (en) 2005-09-29 2005-11-09 Smartlife Technology Ltd Knitting techniques
US7456329B2 (en) 2005-11-30 2008-11-25 Exxonmobil Chemical Patents Inc. Polyolefins from non-conventional feeds
CN101321494B (en) 2005-11-30 2011-04-06 皇家飞利浦电子股份有限公司 Electro-mechanical connector for thin medical monitoring patch
TWI400800B (en) * 2005-12-02 2013-07-01 Semiconductor Energy Lab Semiconductor device
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
NL1030608C2 (en) 2005-12-06 2007-06-07 Patrick Antonius Hendri Meeren Blister package, assembly of a blister package and a holder, and method for packaging objects.
JP2007159631A (en) 2005-12-09 2007-06-28 Taito Corp Game machine and game program
US20070135691A1 (en) 2005-12-12 2007-06-14 General Electric Company Medicament compliance monitoring system, method, and medicament container
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
TWI306023B (en) 2005-12-30 2009-02-11 Ind Tech Res Inst Monitoring apparatus for physical movements of a body organ and method for acouiring the same
JP2009523376A (en) 2006-01-11 2009-06-18 クゥアルコム・インコーポレイテッド Recognition communication
CN100571239C (en) * 2006-01-16 2009-12-16 华为技术有限公司 Synchronizing pilot sequence generation system and method in the communication system
EP1981402B1 (en) 2006-02-06 2016-08-10 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive cardiac monitor
US8200320B2 (en) 2006-03-03 2012-06-12 PhysioWave, Inc. Integrated physiologic monitoring systems and methods
CN102323984A (en) 2006-03-30 2012-01-18 陶氏环球技术有限责任公司 Be used to monitor and analyze the method and system of complying with of body innerlich anwenden scheme
US7806852B1 (en) 2006-04-03 2010-10-05 Jurson Phillip A Method and apparatus for patient-controlled medical therapeutics
MY187399A (en) * 2006-04-28 2021-09-22 Qualcomm Inc Method and apparatus for enhanced paging
CN105468895A (en) 2006-05-02 2016-04-06 普罗透斯数字保健公司 Patient customized therapeutic regimens
WO2007133526A2 (en) * 2006-05-10 2007-11-22 Interdigital Technology Corporation Method and apparatus for battery management in a converged wireless transmit/receive unit
US20080051767A1 (en) 2006-05-19 2008-02-28 Cvrx, Inc. Characterization and modulation of physiologic response using baroreflex activation in conjunction with drug therapy
FI120482B (en) 2006-06-08 2009-11-13 Suunto Oy Anturointijärjestely
US20100143232A1 (en) 2006-06-21 2010-06-10 Benedict James Costello Metal binary and ternary compounds produced by cathodic arc deposition
EP2046434B1 (en) 2006-06-23 2012-02-08 Koninklijke Philips Electronics N.V. Medicament delivery system
US8165896B2 (en) 2006-06-29 2012-04-24 The Invention Science Fund I, Llc Compliance data for health-related procedures
EP1872765B1 (en) 2006-06-29 2009-04-29 Edwin Kohl Personalized blister pack and method for automated packaging of an individually determined composition
IL176712A0 (en) 2006-07-05 2007-10-31 Michael Cohen Alloro Medication dispenser
JP5241714B2 (en) 2006-07-07 2013-07-17 プロテウス デジタル ヘルス, インコーポレイテッド Smart parenteral delivery system
EP2043728A2 (en) 2006-07-11 2009-04-08 Microchips, Inc. Multi-reservoir pump device for dialysis, biosensing, or delivery of substances
US20080020037A1 (en) 2006-07-11 2008-01-24 Robertson Timothy L Acoustic Pharma-Informatics System
EP2063766B1 (en) 2006-09-06 2017-01-18 Innurvation, Inc. Ingestible low power sensor device and system for communicating with same
US8615284B2 (en) * 2006-09-06 2013-12-24 Innurvation, Inc. Method for acoustic information exchange involving an ingestible low power capsule
US20080077028A1 (en) 2006-09-27 2008-03-27 Biotronic Crm Patent Personal health monitoring and care system
CN101522094B (en) 2006-09-29 2013-12-18 皇家飞利浦电子股份有限公司 Miniaturized threshold sensor
US20080091089A1 (en) 2006-10-12 2008-04-17 Kenneth Shane Guillory Single use, self-contained surface physiological monitor
WO2008066617A2 (en) 2006-10-17 2008-06-05 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
KR101611240B1 (en) 2006-10-25 2016-04-11 프로테우스 디지털 헬스, 인코포레이티드 Controlled activation ingestible identifier
US8214007B2 (en) 2006-11-01 2012-07-03 Welch Allyn, Inc. Body worn physiological sensor device having a disposable electrode module
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc Active signal processing personal health signal receivers
US8180425B2 (en) 2006-12-05 2012-05-15 Tyco Healthcare Group Lp ECG lead wire organizer and dispenser
CN101547635B (en) 2006-12-07 2011-09-14 皇家飞利浦电子股份有限公司 Handheld, repositionable ECG detector
KR101475666B1 (en) 2007-02-01 2014-12-23 프로테우스 디지털 헬스, 인코포레이티드 ingestible event marker systems
CN103066226B (en) 2007-02-14 2016-09-14 普罗透斯数字保健公司 There is the in-body power source of high surface area electrode
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
EP2063771A1 (en) 2007-03-09 2009-06-03 Proteus Biomedical, Inc. In-body device having a deployable antenna
US8091790B2 (en) 2007-03-16 2012-01-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Security for blister packs
WO2008120128A2 (en) 2007-03-30 2008-10-09 Koninklijke Philips Electronics N.V. System and method for pill communication and control
US7971414B1 (en) 2007-05-30 2011-07-05 Walgreen Co. Multi-dose filling machine
GB2450517A (en) 2007-06-27 2008-12-31 Smartlife Technology Ltd Electrical resistance of yarn or fabric changes with temperature
CN201076456Y (en) 2007-06-29 2008-06-25 洪金叶 Clamp style wireless transmission pulse detection device
US20090009332A1 (en) 2007-07-03 2009-01-08 Endotronix, Inc. System and method for monitoring ingested medication via rf wireless telemetry
JP4520491B2 (en) 2007-07-09 2010-08-04 オリンパス株式会社 Capsule medical system
US20090062670A1 (en) 2007-08-30 2009-03-05 Gary James Sterling Heart monitoring body patch and system
JP2009061236A (en) 2007-09-07 2009-03-26 Arimasa Nishida Small terminal with functions of reading and inputting multi-data on personal medical information, of data management, analysis, and display, and of entertainment, game, and communication to facilitate self-management for health, having strong bio-feedback effect on life-style related disease, which allows unified management of measured personal data at first when developing medical information database at medical institute, or local/national government
US8249686B2 (en) 2007-09-14 2012-08-21 Corventis, Inc. Adherent device for sleep disordered breathing
WO2009036319A1 (en) 2007-09-14 2009-03-19 Corventis, Inc. Adherent emergency patient monitor
EP2194856B1 (en) 2007-09-14 2021-09-01 Medtronic Monitoring, Inc. Adherent cardiac monitor
US8116841B2 (en) 2007-09-14 2012-02-14 Corventis, Inc. Adherent device with multiple physiological sensors
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US20090105561A1 (en) 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
WO2009070773A1 (en) 2007-11-27 2009-06-04 Proteus Biomedical, Inc. Transbody communication systems employing communication channels
US20090149839A1 (en) 2007-12-11 2009-06-11 Hyde Roderick A Treatment techniques using ingestible device
EP2249908B1 (en) * 2008-01-25 2014-01-01 Medtronic, Inc. Sleep stage detection
JP5156427B2 (en) 2008-02-13 2013-03-06 富士フイルム株式会社 Capsule endoscope system
WO2009112972A2 (en) 2008-03-10 2009-09-17 Koninklijke Philips Electronics, N.V. Continuous outpatient ecg monitoring system
RU2499550C2 (en) 2008-03-10 2013-11-27 Конинклейке Филипс Электроникс Н.В. System of ecg monitoring with configured limits of switching on alarm signal
EP2319389B1 (en) 2008-04-03 2014-02-26 Olympus Medical Systems Corporation Antenna unit and receiving apparatus for capsule medical apparatus
US20090292194A1 (en) 2008-05-23 2009-11-26 Corventis, Inc. Chiropractic Care Management Systems and Methods
CH699071A2 (en) 2008-07-02 2010-01-15 Flakes S A A braking and / or mechanical locking.
DK2313002T3 (en) 2008-07-08 2018-12-03 Proteus Digital Health Inc Data basis for edible event fields
US8152020B2 (en) 2008-07-09 2012-04-10 Flowers Mary E Dosage dispensing and tracking container
AU2009281876B2 (en) 2008-08-13 2014-05-22 Proteus Digital Health, Inc. Ingestible circuitry
KR101028584B1 (en) 2008-08-27 2011-04-12 주식회사 바이오프로테크 Tab electrode and wire leading to the same
GB2463054A (en) 2008-08-30 2010-03-03 Adavanced Telecare Solutions L Device for monitoring the removal of items placed in compartments of a blister package using ambient light
US20100063841A1 (en) 2008-09-05 2010-03-11 Vital Data Technology, Llc System and method of notifying designated entities of access to personal medical records
US8036748B2 (en) 2008-11-13 2011-10-11 Proteus Biomedical, Inc. Ingestible therapy activator system and method
AU2009324536A1 (en) 2008-12-11 2011-07-14 Proteus Digital Health, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
TWI503101B (en) 2008-12-15 2015-10-11 Proteus Digital Health Inc Body-associated receiver and method
US20100160742A1 (en) 2008-12-18 2010-06-24 General Electric Company Telemetry system and method
CA2750151A1 (en) 2009-01-06 2010-07-15 Proteus Biomedical, Inc. High-throughput production of ingestible event markers
CN102341031A (en) 2009-01-06 2012-02-01 普罗秋斯生物医学公司 Ingestion-related biofeedback and personalized medical therapy method and system
KR100927471B1 (en) 2009-01-07 2009-11-19 주식회사 두성기술 The breast attachment type wireless heart rate apparatus
US8224667B1 (en) 2009-02-06 2012-07-17 Sprint Communications Company L.P. Therapy adherence methods and architecture
US8395521B2 (en) 2009-02-06 2013-03-12 University Of Dayton Smart aerospace structures
CN102448365B (en) 2009-04-03 2016-02-10 内测公司 Strengthen the feedback system of obstructive and other obesity process
EP3906845A1 (en) 2009-04-28 2021-11-10 Otsuka Pharmaceutical Co., Ltd. Highly reliable ingestible event markers
WO2010132331A2 (en) 2009-05-12 2010-11-18 Proteus Biomedical, Inc. Ingestible event markers comprising an ingestible component
US20100299155A1 (en) 2009-05-19 2010-11-25 Myca Health, Inc. System and method for providing a multi-dimensional contextual platform for managing a medical practice
US8440274B2 (en) 2009-05-26 2013-05-14 Apple Inc. Electronic device moisture indicators
US8468115B2 (en) 2009-06-25 2013-06-18 George Mason Intellectual Properties, Inc. Cyclical behavior modification
US9024766B2 (en) 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
UA109424C2 (en) 2009-12-02 2015-08-25 PHARMACEUTICAL PRODUCT, PHARMACEUTICAL TABLE WITH ELECTRONIC MARKER AND METHOD OF MANUFACTURING PHARMACEUTICAL TABLETS
US9451897B2 (en) 2009-12-14 2016-09-27 Medtronic Monitoring, Inc. Body adherent patch with electronics for physiologic monitoring
EP2515747A2 (en) 2009-12-23 2012-10-31 DELTA, Dansk Elektronik, Lys & Akustik A monitoring system
US8560040B2 (en) 2010-01-04 2013-10-15 Koninklijke Philips N.V. Shielded biomedical electrode patch
KR101034998B1 (en) 2010-02-18 2011-05-17 대한메디칼시스템(주) Connecting structure for snap electrode and electric wire
US9872637B2 (en) 2010-04-21 2018-01-23 The Rehabilitation Institute Of Chicago Medical evaluation system and method using sensors in mobile devices
KR101513288B1 (en) 2010-05-12 2015-04-17 아이리듬 테크놀로지스, 아이엔씨 Device features and design elements for long-term adhesion
US8301232B2 (en) 2010-06-08 2012-10-30 Alivecor, Inc. Wireless, ultrasonic personal health monitoring system
US20110301439A1 (en) 2010-06-08 2011-12-08 AliveUSA LLC Wireless, ultrasonic personal health monitoring system
US20110304131A1 (en) 2010-06-14 2011-12-15 Trutag Technologies, Inc. Labeling and verifying an item with an identifier
WO2011159338A1 (en) 2010-06-14 2011-12-22 Trutag Technologies, Inc. System for verifying an item in a package
EP2580687A4 (en) 2010-06-14 2014-04-30 Trutag Technologies Inc System for verifying an item in a package using a database
CN103154929A (en) 2010-06-14 2013-06-12 特鲁塔格科技公司 System for producing a packaged item with an identifier
US9585620B2 (en) 2010-07-27 2017-03-07 Carefusion 303, Inc. Vital-signs patch having a flexible attachment to electrodes
US20120089000A1 (en) 2010-10-08 2012-04-12 Jon Mikalson Bishay Ambulatory Electrocardiographic Monitor For Providing Ease Of Use In Women And Method Of Use
USD639437S1 (en) 2010-10-08 2011-06-07 Cardiac Science Corporation Wearable ambulatory electrocardiographic monitor
WO2012097505A1 (en) 2011-01-18 2012-07-26 北京超思电子技术有限责任公司 Measuring apparatus
US20120197144A1 (en) 2011-01-27 2012-08-02 Koninklijke Philips Electronics N.V. Exchangeable electrode and ecg cable snap connector
GB2487758A (en) 2011-02-03 2012-08-08 Isansys Lifecare Ltd Health monitoring electrode assembly
US9626650B2 (en) 2011-04-14 2017-04-18 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies

Patent Citations (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3799802A (en) * 1966-06-28 1974-03-26 F Schneble Plated through hole printed circuit boards
US3642008A (en) * 1968-09-25 1972-02-15 Medical Plastics Inc Ground electrode and test circuit
US3719183A (en) * 1970-03-05 1973-03-06 H Schwartz Method for detecting blockage or insufficiency of pancreatic exocrine function
US4077398A (en) * 1974-10-07 1978-03-07 Baxter Travenol Laboratories, Inc. Diagnostic electrode assembly
US4077397A (en) * 1974-10-07 1978-03-07 Baxter Travenol Laboratories, Inc. Diagnostic electrode assembly
US4251795A (en) * 1977-11-29 1981-02-17 Asahi Kasei Kogyo Kabushiki Kaisha Semiconductor magnetoresistive element having a differential effect
US4578061A (en) * 1980-10-28 1986-03-25 Lemelson Jerome H Injection catheter and method
US4494950A (en) * 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4681111A (en) * 1985-04-05 1987-07-21 Siemens-Pacesetter, Inc. Analog and digital telemetry system for an implantable device
US4635641A (en) * 1985-10-16 1987-01-13 Murray Electronics Associates Limited Multi-element electrode
US5281287A (en) * 1989-07-21 1994-01-25 Iomed, Inc. Method of making a hydratable bioelectrode
US7004395B2 (en) * 1990-05-25 2006-02-28 Broadcom Corporation Multi-level hierarchical radio-frequency communication system
US5279607A (en) * 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
US5394882A (en) * 1993-07-21 1995-03-07 Respironics, Inc. Physiological monitoring system
US5862803A (en) * 1993-09-04 1999-01-26 Besson; Marcus Wireless medical diagnosis and monitoring equipment
US5600548A (en) * 1994-08-11 1997-02-04 Sundstrand Corporation DC content control for an inverter
US5705189A (en) * 1994-08-31 1998-01-06 Roehm Gmbh Chemische Fabrik Thermoplastic material for drug coatings which dissolve in intestinal juices
US20020032385A1 (en) * 1995-02-24 2002-03-14 Raymond Stephen A. Health monitoring system
US6083248A (en) * 1995-06-23 2000-07-04 Medtronic, Inc. World wide patient location and data telemetry system for implantable medical devices
US5868136A (en) * 1996-02-20 1999-02-09 Axelgaard Manufacturing Co. Ltd. Medical electrode
US20090016102A1 (en) * 1996-05-01 2009-01-15 Yusuke Jyouno Nonvolatile semiconductor memory device which stores multi-value information
US5862808A (en) * 1997-08-26 1999-01-26 Cigar Savor Enterprises Llc Cigar punch
US6038464A (en) * 1998-02-09 2000-03-14 Axelgaard Manufacturing Co., Ltd. Medical electrode
US20030028226A1 (en) * 1998-06-19 2003-02-06 Medtronic, Inc. Medical management system integrated programming apparatus for communication with an implantable medical device
US20050021103A1 (en) * 1998-08-05 2005-01-27 Dilorenzo Daniel John Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7164942B2 (en) * 1998-11-09 2007-01-16 Transpharma Medical Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6358202B1 (en) * 1999-01-25 2002-03-19 Sun Microsystems, Inc. Network for implanted computer devices
US6200265B1 (en) * 1999-04-16 2001-03-13 Medtronic, Inc. Peripheral memory patch and access method for use with an implantable medical device
US6845272B1 (en) * 1999-05-25 2005-01-18 Medicotest A/S Skin electrode
US6531026B1 (en) * 1999-06-23 2003-03-11 Sony Chemicals Corp. Method for mounting electronic elements
US20050024198A1 (en) * 1999-07-20 2005-02-03 Ward William H. Impedance matching network and multidimensional electromagnetic field coil for a transponder interrogator
US20060068006A1 (en) * 1999-08-05 2006-03-30 Dimensional Foods Corporation Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same
US7013162B2 (en) * 1999-09-21 2006-03-14 Ipr Licensing, Inc. Dual mode unit for short range, high rate and long range, lower rate data communications
US7668437B1 (en) * 1999-09-30 2010-02-23 Sony Corporation Recording apparatus, recording method, and record medium
US6990082B1 (en) * 1999-11-08 2006-01-24 Intel Corporation Wireless apparatus having a transceiver equipped to support multiple wireless communication protocols
US6526315B1 (en) * 2000-03-17 2003-02-25 Tanita Corporation Portable bioelectrical impedance measuring instrument
US7171166B2 (en) * 2000-04-18 2007-01-30 Motorola Inc. Programmable wireless electrode system for medical monitoring
US6987965B2 (en) * 2000-04-18 2006-01-17 Motorola, Inc. Programmable wireless electrode system for medical monitoring
US6680923B1 (en) * 2000-05-23 2004-01-20 Calypso Wireless, Inc. Communication system and method
US7647185B2 (en) * 2000-06-16 2010-01-12 Oxford Biosignals Limited Combining measurements from different sensors
US6839659B2 (en) * 2000-06-16 2005-01-04 Isis Innovation Limited System and method for acquiring data
US7009946B1 (en) * 2000-06-22 2006-03-07 Intel Corporation Method and apparatus for multi-access wireless communication
US20020026111A1 (en) * 2000-08-28 2002-02-28 Neil Ackerman Methods of monitoring glucose levels in a subject and uses thereof
US20050021370A1 (en) * 2000-08-29 2005-01-27 Medtronic, Inc. Medical device systems implemented network scheme for remote patient management
US20050017841A1 (en) * 2000-09-08 2005-01-27 Matsushita Electric Works, Ltd. Data transmission system using a human body as a signal transmission path
US6864780B2 (en) * 2000-09-08 2005-03-08 Matsushita Electric Works, Ltd. Data transmission system using a human body as a signal transmission path
US20040034295A1 (en) * 2000-09-26 2004-02-19 Marcos Salganicoff Method and apparatus for real-time estimation and control of physiological parameters
US20050192489A1 (en) * 2000-11-08 2005-09-01 Marshall Daniel R. Swallowable data recorder capsule medical device
US6342774B1 (en) * 2001-03-27 2002-01-29 Motorola, Inc. Battery having user charge capacity control
US7161484B2 (en) * 2001-04-17 2007-01-09 Micrel Medical Devices S.A. System for monitoring medical parameters
US7160258B2 (en) * 2001-06-26 2007-01-09 Entrack, Inc. Capsule and method for treating or diagnosing the intestinal tract
US20070060800A1 (en) * 2001-06-29 2007-03-15 Darrel Drinan Gateway platform for biological monitoring and delivery of therapeutic compounds
US20050020887A1 (en) * 2001-10-11 2005-01-27 Jason Goldberg Medical monitoring device and system
US20050027205A1 (en) * 2001-12-14 2005-02-03 Lionel Tarassenko Combining measurements from breathing rate sensors
US7318808B2 (en) * 2001-12-14 2008-01-15 Isis Innovation Limited Combining measurements from breathing rate sensors
US7016648B2 (en) * 2001-12-18 2006-03-21 Ixi Mobile (Israel) Ltd. Method, system and computer readable medium for downloading a software component to a device in a short distance wireless network
US20040121292A1 (en) * 2002-08-08 2004-06-24 Chung Bobby Hsiang-Hua Wireless data communication link embedded in simulated weapon systems
US20060028727A1 (en) * 2002-08-20 2006-02-09 Moon John A Method and apparatus for drug product tracking using encoded optical identification elements
US7020508B2 (en) * 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US20060036134A1 (en) * 2002-09-18 2006-02-16 E-San Limited Telemedicine system
US20040122315A1 (en) * 2002-09-24 2004-06-24 Krill Jerry A. Ingestible medical payload carrying capsule with wireless communication
US6842636B2 (en) * 2002-09-27 2005-01-11 Axelgaard Manufacturing Co., Ltd. Medical electrode
US20090030297A1 (en) * 2002-09-27 2009-01-29 Medtronic Minimed, Inc. Implantable sensor method and system
US20040092296A1 (en) * 2002-10-31 2004-05-13 Tadashi Minotani Transceiver capable of causing series resonance with parasitic capacitance
US20040186365A1 (en) * 2002-12-31 2004-09-23 Therasense, Inc. Continuous glucose monitoring system and methods of use
US7653031B2 (en) * 2003-03-05 2010-01-26 Timothy Gordon Godfrey Advance notification of transmit opportunities on a shared-communications channel
US7382247B2 (en) * 2003-03-21 2008-06-03 Welch Allyn, Inc. Personal status physiologic monitor system and architecture and related monitoring methods
US20070006636A1 (en) * 2003-04-11 2007-01-11 Oxford Biosignals Limited Method and system for analysing tachometer and vibration data from an apparatus having one or more rotary components
US7640802B2 (en) * 2003-04-11 2010-01-05 Oxford Biosignals Limited Method and system for analysing tachometer and vibration data from an apparatus having one or more rotary components
US7171259B2 (en) * 2003-04-17 2007-01-30 Polar Electro Oy Method and device for measuring heart rate, and method for manufacturing the device
US20070027386A1 (en) * 2003-07-16 2007-02-01 Koninklijke Philips Electronics N.V. Portable electronic device and a health management system arranged for monitoring a physiological condition of an individual
US20050070778A1 (en) * 2003-08-20 2005-03-31 Lackey Robert P. Hydration monitoring
US20050043894A1 (en) * 2003-08-22 2005-02-24 Fernandez Dennis S. Integrated biosensor and simulation system for diagnosis and therapy
US20050062644A1 (en) * 2003-09-08 2005-03-24 Leci Jonathan Ilan Capsule device to identify the location of an individual
US20050065407A1 (en) * 2003-09-18 2005-03-24 Olympus Corporation Energy supplying coil and capsule endoscope system
US7176784B2 (en) * 2004-01-21 2007-02-13 Battelle Memorial Institute K1-53 Multi-mode radio frequency device
US7647112B2 (en) * 2004-02-11 2010-01-12 Ethicon, Inc. System and method for selectively stimulating different body parts
US20070002038A1 (en) * 2004-04-07 2007-01-04 Olympus Corporation Intra-subject position display system
US20080051667A1 (en) * 2004-05-16 2008-02-28 Rami Goldreich Method And Device For Measuring Physiological Parameters At The Hand
US20070038054A1 (en) * 2004-05-20 2007-02-15 Peter Zhou Embedded bio-sensor system
US20080033273A1 (en) * 2004-05-20 2008-02-07 Peter Zhou Embedded Bio-Sensor System
US20080021519A1 (en) * 2004-05-28 2008-01-24 Jan De Geest Communication Unit for a Person's Skin
US7336929B2 (en) * 2004-07-05 2008-02-26 Sony Ericsson Mobile Communications Japan, Inc. Short range wireless communication system, portable terminal apparatus, and wireless communication apparatus
US20060030760A1 (en) * 2004-07-20 2006-02-09 Geiger Mark A Vital signs monitoring system with wireless pupilometer interface
US20080027679A1 (en) * 2004-07-21 2008-01-31 Dror Shklarski Wearable Device, System and Method for Measuring Physiological and/or Environmental Parameters
US20080045843A1 (en) * 2004-08-12 2008-02-21 Tomoharu Tsuji Via-Human-Body Information Transmission System and Transmitter-Receiver
US20060058602A1 (en) * 2004-08-17 2006-03-16 Kwiatkowski Krzysztof C Interstitial fluid analyzer
US7171177B2 (en) * 2004-09-07 2007-01-30 Electronics And Telecommunications Research Institute Communication apparatus and method using human body as medium
US20060183993A1 (en) * 2004-12-30 2006-08-17 Eli Horn Device, system, and method for locating an in-vivo signal source
US20060164213A1 (en) * 2005-01-26 2006-07-27 Battelle Memorial Institute Method for autonomous establishment and utilization of an active-RF tag network
US20060229053A1 (en) * 2005-04-06 2006-10-12 Zarlink Semiconductor Ab Implantable RF telemetry devices with power saving mode
US20070016089A1 (en) * 2005-07-15 2007-01-18 Fischell David R Implantable device for vital signs monitoring
US20070123772A1 (en) * 2005-07-20 2007-05-31 Neil Euliano Medication compliance system and associated methods
US20070027388A1 (en) * 2005-08-01 2007-02-01 Chang-An Chou Patch-type physiological monitoring apparatus, system and network
US20070049339A1 (en) * 2005-08-29 2007-03-01 Amit Barak Method and apparatus of multiple entity wireless communication adapter
US20070060797A1 (en) * 2005-08-31 2007-03-15 Ball James J Automatic parameter status on an implantable medical device system
US20100027411A1 (en) * 2005-10-26 2010-02-04 Thomson Licensing System and Method for Compensating for a Satellite Gateway Failure
US20100049006A1 (en) * 2006-02-24 2010-02-25 Surendar Magar Medical signal processing system with distributed wireless sensors
US20080051647A1 (en) * 2006-05-11 2008-02-28 Changwang Wu Non-invasive acquisition of large nerve action potentials (NAPs) with closely spaced surface electrodes and reduced stimulus artifacts
US20080046038A1 (en) * 2006-06-26 2008-02-21 Hill Gerard J Local communications network for distributed sensing and therapy in biomedical applications
US20080014866A1 (en) * 2006-07-12 2008-01-17 Lipowski Joseph T Transceiver architecture and method for wireless base-stations
US20080021521A1 (en) * 2006-07-18 2008-01-24 Cardiac Pacemakers, Inc. Implantable Medical Device Communication System
US20100049012A1 (en) * 2006-11-21 2010-02-25 Koninklijke Philips Electronics N.V. Ingestible electronic capsule and in vivo drug delivery or diagnostic system
US20100049069A1 (en) * 2006-12-01 2010-02-25 Oxford Biosignals Limited Biomedical signal morphology analysis method
US20080316020A1 (en) * 2007-05-24 2008-12-25 Robertson Timothy L Rfid antenna for in-body device
US20100010330A1 (en) * 2007-06-01 2010-01-14 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
US20090009330A1 (en) * 2007-07-03 2009-01-08 Isao Sakama Rfid tag mounting circuit board
US20090043171A1 (en) * 2007-07-16 2009-02-12 Peter Rule Systems And Methods For Determining Physiological Parameters Using Measured Analyte Values
US20090024045A1 (en) * 2007-07-19 2009-01-22 Rajan Prakash Mechanical function marker channel for cardiac monitoring and therapy control
US20090034209A1 (en) * 2007-08-03 2009-02-05 Samsung Electronics Co., Ltd. Multi-module combination type portable electronic device
US20090048498A1 (en) * 2007-08-17 2009-02-19 Frank Riskey System and method of monitoring an animal
US20100049004A1 (en) * 2008-04-21 2010-02-25 Philometron, Inc. Metabolic energy monitoring system
US20100001841A1 (en) * 2008-07-07 2010-01-07 Cardullo Mario W Dynamically distributable nano rfid device and related method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Modulation and Deviation" by Dave Platt, AE6EO, 10/26/2007 *
Collins English Dictionary definition of "Digest" *

Cited By (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119554B2 (en) 2005-04-28 2015-09-01 Proteus Digital Health, Inc. Pharma-informatics system
US10542909B2 (en) 2005-04-28 2020-01-28 Proteus Digital Health, Inc. Communication system with partial power source
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US9597010B2 (en) 2005-04-28 2017-03-21 Proteus Digital Health, Inc. Communication system using an implantable device
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US8816847B2 (en) 2005-04-28 2014-08-26 Proteus Digital Health, Inc. Communication system with partial power source
US11476952B2 (en) 2005-04-28 2022-10-18 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US8674825B2 (en) 2005-04-28 2014-03-18 Proteus Digital Health, Inc. Pharma-informatics system
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US9439582B2 (en) 2005-04-28 2016-09-13 Proteus Digital Health, Inc. Communication system with remote activation
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US9161707B2 (en) 2005-04-28 2015-10-20 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US7978064B2 (en) 2005-04-28 2011-07-12 Proteus Biomedical, Inc. Communication system with partial power source
US10610128B2 (en) 2005-04-28 2020-04-07 Proteus Digital Health, Inc. Pharma-informatics system
US8847766B2 (en) 2005-04-28 2014-09-30 Proteus Digital Health, Inc. Pharma-informatics system
US9649066B2 (en) 2005-04-28 2017-05-16 Proteus Digital Health, Inc. Communication system with partial power source
US10517507B2 (en) 2005-04-28 2019-12-31 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US9681842B2 (en) 2005-04-28 2017-06-20 Proteus Digital Health, Inc. Pharma-informatics system
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US20080284599A1 (en) * 2005-04-28 2008-11-20 Proteus Biomedical, Inc. Pharma-Informatics System
US8547248B2 (en) 2005-09-01 2013-10-01 Proteus Digital Health, Inc. Implantable zero-wire communications system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US20080020037A1 (en) * 2006-07-11 2008-01-24 Robertson Timothy L Acoustic Pharma-Informatics System
US8054140B2 (en) 2006-10-17 2011-11-08 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
US8945005B2 (en) 2006-10-25 2015-02-03 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US10238604B2 (en) 2006-10-25 2019-03-26 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US11357730B2 (en) 2006-10-25 2022-06-14 Otsuka Pharmaceutical Co., Ltd. Controlled activation ingestible identifier
US9083589B2 (en) 2006-11-20 2015-07-14 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US8718193B2 (en) 2006-11-20 2014-05-06 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US9444503B2 (en) 2006-11-20 2016-09-13 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US8858432B2 (en) 2007-02-01 2014-10-14 Proteus Digital Health, Inc. Ingestible event marker systems
US10441194B2 (en) 2007-02-01 2019-10-15 Proteus Digital Heal Th, Inc. Ingestible event marker systems
US11464423B2 (en) 2007-02-14 2022-10-11 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
US8956288B2 (en) 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US10517506B2 (en) 2007-05-24 2019-12-31 Proteus Digital Health, Inc. Low profile antenna for in body device
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
US9433371B2 (en) 2007-09-25 2016-09-06 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US11612321B2 (en) 2007-11-27 2023-03-28 Otsuka Pharmaceutical Co., Ltd. Transbody communication systems employing communication channels
US8542123B2 (en) 2008-03-05 2013-09-24 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9060708B2 (en) 2008-03-05 2015-06-23 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US8810409B2 (en) 2008-03-05 2014-08-19 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9258035B2 (en) 2008-03-05 2016-02-09 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US8258962B2 (en) 2008-03-05 2012-09-04 Proteus Biomedical, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US10682071B2 (en) 2008-07-08 2020-06-16 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US11217342B2 (en) 2008-07-08 2022-01-04 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker data framework
US9415010B2 (en) 2008-08-13 2016-08-16 Proteus Digital Health, Inc. Ingestible circuitry
US8540633B2 (en) 2008-08-13 2013-09-24 Proteus Digital Health, Inc. Identifier circuits for generating unique identifiable indicators and techniques for producing same
US8721540B2 (en) 2008-08-13 2014-05-13 Proteus Digital Health, Inc. Ingestible circuitry
US8036748B2 (en) 2008-11-13 2011-10-11 Proteus Biomedical, Inc. Ingestible therapy activator system and method
US8583227B2 (en) 2008-12-11 2013-11-12 Proteus Digital Health, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same
US8545436B2 (en) 2008-12-15 2013-10-01 Proteus Digital Health, Inc. Body-associated receiver and method
US8114021B2 (en) 2008-12-15 2012-02-14 Proteus Biomedical, Inc. Body-associated receiver and method
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
US9149577B2 (en) 2008-12-15 2015-10-06 Proteus Digital Health, Inc. Body-associated receiver and method
US8597186B2 (en) 2009-01-06 2013-12-03 Proteus Digital Health, Inc. Pharmaceutical dosages delivery system
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US9119918B2 (en) 2009-03-25 2015-09-01 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
US8540664B2 (en) 2009-03-25 2013-09-24 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
US9320455B2 (en) 2009-04-28 2016-04-26 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US8545402B2 (en) 2009-04-28 2013-10-01 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US10588544B2 (en) 2009-04-28 2020-03-17 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
US8558563B2 (en) 2009-08-21 2013-10-15 Proteus Digital Health, Inc. Apparatus and method for measuring biochemical parameters
US8868453B2 (en) 2009-11-04 2014-10-21 Proteus Digital Health, Inc. System for supply chain management
US10305544B2 (en) 2009-11-04 2019-05-28 Proteus Digital Health, Inc. System for supply chain management
US9941931B2 (en) 2009-11-04 2018-04-10 Proteus Digital Health, Inc. System for supply chain management
US8784308B2 (en) 2009-12-02 2014-07-22 Proteus Digital Health, Inc. Integrated ingestible event marker system with pharmaceutical product
US10376218B2 (en) 2010-02-01 2019-08-13 Proteus Digital Health, Inc. Data gathering system
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
US11173290B2 (en) 2010-04-07 2021-11-16 Otsuka Pharmaceutical Co., Ltd. Miniature ingestible device
US10207093B2 (en) 2010-04-07 2019-02-19 Proteus Digital Health, Inc. Miniature ingestible device
US10529044B2 (en) 2010-05-19 2020-01-07 Proteus Digital Health, Inc. Tracking and delivery confirmation of pharmaceutical products
CN103124971A (en) * 2010-09-30 2013-05-29 皇家飞利浦电子股份有限公司 Body worn sensors network with redundant parameter prioritization and temporal alignment
WO2012042437A2 (en) 2010-09-30 2012-04-05 Koninklijke Philips Electronics N.V. Body worn sensors network with redundant parameter prioritization and temporal alignment
US10264968B2 (en) 2010-09-30 2019-04-23 Koninklijke Philips N.V. Body worn sensors network with redundant parameter prioritization and temporal alignment
WO2012042437A3 (en) * 2010-09-30 2012-06-21 Koninklijke Philips Electronics N.V. Body worn sensors network with redundant parameter prioritization and temporal alignment
US11504511B2 (en) 2010-11-22 2022-11-22 Otsuka Pharmaceutical Co., Ltd. Ingestible device with pharmaceutical product
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
CN106534854A (en) * 2011-03-07 2017-03-22 杜比国际公司 Method of coding and decoding images, coding and decoding device and computer programs corresponding thereto
US11343535B2 (en) 2011-03-07 2022-05-24 Dolby International Ab Method of coding and decoding images, coding and decoding device and computer programs corresponding thereto
US11736723B2 (en) 2011-03-07 2023-08-22 Dolby International Ab Method of coding and decoding images, coding and decoding device and computer programs corresponding thereto
US9439599B2 (en) 2011-03-11 2016-09-13 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
US20120315863A1 (en) * 2011-06-07 2012-12-13 Olympus Corporation Wireless communication terminal
US9044137B2 (en) * 2011-06-07 2015-06-02 Olympus Corporation Wireless communication terminal
US11229378B2 (en) 2011-07-11 2022-01-25 Otsuka Pharmaceutical Co., Ltd. Communication system with enhanced partial power source and method of manufacturing same
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
US9271897B2 (en) 2012-07-23 2016-03-01 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
US9031653B2 (en) 2012-07-26 2015-05-12 Nyxoah SA Internal resonance matching between an implanted device and an external device
US9268909B2 (en) 2012-10-18 2016-02-23 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US11741771B2 (en) 2013-03-15 2023-08-29 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US11158149B2 (en) 2013-03-15 2021-10-26 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US10421658B2 (en) 2013-08-30 2019-09-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9787511B2 (en) 2013-09-20 2017-10-10 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10498572B2 (en) 2013-09-20 2019-12-03 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9270503B2 (en) 2013-09-20 2016-02-23 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US11102038B2 (en) 2013-09-20 2021-08-24 Otsuka Pharmaceutical Co., Ltd. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10097388B2 (en) 2013-09-20 2018-10-09 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9577864B2 (en) 2013-09-24 2017-02-21 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
CN105612492A (en) * 2013-10-02 2016-05-25 高通股份有限公司 Method and apparatus for producing programmable probability distribution function of pseudo-random numbers
US9417845B2 (en) * 2013-10-02 2016-08-16 Qualcomm Incorporated Method and apparatus for producing programmable probability distribution function of pseudo-random numbers
US20150095274A1 (en) * 2013-10-02 2015-04-02 Qualcomm Incorporated Method and apparatus for producing programmable probability distribution function of pseudo-random numbers
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US9592391B2 (en) 2014-01-10 2017-03-14 Cardiac Pacemakers, Inc. Systems and methods for detecting cardiac arrhythmias
US10722720B2 (en) 2014-01-10 2020-07-28 Cardiac Pacemakers, Inc. Methods and systems for improved communication between medical devices
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
US10912943B2 (en) 2014-08-06 2021-02-09 Cardiac Pacemakers, Inc. Communications between a plurality of medical devices using time delays between communication pulses between symbols
US9757570B2 (en) 2014-08-06 2017-09-12 Cardiac Pacemakers, Inc. Communications in a medical device system
US9694189B2 (en) 2014-08-06 2017-07-04 Cardiac Pacemakers, Inc. Method and apparatus for communicating between medical devices
US9808631B2 (en) 2014-08-06 2017-11-07 Cardiac Pacemakers, Inc. Communication between a plurality of medical devices using time delays between communication pulses to distinguish between symbols
US9526909B2 (en) 2014-08-28 2016-12-27 Cardiac Pacemakers, Inc. Medical device with triggered blanking period
US11020595B2 (en) 2015-02-06 2021-06-01 Cardiac Pacemakers, Inc. Systems and methods for treating cardiac arrhythmias
US11224751B2 (en) 2015-02-06 2022-01-18 Cardiac Pacemakers, Inc. Systems and methods for safe delivery of electrical stimulation therapy
US10238882B2 (en) 2015-02-06 2019-03-26 Cardiac Pacemakers Systems and methods for treating cardiac arrhythmias
US10220213B2 (en) 2015-02-06 2019-03-05 Cardiac Pacemakers, Inc. Systems and methods for safe delivery of electrical stimulation therapy
US9669230B2 (en) 2015-02-06 2017-06-06 Cardiac Pacemakers, Inc. Systems and methods for treating cardiac arrhythmias
US10046167B2 (en) 2015-02-09 2018-08-14 Cardiac Pacemakers, Inc. Implantable medical device with radiopaque ID tag
US11020600B2 (en) 2015-02-09 2021-06-01 Cardiac Pacemakers, Inc. Implantable medical device with radiopaque ID tag
US11285326B2 (en) 2015-03-04 2022-03-29 Cardiac Pacemakers, Inc. Systems and methods for treating cardiac arrhythmias
US10946202B2 (en) 2015-03-18 2021-03-16 Cardiac Pacemakers, Inc. Communications in a medical device system with link quality assessment
US10050700B2 (en) 2015-03-18 2018-08-14 Cardiac Pacemakers, Inc. Communications in a medical device system with temporal optimization
US11476927B2 (en) 2015-03-18 2022-10-18 Cardiac Pacemakers, Inc. Communications in a medical device system with temporal optimization
US10213610B2 (en) 2015-03-18 2019-02-26 Cardiac Pacemakers, Inc. Communications in a medical device system with link quality assessment
EP3070982A1 (en) * 2015-03-19 2016-09-21 Albert-Ludwigs-Universität Freiburg Receiving device and method for operating a receiving device
US9985730B2 (en) 2015-03-19 2018-05-29 Albert-Ludwigs-Universität Freiburg Wake-up circuit in receiving device and method of operating the receiving device
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US10357159B2 (en) 2015-08-20 2019-07-23 Cardiac Pacemakers, Inc Systems and methods for communication between medical devices
US9853743B2 (en) 2015-08-20 2017-12-26 Cardiac Pacemakers, Inc. Systems and methods for communication between medical devices
US9968787B2 (en) 2015-08-27 2018-05-15 Cardiac Pacemakers, Inc. Spatial configuration of a motion sensor in an implantable medical device
US9956414B2 (en) 2015-08-27 2018-05-01 Cardiac Pacemakers, Inc. Temporal configuration of a motion sensor in an implantable medical device
US10709892B2 (en) 2015-08-27 2020-07-14 Cardiac Pacemakers, Inc. Temporal configuration of a motion sensor in an implantable medical device
US10589101B2 (en) 2015-08-28 2020-03-17 Cardiac Pacemakers, Inc. System and method for detecting tamponade
US10226631B2 (en) 2015-08-28 2019-03-12 Cardiac Pacemakers, Inc. Systems and methods for infarct detection
US10137305B2 (en) 2015-08-28 2018-11-27 Cardiac Pacemakers, Inc. Systems and methods for behaviorally responsive signal detection and therapy delivery
US10159842B2 (en) 2015-08-28 2018-12-25 Cardiac Pacemakers, Inc. System and method for detecting tamponade
US10092760B2 (en) 2015-09-11 2018-10-09 Cardiac Pacemakers, Inc. Arrhythmia detection and confirmation
US10065041B2 (en) 2015-10-08 2018-09-04 Cardiac Pacemakers, Inc. Devices and methods for adjusting pacing rates in an implantable medical device
US10183170B2 (en) 2015-12-17 2019-01-22 Cardiac Pacemakers, Inc. Conducted communication in a medical device system
US10933245B2 (en) 2015-12-17 2021-03-02 Cardiac Pacemakers, Inc. Conducted communication in a medical device system
US10905886B2 (en) 2015-12-28 2021-02-02 Cardiac Pacemakers, Inc. Implantable medical device for deployment across the atrioventricular septum
US10583303B2 (en) 2016-01-19 2020-03-10 Cardiac Pacemakers, Inc. Devices and methods for wirelessly recharging a rechargeable battery of an implantable medical device
US10350423B2 (en) 2016-02-04 2019-07-16 Cardiac Pacemakers, Inc. Delivery system with force sensor for leadless cardiac device
US11116988B2 (en) 2016-03-31 2021-09-14 Cardiac Pacemakers, Inc. Implantable medical device with rechargeable battery
US10668294B2 (en) 2016-05-10 2020-06-02 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker configured for over the wire delivery
US10328272B2 (en) 2016-05-10 2019-06-25 Cardiac Pacemakers, Inc. Retrievability for implantable medical devices
US11497921B2 (en) 2016-06-27 2022-11-15 Cardiac Pacemakers, Inc. Cardiac therapy system using subcutaneously sensed p-waves for resynchronization pacing management
US10512784B2 (en) 2016-06-27 2019-12-24 Cardiac Pacemakers, Inc. Cardiac therapy system using subcutaneously sensed P-waves for resynchronization pacing management
US11207527B2 (en) 2016-07-06 2021-12-28 Cardiac Pacemakers, Inc. Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system
US10426962B2 (en) 2016-07-07 2019-10-01 Cardiac Pacemakers, Inc. Leadless pacemaker using pressure measurements for pacing capture verification
US10688304B2 (en) 2016-07-20 2020-06-23 Cardiac Pacemakers, Inc. Method and system for utilizing an atrial contraction timing fiducial in a leadless cardiac pacemaker system
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10797758B2 (en) 2016-07-22 2020-10-06 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10391319B2 (en) 2016-08-19 2019-08-27 Cardiac Pacemakers, Inc. Trans septal implantable medical device
US10870008B2 (en) 2016-08-24 2020-12-22 Cardiac Pacemakers, Inc. Cardiac resynchronization using fusion promotion for timing management
US11464982B2 (en) 2016-08-24 2022-10-11 Cardiac Pacemakers, Inc. Integrated multi-device cardiac resynchronization therapy using p-wave to pace timing
US10780278B2 (en) 2016-08-24 2020-09-22 Cardiac Pacemakers, Inc. Integrated multi-device cardiac resynchronization therapy using P-wave to pace timing
US10905889B2 (en) 2016-09-21 2021-02-02 Cardiac Pacemakers, Inc. Leadless stimulation device with a housing that houses internal components of the leadless stimulation device and functions as the battery case and a terminal of an internal battery
US10758737B2 (en) 2016-09-21 2020-09-01 Cardiac Pacemakers, Inc. Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter
US10994145B2 (en) 2016-09-21 2021-05-04 Cardiac Pacemakers, Inc. Implantable cardiac monitor
US11793419B2 (en) 2016-10-26 2023-10-24 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US10463305B2 (en) 2016-10-27 2019-11-05 Cardiac Pacemakers, Inc. Multi-device cardiac resynchronization therapy with timing enhancements
US11305125B2 (en) 2016-10-27 2022-04-19 Cardiac Pacemakers, Inc. Implantable medical device with gyroscope
US10434314B2 (en) 2016-10-27 2019-10-08 Cardiac Pacemakers, Inc. Use of a separate device in managing the pace pulse energy of a cardiac pacemaker
US10765871B2 (en) 2016-10-27 2020-09-08 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
US10413733B2 (en) 2016-10-27 2019-09-17 Cardiac Pacemakers, Inc. Implantable medical device with gyroscope
US10758724B2 (en) 2016-10-27 2020-09-01 Cardiac Pacemakers, Inc. Implantable medical device delivery system with integrated sensor
US10561330B2 (en) 2016-10-27 2020-02-18 Cardiac Pacemakers, Inc. Implantable medical device having a sense channel with performance adjustment
US10434317B2 (en) 2016-10-31 2019-10-08 Cardiac Pacemakers, Inc. Systems and methods for activity level pacing
US10617874B2 (en) 2016-10-31 2020-04-14 Cardiac Pacemakers, Inc. Systems and methods for activity level pacing
US10583301B2 (en) 2016-11-08 2020-03-10 Cardiac Pacemakers, Inc. Implantable medical device for atrial deployment
US10632313B2 (en) 2016-11-09 2020-04-28 Cardiac Pacemakers, Inc. Systems, devices, and methods for setting cardiac pacing pulse parameters for a cardiac pacing device
US10894163B2 (en) 2016-11-21 2021-01-19 Cardiac Pacemakers, Inc. LCP based predictive timing for cardiac resynchronization
US10639486B2 (en) 2016-11-21 2020-05-05 Cardiac Pacemakers, Inc. Implantable medical device with recharge coil
US10881863B2 (en) 2016-11-21 2021-01-05 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker with multimode communication
US11147979B2 (en) 2016-11-21 2021-10-19 Cardiac Pacemakers, Inc. Implantable medical device with a magnetically permeable housing and an inductive coil disposed about the housing
US10881869B2 (en) 2016-11-21 2021-01-05 Cardiac Pacemakers, Inc. Wireless re-charge of an implantable medical device
US11207532B2 (en) 2017-01-04 2021-12-28 Cardiac Pacemakers, Inc. Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system
US10835753B2 (en) 2017-01-26 2020-11-17 Cardiac Pacemakers, Inc. Intra-body device communication with redundant message transmission
US11590353B2 (en) 2017-01-26 2023-02-28 Cardiac Pacemakers, Inc. Intra-body device communication with redundant message transmission
US10737102B2 (en) 2017-01-26 2020-08-11 Cardiac Pacemakers, Inc. Leadless implantable device with detachable fixation
US10029107B1 (en) 2017-01-26 2018-07-24 Cardiac Pacemakers, Inc. Leadless device with overmolded components
US10821288B2 (en) 2017-04-03 2020-11-03 Cardiac Pacemakers, Inc. Cardiac pacemaker with pacing pulse energy adjustment based on sensed heart rate
US10905872B2 (en) 2017-04-03 2021-02-02 Cardiac Pacemakers, Inc. Implantable medical device with a movable electrode biased toward an extended position
US11065459B2 (en) 2017-08-18 2021-07-20 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
US10918875B2 (en) 2017-08-18 2021-02-16 Cardiac Pacemakers, Inc. Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator
US11235163B2 (en) 2017-09-20 2022-02-01 Cardiac Pacemakers, Inc. Implantable medical device with multiple modes of operation
US11928614B2 (en) 2017-09-28 2024-03-12 Otsuka Pharmaceutical Co., Ltd. Patient customized therapeutic regimens
US11185703B2 (en) 2017-11-07 2021-11-30 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker for bundle of his pacing
WO2019108787A1 (en) * 2017-11-29 2019-06-06 Medtronic, Inc. Tissue conduction communication between devices
CN111417430A (en) * 2017-11-29 2020-07-14 美敦力公司 Tissue-conducted communication between devices
US11235162B2 (en) 2017-11-29 2022-02-01 Medtronic, Inc. Tissue conduction communication between devices
US11234280B2 (en) 2017-11-29 2022-01-25 Samsung Electronics Co., Ltd. Method for RF communication connection using electronic device and user touch input
US11071870B2 (en) 2017-12-01 2021-07-27 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials and determining a cardiac interval from a ventricularly implanted leadless cardiac pacemaker
US11260216B2 (en) 2017-12-01 2022-03-01 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker
US11052258B2 (en) 2017-12-01 2021-07-06 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker
US11813463B2 (en) 2017-12-01 2023-11-14 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker with reversionary behavior
US10874861B2 (en) 2018-01-04 2020-12-29 Cardiac Pacemakers, Inc. Dual chamber pacing without beat-to-beat communication
US11529523B2 (en) 2018-01-04 2022-12-20 Cardiac Pacemakers, Inc. Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone
US11819699B2 (en) 2018-03-23 2023-11-21 Medtronic, Inc. VfA cardiac resynchronization therapy
US11058880B2 (en) 2018-03-23 2021-07-13 Medtronic, Inc. VFA cardiac therapy for tachycardia
US11235159B2 (en) 2018-03-23 2022-02-01 Medtronic, Inc. VFA cardiac resynchronization therapy
US11400296B2 (en) 2018-03-23 2022-08-02 Medtronic, Inc. AV synchronous VfA cardiac therapy
US11235161B2 (en) 2018-09-26 2022-02-01 Medtronic, Inc. Capture in ventricle-from-atrium cardiac therapy
US11679265B2 (en) 2019-02-14 2023-06-20 Medtronic, Inc. Lead-in-lead systems and methods for cardiac therapy
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
US11213676B2 (en) 2019-04-01 2022-01-04 Medtronic, Inc. Delivery systems for VfA cardiac therapy
US11712188B2 (en) 2019-05-07 2023-08-01 Medtronic, Inc. Posterior left bundle branch engagement
US11305127B2 (en) 2019-08-26 2022-04-19 Medtronic Inc. VfA delivery and implant region detection
US11813466B2 (en) 2020-01-27 2023-11-14 Medtronic, Inc. Atrioventricular nodal stimulation
US11911168B2 (en) 2020-04-03 2024-02-27 Medtronic, Inc. Cardiac conduction system therapy benefit determination
US11813464B2 (en) 2020-07-31 2023-11-14 Medtronic, Inc. Cardiac conduction system evaluation
WO2023028164A1 (en) * 2021-08-24 2023-03-02 Canary Medical Switzerland Ag Implantable medical device with sensing and communication functionality

Also Published As

Publication number Publication date
AU2008329620B2 (en) 2014-05-08
KR101586193B1 (en) 2016-01-18
AU2016201924A1 (en) 2016-05-19
CN101926097A (en) 2010-12-22
JP5794782B2 (en) 2015-10-14
AU2014203793A1 (en) 2014-07-31
IL206049A (en) 2015-03-31
MY154699A (en) 2015-07-15
US11612321B2 (en) 2023-03-28
JP2015122811A (en) 2015-07-02
AU2008329620A1 (en) 2009-06-04
CA2717809A1 (en) 2009-06-04
KR20100086050A (en) 2010-07-29
CN101926097B (en) 2016-10-05
IL206049A0 (en) 2010-11-30
WO2009070773A1 (en) 2009-06-04
US20200254268A1 (en) 2020-08-13
DK2215726T3 (en) 2018-04-09
EP2215726B1 (en) 2018-01-10
EP2215726A4 (en) 2012-05-09
SG190590A1 (en) 2013-06-28
ES2661739T3 (en) 2018-04-03
JP2011505108A (en) 2011-02-17
EP2215726A1 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
US11612321B2 (en) Transbody communication systems employing communication channels
US9444503B2 (en) Active signal processing personal health signal receivers
US10441194B2 (en) Ingestible event marker systems
US8115618B2 (en) RFID antenna for in-body device
US20160380708A1 (en) Systems and methods for resolving ingestible event marker (iem) contention
US20140309505A1 (en) Electronic medication compliance monitoring system and associated methods
CA2909033C (en) Electronic medication compliance monitoring system and associated methods
AU2012247015B2 (en) Ingestible event marker systems

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROTEUS BIOMEDICAL, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBERTSON, TIMOTHY;CRANDALL, KENNETH C.;ARNE, LAWRENCE W.;REEL/FRAME:022395/0806

Effective date: 20081126

AS Assignment

Owner name: PROTEUS DIGITAL HEALTH, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:PROTEUS BIOMEDICAL, INC.;REEL/FRAME:029228/0436

Effective date: 20120705

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION